#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Loss of brain graph network efficiency in alcohol dependence
#Text=Alcohol dependence (AD) is characterized by corticostriatal impairments in individual brain areas such as the striatum.
1-1	0-4	Loss	_
1-2	5-7	of	_
1-3	8-13	brain	_
1-4	14-19	graph	_
1-5	20-27	network	_
1-6	28-38	efficiency	_
1-7	39-41	in	_
1-8	42-49	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[1]
1-9	50-60	dependence	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[1]
1-10	61-68	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]
1-11	69-79	dependence	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]
1-12	80-81	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]
1-13	81-83	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]
1-14	83-84	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]
1-15	85-87	is	_
1-16	88-101	characterized	_
1-17	102-104	by	_
1-18	105-120	corticostriatal	_
1-19	121-132	impairments	_
1-20	133-135	in	_
1-21	136-146	individual	_
1-22	147-152	brain	_
1-23	153-158	areas	_
1-24	159-163	such	_
1-25	164-166	as	_
1-26	167-170	the	_
1-27	171-179	striatum	_
1-28	179-180	.	_

#Text=As yet however, complex brain network topology in AD and its association with disease progression are unknown.
2-1	181-183	As	_
2-2	184-187	yet	_
2-3	188-195	however	_
2-4	195-196	,	_
2-5	197-204	complex	_
2-6	205-210	brain	_
2-7	211-218	network	_
2-8	219-227	topology	_
2-9	228-230	in	_
2-10	231-233	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
2-11	234-237	and	_
2-12	238-241	its	_
2-13	242-253	association	_
2-14	254-258	with	_
2-15	259-266	disease	_
2-16	267-278	progression	_
2-17	279-282	are	_
2-18	283-290	unknown	_
2-19	290-291	.	_

#Text=We applied graph theory to resting-state functional magnetic resonance imaging (RS-fMRI) to examine weighted global efficiency and local (clustering coefficient, degree and eigenvector centrality) network topology and the functional role of the striatum in 24 AD patients compared with 20 matched healthy controls (HCs), and their association with dependence characteristics.
3-1	292-294	We	_
3-2	295-302	applied	_
3-3	303-308	graph	_
3-4	309-315	theory	_
3-5	316-318	to	_
3-6	319-332	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[3]
3-7	333-343	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[3]
3-8	344-352	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[3]
3-9	353-362	resonance	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[3]
3-10	363-370	imaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[3]
3-11	371-372	(	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[3]
3-12	372-379	RS-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[3]
3-13	379-380	)	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[3]
3-14	381-383	to	_
3-15	384-391	examine	_
3-16	392-400	weighted	_
3-17	401-407	global	_
3-18	408-418	efficiency	_
3-19	419-422	and	_
3-20	423-428	local	_
3-21	429-430	(	_
3-22	430-440	clustering	_
3-23	441-452	coefficient	_
3-24	452-453	,	_
3-25	454-460	degree	_
3-26	461-464	and	_
3-27	465-476	eigenvector	_
3-28	477-487	centrality	_
3-29	487-488	)	_
3-30	489-496	network	_
3-31	497-505	topology	_
3-32	506-509	and	_
3-33	510-513	the	_
3-34	514-524	functional	_
3-35	525-529	role	_
3-36	530-532	of	_
3-37	533-536	the	_
3-38	537-545	striatum	_
3-39	546-548	in	_
3-40	549-551	24	_
3-41	552-554	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[4]
3-42	555-563	patients	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[4]
3-43	564-572	compared	_
3-44	573-577	with	_
3-45	578-580	20	_
3-46	581-588	matched	_
3-47	589-596	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]
3-48	597-605	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]
3-49	606-607	(	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]
3-50	607-610	HCs	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]
3-51	610-611	)	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]
3-52	611-612	,	_
3-53	613-616	and	_
3-54	617-622	their	_
3-55	623-634	association	_
3-56	635-639	with	_
3-57	640-650	dependence	_
3-58	651-666	characteristics	_
3-59	666-667	.	_

#Text=Graph analyses were performed based on Pearson’s correlations between RS-fMRI time series, while correcting for age, gender and head motion.
4-1	668-673	Graph	_
4-2	674-682	analyses	_
4-3	683-687	were	_
4-4	688-697	performed	_
4-5	698-703	based	_
4-6	704-706	on	_
4-7	707-714	Pearson	_
4-8	714-715	’	_
4-9	715-716	s	_
4-10	717-729	correlations	_
4-11	730-737	between	_
4-12	738-745	RS-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[6]
4-13	746-750	time	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[6]
4-14	751-757	series	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[6]
4-15	757-758	,	_
4-16	759-764	while	_
4-17	765-775	correcting	_
4-18	776-779	for	_
4-19	780-783	age	_
4-20	783-784	,	_
4-21	785-791	gender	_
4-22	792-795	and	_
4-23	796-800	head	_
4-24	801-807	motion	_
4-25	807-808	.	_

#Text=We found no significant group differences between AD patients and HCs in network topology.
5-1	809-811	We	_
5-2	812-817	found	_
5-3	818-820	no	_
5-4	821-832	significant	_
5-5	833-838	group	_
5-6	839-850	differences	_
5-7	851-858	between	_
5-8	859-861	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[7]
5-9	862-870	patients	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[7]
5-10	871-874	and	_
5-11	875-878	HCs	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-12	879-881	in	_
5-13	882-889	network	_
5-14	890-898	topology	_
5-15	898-899	.	_

#Text=Notably, within the patient group, but not in HCs, the whole-brain network showed reduced average cluster coefficient with more severe alcohol use, whereas longer AD duration within the patient group was associated with a global decrease in efficiency, degree and clustering coefficient.
6-1	900-907	Notably	_
6-2	907-908	,	_
6-3	909-915	within	_
6-4	916-919	the	_
6-5	920-927	patient	_
6-6	928-933	group	_
6-7	933-934	,	_
6-8	935-938	but	_
6-9	939-942	not	_
6-10	943-945	in	_
6-11	946-949	HCs	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
6-12	949-950	,	_
6-13	951-954	the	_
6-14	955-966	whole-brain	_
6-15	967-974	network	_
6-16	975-981	showed	_
6-17	982-989	reduced	_
6-18	990-997	average	_
6-19	998-1005	cluster	_
6-20	1006-1017	coefficient	_
6-21	1018-1022	with	_
6-22	1023-1027	more	_
6-23	1028-1034	severe	_
6-24	1035-1042	alcohol	_
6-25	1043-1046	use	_
6-26	1046-1047	,	_
6-27	1048-1055	whereas	_
6-28	1056-1062	longer	_
6-29	1063-1065	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
6-30	1066-1074	duration	_
6-31	1075-1081	within	_
6-32	1082-1085	the	_
6-33	1086-1093	patient	_
6-34	1094-1099	group	_
6-35	1100-1103	was	_
6-36	1104-1114	associated	_
6-37	1115-1119	with	_
6-38	1120-1121	a	_
6-39	1122-1128	global	_
6-40	1129-1137	decrease	_
6-41	1138-1140	in	_
6-42	1141-1151	efficiency	_
6-43	1151-1152	,	_
6-44	1153-1159	degree	_
6-45	1160-1163	and	_
6-46	1164-1174	clustering	_
6-47	1175-1186	coefficient	_
6-48	1186-1187	.	_

#Text=Additionally, within four a-priori chosen bilateral striatal nodes, alcohol use severity was associated with lower clustering coefficient in the left caudate.
7-1	1188-1200	Additionally	_
7-2	1200-1201	,	_
7-3	1202-1208	within	_
7-4	1209-1213	four	_
7-5	1214-1222	a-priori	_
7-6	1223-1229	chosen	_
7-7	1230-1239	bilateral	_
7-8	1240-1248	striatal	_
7-9	1249-1254	nodes	_
7-10	1254-1255	,	_
7-11	1256-1263	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[8]
7-12	1264-1267	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[8]
7-13	1268-1276	severity	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[8]
7-14	1277-1280	was	_
7-15	1281-1291	associated	_
7-16	1292-1296	with	_
7-17	1297-1302	lower	_
7-18	1303-1313	clustering	_
7-19	1314-1325	coefficient	_
7-20	1326-1328	in	_
7-21	1329-1332	the	_
7-22	1333-1337	left	_
7-23	1338-1345	caudate	_
7-24	1345-1346	.	_

#Text=Longer AD duration was associated with reduced clustering coefficient in caudate and putamen, and reduced degree in bilateral caudate, but with increased eigenvector centrality in left posterior putamen.
8-1	1347-1353	Longer	_
8-2	1354-1356	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
8-3	1357-1365	duration	_
8-4	1366-1369	was	_
8-5	1370-1380	associated	_
8-6	1381-1385	with	_
8-7	1386-1393	reduced	_
8-8	1394-1404	clustering	_
8-9	1405-1416	coefficient	_
8-10	1417-1419	in	_
8-11	1420-1427	caudate	_
8-12	1428-1431	and	_
8-13	1432-1439	putamen	_
8-14	1439-1440	,	_
8-15	1441-1444	and	_
8-16	1445-1452	reduced	_
8-17	1453-1459	degree	_
8-18	1460-1462	in	_
8-19	1463-1472	bilateral	_
8-20	1473-1480	caudate	_
8-21	1480-1481	,	_
8-22	1482-1485	but	_
8-23	1486-1490	with	_
8-24	1491-1500	increased	_
8-25	1501-1512	eigenvector	_
8-26	1513-1523	centrality	_
8-27	1524-1526	in	_
8-28	1527-1531	left	_
8-29	1532-1541	posterior	_
8-30	1542-1549	putamen	_
8-31	1549-1550	.	_

#Text=Especially changes in global network topology and clustering coefficient in anterior striatum remained strikingly robust after exploratory variations in network weight.
9-1	1551-1561	Especially	_
9-2	1562-1569	changes	_
9-3	1570-1572	in	_
9-4	1573-1579	global	_
9-5	1580-1587	network	_
9-6	1588-1596	topology	_
9-7	1597-1600	and	_
9-8	1601-1611	clustering	_
9-9	1612-1623	coefficient	_
9-10	1624-1626	in	_
9-11	1627-1635	anterior	_
9-12	1636-1644	striatum	_
9-13	1645-1653	remained	_
9-14	1654-1664	strikingly	_
9-15	1665-1671	robust	_
9-16	1672-1677	after	_
9-17	1678-1689	exploratory	_
9-18	1690-1700	variations	_
9-19	1701-1703	in	_
9-20	1704-1711	network	_
9-21	1712-1718	weight	_
9-22	1718-1719	.	_

#Text=Our results show adverse effects of AD on overall network integration and possibly on striatal efficiency, putatively contributing to the increasing behavioral impairments seen in chronically addicted patients.
10-1	1720-1723	Our	_
10-2	1724-1731	results	_
10-3	1732-1736	show	_
10-4	1737-1744	adverse	_
10-5	1745-1752	effects	_
10-6	1753-1755	of	_
10-7	1756-1758	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
10-8	1759-1761	on	_
10-9	1762-1769	overall	_
10-10	1770-1777	network	_
10-11	1778-1789	integration	_
10-12	1790-1793	and	_
10-13	1794-1802	possibly	_
10-14	1803-1805	on	_
10-15	1806-1814	striatal	_
10-16	1815-1825	efficiency	_
10-17	1825-1826	,	_
10-18	1827-1837	putatively	_
10-19	1838-1850	contributing	_
10-20	1851-1853	to	_
10-21	1854-1857	the	_
10-22	1858-1868	increasing	_
10-23	1869-1879	behavioral	_
10-24	1880-1891	impairments	_
10-25	1892-1896	seen	_
10-26	1897-1899	in	_
10-27	1900-1911	chronically	_
10-28	1912-1920	addicted	_
10-29	1921-1929	patients	_
10-30	1929-1930	.	_

#Text=INTRODUCTION
#Text=Alcohol dependence (AD) is a psychiatric disorder, characterized by a maladaptive pattern of alcohol use despite adverse consequences.
11-1	1931-1943	INTRODUCTION	_
11-2	1944-1951	Alcohol	_
11-3	1952-1962	dependence	_
11-4	1963-1964	(	_
11-5	1964-1966	AD	_
11-6	1966-1967	)	_
11-7	1968-1970	is	_
11-8	1971-1972	a	_
11-9	1973-1984	psychiatric	_
11-10	1985-1993	disorder	_
11-11	1993-1994	,	_
11-12	1995-2008	characterized	_
11-13	2009-2011	by	_
11-14	2012-2013	a	_
11-15	2014-2025	maladaptive	_
11-16	2026-2033	pattern	_
11-17	2034-2036	of	_
11-18	2037-2044	alcohol	_
11-19	2045-2048	use	_
11-20	2049-2056	despite	_
11-21	2057-2064	adverse	_
11-22	2065-2077	consequences	_
11-23	2077-2078	.	_

#Text=AD and other substance use disorders are regarded as disorders of the brain, and knowledge on the underlying neurobiology has increased tremendously over the past decades (for reviews see e.g.).
12-1	2079-2081	AD	_
12-2	2082-2085	and	_
12-3	2086-2091	other	_
12-4	2092-2101	substance	_
12-5	2102-2105	use	_
12-6	2106-2115	disorders	_
12-7	2116-2119	are	_
12-8	2120-2128	regarded	_
12-9	2129-2131	as	_
12-10	2132-2141	disorders	_
12-11	2142-2144	of	_
12-12	2145-2148	the	_
12-13	2149-2154	brain	_
12-14	2154-2155	,	_
12-15	2156-2159	and	_
12-16	2160-2169	knowledge	_
12-17	2170-2172	on	_
12-18	2173-2176	the	_
12-19	2177-2187	underlying	_
12-20	2188-2200	neurobiology	_
12-21	2201-2204	has	_
12-22	2205-2214	increased	_
12-23	2215-2227	tremendously	_
12-24	2228-2232	over	_
12-25	2233-2236	the	_
12-26	2237-2241	past	_
12-27	2242-2249	decades	_
12-28	2250-2251	(	_
12-29	2251-2254	for	_
12-30	2255-2262	reviews	_
12-31	2263-2266	see	_
12-32	2267-2270	e.g	_
12-33	2270-2271	.	_
12-34	2271-2272	)	_
12-35	2272-2273	.	_

#Text=In this process, functional neuro-imaging techniques have been widely used to show cue-specific or task-specific changes in local brain activity.
13-1	2274-2276	In	_
13-2	2277-2281	this	_
13-3	2282-2289	process	_
13-4	2289-2290	,	_
13-5	2291-2301	functional	_
13-6	2302-2315	neuro-imaging	_
13-7	2316-2326	techniques	_
13-8	2327-2331	have	_
13-9	2332-2336	been	_
13-10	2337-2343	widely	_
13-11	2344-2348	used	_
13-12	2349-2351	to	_
13-13	2352-2356	show	_
13-14	2357-2369	cue-specific	_
13-15	2370-2372	or	_
13-16	2373-2386	task-specific	_
13-17	2387-2394	changes	_
13-18	2395-2397	in	_
13-19	2398-2403	local	_
13-20	2404-2409	brain	_
13-21	2410-2418	activity	_
13-22	2418-2419	.	_

#Text=These studies have shown a central role of the striatum in addiction, as it is highly involved in reward-related behaviors as well as habit formation, constructs that are pivotal in addictive behaviors.
14-1	2420-2425	These	_
14-2	2426-2433	studies	_
14-3	2434-2438	have	_
14-4	2439-2444	shown	_
14-5	2445-2446	a	_
14-6	2447-2454	central	_
14-7	2455-2459	role	_
14-8	2460-2462	of	_
14-9	2463-2466	the	_
14-10	2467-2475	striatum	_
14-11	2476-2478	in	_
14-12	2479-2488	addiction	_
14-13	2488-2489	,	_
14-14	2490-2492	as	_
14-15	2493-2495	it	_
14-16	2496-2498	is	_
14-17	2499-2505	highly	_
14-18	2506-2514	involved	_
14-19	2515-2517	in	_
14-20	2518-2532	reward-related	_
14-21	2533-2542	behaviors	_
14-22	2543-2545	as	_
14-23	2546-2550	well	_
14-24	2551-2553	as	_
14-25	2554-2559	habit	_
14-26	2560-2569	formation	_
14-27	2569-2570	,	_
14-28	2571-2581	constructs	_
14-29	2582-2586	that	_
14-30	2587-2590	are	_
14-31	2591-2598	pivotal	_
14-32	2599-2601	in	_
14-33	2602-2611	addictive	_
14-34	2612-2621	behaviors	_
14-35	2621-2622	.	_

#Text=A change in striatal involvement over the course of the disorder is also shown, such as increased involvement of posterior putamen during cue-reactivity and instrumental learning in more chronic and more compulsive alcohol dependent subjects.
15-1	2623-2624	A	_
15-2	2625-2631	change	_
15-3	2632-2634	in	_
15-4	2635-2643	striatal	_
15-5	2644-2655	involvement	_
15-6	2656-2660	over	_
15-7	2661-2664	the	_
15-8	2665-2671	course	_
15-9	2672-2674	of	_
15-10	2675-2678	the	_
15-11	2679-2687	disorder	_
15-12	2688-2690	is	_
15-13	2691-2695	also	_
15-14	2696-2701	shown	_
15-15	2701-2702	,	_
15-16	2703-2707	such	_
15-17	2708-2710	as	_
15-18	2711-2720	increased	_
15-19	2721-2732	involvement	_
15-20	2733-2735	of	_
15-21	2736-2745	posterior	_
15-22	2746-2753	putamen	_
15-23	2754-2760	during	_
15-24	2761-2775	cue-reactivity	_
15-25	2776-2779	and	_
15-26	2780-2792	instrumental	_
15-27	2793-2801	learning	_
15-28	2802-2804	in	_
15-29	2805-2809	more	_
15-30	2810-2817	chronic	_
15-31	2818-2821	and	_
15-32	2822-2826	more	_
15-33	2827-2837	compulsive	_
15-34	2838-2845	alcohol	_
15-35	2846-2855	dependent	_
15-36	2856-2864	subjects	_
15-37	2864-2865	.	_

#Text=Still, focusing solely on local functional alterations under task-specific circumstances hampers insights into integrated global brain functioning in non-task related circumstances, which contributes to behavioral variability.
16-1	2866-2871	Still	_
16-2	2871-2872	,	_
16-3	2873-2881	focusing	_
16-4	2882-2888	solely	_
16-5	2889-2891	on	_
16-6	2892-2897	local	_
16-7	2898-2908	functional	_
16-8	2909-2920	alterations	_
16-9	2921-2926	under	_
16-10	2927-2940	task-specific	_
16-11	2941-2954	circumstances	_
16-12	2955-2962	hampers	_
16-13	2963-2971	insights	_
16-14	2972-2976	into	_
16-15	2977-2987	integrated	_
16-16	2988-2994	global	_
16-17	2995-3000	brain	_
16-18	3001-3012	functioning	_
16-19	3013-3015	in	_
16-20	3016-3024	non-task	_
16-21	3025-3032	related	_
16-22	3033-3046	circumstances	_
16-23	3046-3047	,	_
16-24	3048-3053	which	_
16-25	3054-3065	contributes	_
16-26	3066-3068	to	_
16-27	3069-3079	behavioral	_
16-28	3080-3091	variability	_
16-29	3091-3092	.	_

#Text=Moreover, it remains unclear how integration between striatal brain areas into a broader functional network in the brain is related to the duration and severity characteristics of AD.
17-1	3093-3101	Moreover	_
17-2	3101-3102	,	_
17-3	3103-3105	it	_
17-4	3106-3113	remains	_
17-5	3114-3121	unclear	_
17-6	3122-3125	how	_
17-7	3126-3137	integration	_
17-8	3138-3145	between	_
17-9	3146-3154	striatal	_
17-10	3155-3160	brain	_
17-11	3161-3166	areas	_
17-12	3167-3171	into	_
17-13	3172-3173	a	_
17-14	3174-3181	broader	_
17-15	3182-3192	functional	_
17-16	3193-3200	network	_
17-17	3201-3203	in	_
17-18	3204-3207	the	_
17-19	3208-3213	brain	_
17-20	3214-3216	is	_
17-21	3217-3224	related	_
17-22	3225-3227	to	_
17-23	3228-3231	the	_
17-24	3232-3240	duration	_
17-25	3241-3244	and	_
17-26	3245-3253	severity	_
17-27	3254-3269	characteristics	_
17-28	3270-3272	of	_
17-29	3273-3275	AD	_
17-30	3275-3276	.	_

#Text=Recently, in the study of substance use disorders, integration between brain areas has been studied by examining functional connectivity with techniques such as independent or principal component analysis, dynamic causal modeling or a priori defined seed-based connectivity.
18-1	3277-3285	Recently	_
18-2	3285-3286	,	_
18-3	3287-3289	in	_
18-4	3290-3293	the	_
18-5	3294-3299	study	_
18-6	3300-3302	of	_
18-7	3303-3312	substance	_
18-8	3313-3316	use	_
18-9	3317-3326	disorders	_
18-10	3326-3327	,	_
18-11	3328-3339	integration	_
18-12	3340-3347	between	_
18-13	3348-3353	brain	_
18-14	3354-3359	areas	_
18-15	3360-3363	has	_
18-16	3364-3368	been	_
18-17	3369-3376	studied	_
18-18	3377-3379	by	_
18-19	3380-3389	examining	_
18-20	3390-3400	functional	_
18-21	3401-3413	connectivity	_
18-22	3414-3418	with	_
18-23	3419-3429	techniques	_
18-24	3430-3434	such	_
18-25	3435-3437	as	_
18-26	3438-3449	independent	_
18-27	3450-3452	or	_
18-28	3453-3462	principal	_
18-29	3463-3472	component	_
18-30	3473-3481	analysis	_
18-31	3481-3482	,	_
18-32	3483-3490	dynamic	_
18-33	3491-3497	causal	_
18-34	3498-3506	modeling	_
18-35	3507-3509	or	_
18-36	3510-3511	a	_
18-37	3512-3518	priori	_
18-38	3519-3526	defined	_
18-39	3527-3537	seed-based	_
18-40	3538-3550	connectivity	_
18-41	3550-3551	.	_

#Text=With these approaches, particular behaviors have been associated with specific brain regions or specialized sub-networks of the brain.
19-1	3552-3556	With	_
19-2	3557-3562	these	_
19-3	3563-3573	approaches	_
19-4	3573-3574	,	_
19-5	3575-3585	particular	_
19-6	3586-3595	behaviors	_
19-7	3596-3600	have	_
19-8	3601-3605	been	_
19-9	3606-3616	associated	_
19-10	3617-3621	with	_
19-11	3622-3630	specific	_
19-12	3631-3636	brain	_
19-13	3637-3644	regions	_
19-14	3645-3647	or	_
19-15	3648-3659	specialized	_
19-16	3660-3672	sub-networks	_
19-17	3673-3675	of	_
19-18	3676-3679	the	_
19-19	3680-3685	brain	_
19-20	3685-3686	.	_

#Text=However, the brain is increasingly considered a connectome, representing a complex network of highly intercommunicating neural components.
20-1	3687-3694	However	_
20-2	3694-3695	,	_
20-3	3696-3699	the	_
20-4	3700-3705	brain	_
20-5	3706-3708	is	_
20-6	3709-3721	increasingly	_
20-7	3722-3732	considered	_
20-8	3733-3734	a	_
20-9	3735-3745	connectome	_
20-10	3745-3746	,	_
20-11	3747-3759	representing	_
20-12	3760-3761	a	_
20-13	3762-3769	complex	_
20-14	3770-3777	network	_
20-15	3778-3780	of	_
20-16	3781-3787	highly	_
20-17	3788-3806	intercommunicating	_
20-18	3807-3813	neural	_
20-19	3814-3824	components	_
20-20	3824-3825	.	_

#Text=Knowledge about the connectome in patients with a substance use disorder is scarce and to our knowledge absent in patients with AD.
21-1	3826-3835	Knowledge	_
21-2	3836-3841	about	_
21-3	3842-3845	the	_
21-4	3846-3856	connectome	_
21-5	3857-3859	in	_
21-6	3860-3868	patients	_
21-7	3869-3873	with	_
21-8	3874-3875	a	_
21-9	3876-3885	substance	_
21-10	3886-3889	use	_
21-11	3890-3898	disorder	_
21-12	3899-3901	is	_
21-13	3902-3908	scarce	_
21-14	3909-3912	and	_
21-15	3913-3915	to	_
21-16	3916-3919	our	_
21-17	3920-3929	knowledge	_
21-18	3930-3936	absent	_
21-19	3937-3939	in	_
21-20	3940-3948	patients	_
21-21	3949-3953	with	_
21-22	3954-3956	AD	_
21-23	3956-3957	.	_

#Text=Considering the high prevalence of AD and the known neurotoxic effects of alcohol, it is essential to further unravel complex brain network abnormalities in AD patients.
22-1	3958-3969	Considering	_
22-2	3970-3973	the	_
22-3	3974-3978	high	_
22-4	3979-3989	prevalence	_
22-5	3990-3992	of	_
22-6	3993-3995	AD	_
22-7	3996-3999	and	_
22-8	4000-4003	the	_
22-9	4004-4009	known	_
22-10	4010-4020	neurotoxic	_
22-11	4021-4028	effects	_
22-12	4029-4031	of	_
22-13	4032-4039	alcohol	_
22-14	4039-4040	,	_
22-15	4041-4043	it	_
22-16	4044-4046	is	_
22-17	4047-4056	essential	_
22-18	4057-4059	to	_
22-19	4060-4067	further	_
22-20	4068-4075	unravel	_
22-21	4076-4083	complex	_
22-22	4084-4089	brain	_
22-23	4090-4097	network	_
22-24	4098-4111	abnormalities	_
22-25	4112-4114	in	_
22-26	4115-4117	AD	_
22-27	4118-4126	patients	_
22-28	4126-4127	.	_

#Text=In the current study, we fulfill this aim by considering the brain of alcohol dependent patients as a mathematical graph, with nodes as individual units, such as individual brain areas based on an anatomical atlas, and links or edges representing the connections between them.
23-1	4128-4130	In	_
23-2	4131-4134	the	_
23-3	4135-4142	current	_
23-4	4143-4148	study	_
23-5	4148-4149	,	_
23-6	4150-4152	we	_
23-7	4153-4160	fulfill	_
23-8	4161-4165	this	_
23-9	4166-4169	aim	_
23-10	4170-4172	by	_
23-11	4173-4184	considering	_
23-12	4185-4188	the	_
23-13	4189-4194	brain	_
23-14	4195-4197	of	_
23-15	4198-4205	alcohol	_
23-16	4206-4215	dependent	_
23-17	4216-4224	patients	_
23-18	4225-4227	as	_
23-19	4228-4229	a	_
23-20	4230-4242	mathematical	_
23-21	4243-4248	graph	_
23-22	4248-4249	,	_
23-23	4250-4254	with	_
23-24	4255-4260	nodes	_
23-25	4261-4263	as	_
23-26	4264-4274	individual	_
23-27	4275-4280	units	_
23-28	4280-4281	,	_
23-29	4282-4286	such	_
23-30	4287-4289	as	_
23-31	4290-4300	individual	_
23-32	4301-4306	brain	_
23-33	4307-4312	areas	_
23-34	4313-4318	based	_
23-35	4319-4321	on	_
23-36	4322-4324	an	_
23-37	4325-4335	anatomical	_
23-38	4336-4341	atlas	_
23-39	4341-4342	,	_
23-40	4343-4346	and	_
23-41	4347-4352	links	_
23-42	4353-4355	or	_
23-43	4356-4361	edges	_
23-44	4362-4374	representing	_
23-45	4375-4378	the	_
23-46	4379-4390	connections	_
23-47	4391-4398	between	_
23-48	4399-4403	them	_
23-49	4403-4404	.	_

#Text=Graph theory is an elegantly simple but wellvetted branch of science for the analysis of complex systems and is valuable for application to the brain network.
24-1	4405-4410	Graph	_
24-2	4411-4417	theory	_
24-3	4418-4420	is	_
24-4	4421-4423	an	_
24-5	4424-4433	elegantly	_
24-6	4434-4440	simple	_
24-7	4441-4444	but	_
24-8	4445-4455	wellvetted	_
24-9	4456-4462	branch	_
24-10	4463-4465	of	_
24-11	4466-4473	science	_
24-12	4474-4477	for	_
24-13	4478-4481	the	_
24-14	4482-4490	analysis	_
24-15	4491-4493	of	_
24-16	4494-4501	complex	_
24-17	4502-4509	systems	_
24-18	4510-4513	and	_
24-19	4514-4516	is	_
24-20	4517-4525	valuable	_
24-21	4526-4529	for	_
24-22	4530-4541	application	_
24-23	4542-4544	to	_
24-24	4545-4548	the	_
24-25	4549-4554	brain	_
24-26	4555-4562	network	_
24-27	4562-4563	.	_

#Text=It offers tools for the study of the complexity of the brain by uncovering system-level characteristics, and provides information on both global integration and local specialization in strongly connected brain areas.
25-1	4564-4566	It	_
25-2	4567-4573	offers	_
25-3	4574-4579	tools	_
25-4	4580-4583	for	_
25-5	4584-4587	the	_
25-6	4588-4593	study	_
25-7	4594-4596	of	_
25-8	4597-4600	the	_
25-9	4601-4611	complexity	_
25-10	4612-4614	of	_
25-11	4615-4618	the	_
25-12	4619-4624	brain	_
25-13	4625-4627	by	_
25-14	4628-4638	uncovering	_
25-15	4639-4651	system-level	_
25-16	4652-4667	characteristics	_
25-17	4667-4668	,	_
25-18	4669-4672	and	_
25-19	4673-4681	provides	_
25-20	4682-4693	information	_
25-21	4694-4696	on	_
25-22	4697-4701	both	_
25-23	4702-4708	global	_
25-24	4709-4720	integration	_
25-25	4721-4724	and	_
25-26	4725-4730	local	_
25-27	4731-4745	specialization	_
25-28	4746-4748	in	_
25-29	4749-4757	strongly	_
25-30	4758-4767	connected	_
25-31	4768-4773	brain	_
25-32	4774-4779	areas	_
25-33	4779-4780	.	_

#Text=Graph theory analysis is typically applied to the brain network at rest, for example as measured by resting-state functional magnetic resonance imaging (RS-fMRI), which does not merely involve specific task-related functions, but provides a comprehensive view of brain functioning by identifying a major whole-brain network that contributes to behavioral variability.
26-1	4781-4786	Graph	_
26-2	4787-4793	theory	_
26-3	4794-4802	analysis	_
26-4	4803-4805	is	_
26-5	4806-4815	typically	_
26-6	4816-4823	applied	_
26-7	4824-4826	to	_
26-8	4827-4830	the	_
26-9	4831-4836	brain	_
26-10	4837-4844	network	_
26-11	4845-4847	at	_
26-12	4848-4852	rest	_
26-13	4852-4853	,	_
26-14	4854-4857	for	_
26-15	4858-4865	example	_
26-16	4866-4868	as	_
26-17	4869-4877	measured	_
26-18	4878-4880	by	_
26-19	4881-4894	resting-state	_
26-20	4895-4905	functional	_
26-21	4906-4914	magnetic	_
26-22	4915-4924	resonance	_
26-23	4925-4932	imaging	_
26-24	4933-4934	(	_
26-25	4934-4941	RS-fMRI	_
26-26	4941-4942	)	_
26-27	4942-4943	,	_
26-28	4944-4949	which	_
26-29	4950-4954	does	_
26-30	4955-4958	not	_
26-31	4959-4965	merely	_
26-32	4966-4973	involve	_
26-33	4974-4982	specific	_
26-34	4983-4995	task-related	_
26-35	4996-5005	functions	_
26-36	5005-5006	,	_
26-37	5007-5010	but	_
26-38	5011-5019	provides	_
26-39	5020-5021	a	_
26-40	5022-5035	comprehensive	_
26-41	5036-5040	view	_
26-42	5041-5043	of	_
26-43	5044-5049	brain	_
26-44	5050-5061	functioning	_
26-45	5062-5064	by	_
26-46	5065-5076	identifying	_
26-47	5077-5078	a	_
26-48	5079-5084	major	_
26-49	5085-5096	whole-brain	_
26-50	5097-5104	network	_
26-51	5105-5109	that	_
26-52	5110-5121	contributes	_
26-53	5122-5124	to	_
26-54	5125-5135	behavioral	_
26-55	5136-5147	variability	_
26-56	5147-5148	.	_

#Text=In general, RS-fMRI is a reliable and valid technique that shows proficient testretest reliability, meaningfully correlates with the (neuronal) EEG-signal, and is associated with cognitive functioning both in health and disease.
27-1	5149-5151	In	_
27-2	5152-5159	general	_
27-3	5159-5160	,	_
27-4	5161-5168	RS-fMRI	_
27-5	5169-5171	is	_
27-6	5172-5173	a	_
27-7	5174-5182	reliable	_
27-8	5183-5186	and	_
27-9	5187-5192	valid	_
27-10	5193-5202	technique	_
27-11	5203-5207	that	_
27-12	5208-5213	shows	_
27-13	5214-5224	proficient	_
27-14	5225-5235	testretest	_
27-15	5236-5247	reliability	_
27-16	5247-5248	,	_
27-17	5249-5261	meaningfully	_
27-18	5262-5272	correlates	_
27-19	5273-5277	with	_
27-20	5278-5281	the	_
27-21	5282-5283	(	_
27-22	5283-5291	neuronal	_
27-23	5291-5292	)	_
27-24	5293-5303	EEG-signal	_
27-25	5303-5304	,	_
27-26	5305-5308	and	_
27-27	5309-5311	is	_
27-28	5312-5322	associated	_
27-29	5323-5327	with	_
27-30	5328-5337	cognitive	_
27-31	5338-5349	functioning	_
27-32	5350-5354	both	_
27-33	5355-5357	in	_
27-34	5358-5364	health	_
27-35	5365-5368	and	_
27-36	5369-5376	disease	_
27-37	5376-5377	.	_

#Text=The application of graph theory on RS-fMRI has been used in numerous neurological disorders to demonstrate an altered resting-state brain network with reduced integrity and reduced efficiency of disease-related networks (e.g.).
28-1	5378-5381	The	_
28-2	5382-5393	application	_
28-3	5394-5396	of	_
28-4	5397-5402	graph	_
28-5	5403-5409	theory	_
28-6	5410-5412	on	_
28-7	5413-5420	RS-fMRI	_
28-8	5421-5424	has	_
28-9	5425-5429	been	_
28-10	5430-5434	used	_
28-11	5435-5437	in	_
28-12	5438-5446	numerous	_
28-13	5447-5459	neurological	_
28-14	5460-5469	disorders	_
28-15	5470-5472	to	_
28-16	5473-5484	demonstrate	_
28-17	5485-5487	an	_
28-18	5488-5495	altered	_
28-19	5496-5509	resting-state	_
28-20	5510-5515	brain	_
28-21	5516-5523	network	_
28-22	5524-5528	with	_
28-23	5529-5536	reduced	_
28-24	5537-5546	integrity	_
28-25	5547-5550	and	_
28-26	5551-5558	reduced	_
28-27	5559-5569	efficiency	_
28-28	5570-5572	of	_
28-29	5573-5588	disease-related	_
28-30	5589-5597	networks	_
28-31	5598-5599	(	_
28-32	5599-5602	e.g	_
28-33	5602-5603	.	_
28-34	5603-5604	)	_
28-35	5604-5605	.	_

#Text=The graph theoretical approach is fairly new within the field of psychiatry, but it rapidly gains attention.
29-1	5606-5609	The	_
29-2	5610-5615	graph	_
29-3	5616-5627	theoretical	_
29-4	5628-5636	approach	_
29-5	5637-5639	is	_
29-6	5640-5646	fairly	_
29-7	5647-5650	new	_
29-8	5651-5657	within	_
29-9	5658-5661	the	_
29-10	5662-5667	field	_
29-11	5668-5670	of	_
29-12	5671-5681	psychiatry	_
29-13	5681-5682	,	_
29-14	5683-5686	but	_
29-15	5687-5689	it	_
29-16	5690-5697	rapidly	_
29-17	5698-5703	gains	_
29-18	5704-5713	attention	_
29-19	5713-5714	.	_

#Text=With regard to addictive disorders, network disruptions such as reduced efficiency were reported in e.g. poly-substance users, gambling, and internet gaming disorder.
30-1	5715-5719	With	_
30-2	5720-5726	regard	_
30-3	5727-5729	to	_
30-4	5730-5739	addictive	_
30-5	5740-5749	disorders	_
30-6	5749-5750	,	_
30-7	5751-5758	network	_
30-8	5759-5770	disruptions	_
30-9	5771-5775	such	_
30-10	5776-5778	as	_
30-11	5779-5786	reduced	_
30-12	5787-5797	efficiency	_
30-13	5798-5802	were	_
30-14	5803-5811	reported	_
30-15	5812-5814	in	_
30-16	5815-5818	e.g	_
30-17	5818-5819	.	_
30-18	5820-5834	poly-substance	_
30-19	5835-5840	users	_
30-20	5840-5841	,	_
30-21	5842-5850	gambling	_
30-22	5850-5851	,	_
30-23	5852-5855	and	_
30-24	5856-5864	internet	_
30-25	5865-5871	gaming	_
30-26	5872-5880	disorder	_
30-27	5880-5881	.	_

#Text=However, to our knowledge graph theoretical approaches for intrinsic functional network analysis (RS-fMRI data) have hitherto not been applied in humans with AD.
31-1	5882-5889	However	_
31-2	5889-5890	,	_
31-3	5891-5893	to	_
31-4	5894-5897	our	_
31-5	5898-5907	knowledge	_
31-6	5908-5913	graph	_
31-7	5914-5925	theoretical	_
31-8	5926-5936	approaches	_
31-9	5937-5940	for	_
31-10	5941-5950	intrinsic	_
31-11	5951-5961	functional	_
31-12	5962-5969	network	_
31-13	5970-5978	analysis	_
31-14	5979-5980	(	_
31-15	5980-5987	RS-fMRI	_
31-16	5988-5992	data	_
31-17	5992-5993	)	_
31-18	5994-5998	have	_
31-19	5999-6007	hitherto	_
31-20	6008-6011	not	_
31-21	6012-6016	been	_
31-22	6017-6024	applied	_
31-23	6025-6027	in	_
31-24	6028-6034	humans	_
31-25	6035-6039	with	_
31-26	6040-6042	AD	_
31-27	6042-6043	.	_

#Text=Therefore, we examined the resting-state complex network in AD patients compared with healthy controls (HCs) and associated with illness duration and severity.
32-1	6044-6053	Therefore	_
32-2	6053-6054	,	_
32-3	6055-6057	we	_
32-4	6058-6066	examined	_
32-5	6067-6070	the	_
32-6	6071-6084	resting-state	_
32-7	6085-6092	complex	_
32-8	6093-6100	network	_
32-9	6101-6103	in	_
32-10	6104-6106	AD	_
32-11	6107-6115	patients	_
32-12	6116-6124	compared	_
32-13	6125-6129	with	_
32-14	6130-6137	healthy	_
32-15	6138-6146	controls	_
32-16	6147-6148	(	_
32-17	6148-6151	HCs	_
32-18	6151-6152	)	_
32-19	6153-6156	and	_
32-20	6157-6167	associated	_
32-21	6168-6172	with	_
32-22	6173-6180	illness	_
32-23	6181-6189	duration	_
32-24	6190-6193	and	_
32-25	6194-6202	severity	_
32-26	6202-6203	.	_

#Text=In addition to studying the global brain network, we specifically considered striatal foci of a priori interest to examine putative network-related abnormalities in these addiction hubs.
33-1	6204-6206	In	_
33-2	6207-6215	addition	_
33-3	6216-6218	to	_
33-4	6219-6227	studying	_
33-5	6228-6231	the	_
33-6	6232-6238	global	_
33-7	6239-6244	brain	_
33-8	6245-6252	network	_
33-9	6252-6253	,	_
33-10	6254-6256	we	_
33-11	6257-6269	specifically	_
33-12	6270-6280	considered	_
33-13	6281-6289	striatal	_
33-14	6290-6294	foci	_
33-15	6295-6297	of	_
33-16	6298-6299	a	_
33-17	6300-6306	priori	_
33-18	6307-6315	interest	_
33-19	6316-6318	to	_
33-20	6319-6326	examine	_
33-21	6327-6335	putative	_
33-22	6336-6351	network-related	_
33-23	6352-6365	abnormalities	_
33-24	6366-6368	in	_
33-25	6369-6374	these	_
33-26	6375-6384	addiction	_
33-27	6385-6389	hubs	_
33-28	6389-6390	.	_

#Text=We hypothesize distinct brain network topology in AD compared with HCs.
34-1	6391-6393	We	_
34-2	6394-6405	hypothesize	_
34-3	6406-6414	distinct	_
34-4	6415-6420	brain	_
34-5	6421-6428	network	_
34-6	6429-6437	topology	_
34-7	6438-6440	in	_
34-8	6441-6443	AD	_
34-9	6444-6452	compared	_
34-10	6453-6457	with	_
34-11	6458-6461	HCs	_
34-12	6461-6462	.	_

#Text=More importantly, we hypothesize resting-state topological properties to be impaired as a function of AD duration and severity.
35-1	6463-6467	More	_
35-2	6468-6479	importantly	_
35-3	6479-6480	,	_
35-4	6481-6483	we	_
35-5	6484-6495	hypothesize	_
35-6	6496-6509	resting-state	_
35-7	6510-6521	topological	_
35-8	6522-6532	properties	_
35-9	6533-6535	to	_
35-10	6536-6538	be	_
35-11	6539-6547	impaired	_
35-12	6548-6550	as	_
35-13	6551-6552	a	_
35-14	6553-6561	function	_
35-15	6562-6564	of	_
35-16	6565-6567	AD	_
35-17	6568-6576	duration	_
35-18	6577-6580	and	_
35-19	6581-6589	severity	_
35-20	6589-6590	.	_

#Text=We expect to see a shift in the role of striatal areas within the whole-brain resting-state network, specifically, a decrease in involvement of striatal areas implicated in goal-directed behavior (e.g. caudate nucleus), and an increase in the prominence of brain areas implicated in habitual drug use (posterior putamen) with longer lasting and/or more severe AD.
36-1	6591-6593	We	_
36-2	6594-6600	expect	_
36-3	6601-6603	to	_
36-4	6604-6607	see	_
36-5	6608-6609	a	_
36-6	6610-6615	shift	_
36-7	6616-6618	in	_
36-8	6619-6622	the	_
36-9	6623-6627	role	_
36-10	6628-6630	of	_
36-11	6631-6639	striatal	_
36-12	6640-6645	areas	_
36-13	6646-6652	within	_
36-14	6653-6656	the	_
36-15	6657-6668	whole-brain	_
36-16	6669-6682	resting-state	_
36-17	6683-6690	network	_
36-18	6690-6691	,	_
36-19	6692-6704	specifically	_
36-20	6704-6705	,	_
36-21	6706-6707	a	_
36-22	6708-6716	decrease	_
36-23	6717-6719	in	_
36-24	6720-6731	involvement	_
36-25	6732-6734	of	_
36-26	6735-6743	striatal	_
36-27	6744-6749	areas	_
36-28	6750-6760	implicated	_
36-29	6761-6763	in	_
36-30	6764-6777	goal-directed	_
36-31	6778-6786	behavior	_
36-32	6787-6788	(	_
36-33	6788-6791	e.g	_
36-34	6791-6792	.	_
36-35	6793-6800	caudate	_
36-36	6801-6808	nucleus	_
36-37	6808-6809	)	_
36-38	6809-6810	,	_
36-39	6811-6814	and	_
36-40	6815-6817	an	_
36-41	6818-6826	increase	_
36-42	6827-6829	in	_
36-43	6830-6833	the	_
36-44	6834-6844	prominence	_
36-45	6845-6847	of	_
36-46	6848-6853	brain	_
36-47	6854-6859	areas	_
36-48	6860-6870	implicated	_
36-49	6871-6873	in	_
36-50	6874-6882	habitual	_
36-51	6883-6887	drug	_
36-52	6888-6891	use	_
36-53	6892-6893	(	_
36-54	6893-6902	posterior	_
36-55	6903-6910	putamen	_
36-56	6910-6911	)	_
36-57	6912-6916	with	_
36-58	6917-6923	longer	_
36-59	6924-6931	lasting	_
36-60	6932-6935	and	_
36-61	6935-6936	/	_
36-62	6936-6938	or	_
36-63	6939-6943	more	_
36-64	6944-6950	severe	_
36-65	6951-6953	AD	_
36-66	6953-6954	.	_

#Text=MATERIALS AND METHODS
#Text=Participants
#Text=A total of 43 patients with a current (<6 months) DSM-IV-TR diagnosis of AD were recruited from addiction treatment centers in Amsterdam and from the observational multi-center Netherlands Study of Depression and Anxiety (NESDA).
37-1	6955-6964	MATERIALS	http://www.case.edu/ProvCaRe/provcare#StudyMethod[9]
37-2	6965-6968	AND	http://www.case.edu/ProvCaRe/provcare#StudyMethod[9]
37-3	6969-6976	METHODS	http://www.case.edu/ProvCaRe/provcare#StudyMethod[9]
37-4	6977-6989	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
37-5	6990-6991	A	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-6	6992-6997	total	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-7	6998-7000	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-8	7001-7003	43	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-9	7004-7012	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[12]
37-10	7013-7017	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[12]
37-11	7018-7019	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[12]
37-12	7020-7027	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[12]
37-13	7028-7029	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[12]
37-14	7029-7030	<	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[12]
37-15	7030-7031	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[12]
37-16	7032-7038	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[12]
37-17	7038-7039	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[12]
37-18	7040-7049	DSM-IV-TR	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[12]
37-19	7050-7059	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[12]
37-20	7060-7062	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[12]
37-21	7063-7065	AD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[12]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[13]
37-22	7066-7070	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-23	7071-7080	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-24	7081-7085	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-25	7086-7095	addiction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-26	7096-7105	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-27	7106-7113	centers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-28	7114-7116	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-29	7117-7126	Amsterdam	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-30	7127-7130	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-31	7131-7135	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-32	7136-7139	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-33	7140-7153	observational	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-34	7154-7166	multi-center	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-35	7167-7178	Netherlands	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-36	7179-7184	Study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-37	7185-7187	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-38	7188-7198	Depression	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-39	7199-7202	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-40	7203-7210	Anxiety	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-41	7211-7212	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-42	7212-7217	NESDA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-43	7217-7218	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-44	7218-7219	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]

#Text=NESDA is a large Dutch cohort-study, providing a variety of clinical and demographic information on participants from the general population, primary care and community mental health services, thus allowing for the selection of participants with a current AD diagnosis from a large sample.
38-1	7220-7225	NESDA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-2	7226-7228	is	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-3	7229-7230	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-4	7231-7236	large	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-5	7237-7242	Dutch	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-6	7243-7255	cohort-study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-7	7255-7256	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-8	7257-7266	providing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-9	7267-7268	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-10	7269-7276	variety	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-11	7277-7279	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-12	7280-7288	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-13	7289-7292	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-14	7293-7304	demographic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-15	7305-7316	information	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-16	7317-7319	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-17	7320-7332	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-18	7333-7337	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-19	7338-7341	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-20	7342-7349	general	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-21	7350-7360	population	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-22	7360-7361	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-23	7362-7369	primary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-24	7370-7374	care	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-25	7375-7378	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-26	7379-7388	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-27	7389-7395	mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-28	7396-7402	health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-29	7403-7411	services	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-30	7411-7412	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-31	7413-7417	thus	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-32	7418-7426	allowing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-33	7427-7430	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-34	7431-7434	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-35	7435-7444	selection	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-36	7445-7447	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-37	7448-7460	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[15]
38-38	7461-7465	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[15]
38-39	7466-7467	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[15]
38-40	7468-7475	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[15]
38-41	7476-7478	AD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[15]
38-42	7479-7488	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[15]
38-43	7489-7493	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-44	7494-7495	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-45	7496-7501	large	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-46	7502-7508	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
38-47	7508-7509	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]

#Text=In addition, 29 age, gender and education matched HCs without any lifetime psychiatric diagnoses (DSM-IV, axis I) were selected from the NESDA cohort and underwent a similar scanning protocol as the AD patients.
39-1	7510-7512	In	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
39-2	7513-7521	addition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
39-3	7521-7522	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
39-4	7523-7525	29	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
39-5	7526-7529	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
39-6	7529-7530	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
39-7	7531-7537	gender	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
39-8	7538-7541	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
39-9	7542-7551	education	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
39-10	7552-7559	matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
39-11	7560-7563	HCs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[17]
39-12	7564-7571	without	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[17]
39-13	7572-7575	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[17]
39-14	7576-7584	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[17]
39-15	7585-7596	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[17]
39-16	7597-7606	diagnoses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[17]
39-17	7607-7608	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[17]
39-18	7608-7614	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[17]
39-19	7614-7615	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[17]
39-20	7616-7620	axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[17]
39-21	7621-7622	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[17]
39-22	7622-7623	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[17]
39-23	7624-7628	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
39-24	7629-7637	selected	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
39-25	7638-7642	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
39-26	7643-7646	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
39-27	7647-7652	NESDA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
39-28	7653-7659	cohort	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
39-29	7660-7663	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
39-30	7664-7673	underwent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
39-31	7674-7675	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
39-32	7676-7683	similar	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
39-33	7684-7692	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
39-34	7693-7701	protocol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
39-35	7702-7704	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
39-36	7705-7708	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
39-37	7709-7711	AD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[18]
39-38	7712-7720	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[18]
39-39	7720-7721	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]

#Text=All participants were asked to abstain from alcohol at least 24 hours prior to the assessments.
40-1	7722-7725	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
40-2	7726-7738	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
40-3	7739-7743	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
40-4	7744-7749	asked	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
40-5	7750-7752	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
40-6	7753-7760	abstain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
40-7	7761-7765	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
40-8	7766-7773	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
40-9	7774-7776	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
40-10	7777-7782	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
40-11	7783-7785	24	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
40-12	7786-7791	hours	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
40-13	7792-7797	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
40-14	7798-7800	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
40-15	7801-7804	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
40-16	7805-7816	assessments	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
40-17	7816-7817	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]

#Text=At the day of scanning, a urine test was performed to check for unreported use of benzodiazepines and drugs of abuse, and all participants had a confirmed breath alcohol level of 0.00% (Alcoscan Daisy-AL7000).
41-1	7818-7820	At	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-2	7821-7824	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-3	7825-7828	day	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-4	7829-7831	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-5	7832-7840	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-6	7840-7841	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-7	7842-7843	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-8	7844-7849	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-9	7850-7854	test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-10	7855-7858	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-11	7859-7868	performed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-12	7869-7871	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-13	7872-7877	check	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-14	7878-7881	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-15	7882-7892	unreported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-16	7893-7896	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-17	7897-7899	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-18	7900-7915	benzodiazepines	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-19	7916-7919	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-20	7920-7925	drugs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-21	7926-7928	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-22	7929-7934	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-23	7934-7935	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-24	7936-7939	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-25	7940-7943	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-26	7944-7956	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-27	7957-7960	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-28	7961-7962	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-29	7963-7972	confirmed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-30	7973-7979	breath	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-31	7980-7987	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-32	7988-7993	level	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-33	7994-7996	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-34	7997-8002	0.00%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-35	8003-8004	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-36	8004-8012	Alcoscan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-37	8013-8025	Daisy-AL7000	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-38	8025-8026	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
41-39	8026-8027	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]

#Text=Mean alcohol abstinence duration in AD patients was 2 weeks (Table 1), with a minimum of 24 hours.
42-1	8028-8032	Mean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
42-2	8033-8040	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
42-3	8041-8051	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
42-4	8052-8060	duration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
42-5	8061-8063	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
42-6	8064-8066	AD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[22]
42-7	8067-8075	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[22]
42-8	8076-8079	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
42-9	8080-8081	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
42-10	8082-8087	weeks	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
42-11	8088-8089	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
42-12	8089-8094	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
42-13	8095-8096	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
42-14	8096-8097	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
42-15	8097-8098	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
42-16	8099-8103	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
42-17	8104-8105	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
42-18	8106-8113	minimum	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
42-19	8114-8116	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
42-20	8117-8119	24	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
42-21	8120-8125	hours	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
42-22	8125-8126	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]

#Text=All AD patients were withdrawal-free.
43-1	8127-8130	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
43-2	8131-8133	AD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[24]
43-3	8134-8142	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[24]
43-4	8143-8147	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
43-5	8148-8163	withdrawal-free	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
43-6	8163-8164	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]

#Text=For further details on clinical screening and assessment, see Supporting Information.
44-1	8165-8168	For	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
44-2	8169-8176	further	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
44-3	8177-8184	details	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
44-4	8185-8187	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
44-5	8188-8196	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
44-6	8197-8206	screening	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
44-7	8207-8210	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
44-8	8211-8221	assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
44-9	8221-8222	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
44-10	8223-8226	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
44-11	8227-8237	Supporting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
44-12	8238-8249	Information	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
44-13	8249-8250	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]

#Text=Valid and complete resting state as well as structural MRI data were available for 31 AD patients and 21 HC participants.
45-1	8251-8256	Valid	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
45-2	8257-8260	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
45-3	8261-8269	complete	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
45-4	8270-8277	resting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[27]
45-5	8278-8283	state	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[27]
45-6	8284-8286	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
45-7	8287-8291	well	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
45-8	8292-8294	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
45-9	8295-8305	structural	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[28]
45-10	8306-8309	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[28]
45-11	8310-8314	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
45-12	8315-8319	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
45-13	8320-8329	available	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
45-14	8330-8333	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
45-15	8334-8336	31	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
45-16	8337-8339	AD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[29]
45-17	8340-8348	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[29]
45-18	8349-8352	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
45-19	8353-8355	21	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
45-20	8356-8358	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[30]
45-21	8359-8371	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[30]
45-22	8371-8372	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]

#Text=Of this sample, data of eight participants (seven AD and one HC) were excluded from analysis for the following reasons: one HC due to previously unreported concussion and coma during early adulthood; one AD patient due to motion greater than 3 mm during scanning; and six AD patients due to positive urine testing for benzodiazepines on the scanning day.
46-1	8373-8375	Of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-2	8376-8380	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-3	8381-8387	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-4	8387-8388	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-5	8389-8393	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-6	8394-8396	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-7	8397-8402	eight	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-8	8403-8415	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-9	8416-8417	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-10	8417-8422	seven	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-11	8423-8425	AD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[32]
46-12	8426-8429	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-13	8430-8433	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-14	8434-8436	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[33]
46-15	8436-8437	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-16	8438-8442	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-17	8443-8451	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-18	8452-8456	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-19	8457-8465	analysis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-20	8466-8469	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-21	8470-8473	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-22	8474-8483	following	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-23	8484-8491	reasons	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-24	8491-8492	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-25	8493-8496	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-26	8497-8499	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[34]
46-27	8500-8503	due	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-28	8504-8506	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-29	8507-8517	previously	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-30	8518-8528	unreported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-31	8529-8539	concussion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-32	8540-8543	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-33	8544-8548	coma	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-34	8549-8555	during	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-35	8556-8561	early	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-36	8562-8571	adulthood	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-37	8571-8572	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-38	8573-8576	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-39	8577-8579	AD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[35]
46-40	8580-8587	patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[35]
46-41	8588-8591	due	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-42	8592-8594	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-43	8595-8601	motion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-44	8602-8609	greater	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-45	8610-8614	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-46	8615-8616	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-47	8617-8619	mm	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-48	8620-8626	during	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-49	8627-8635	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-50	8635-8636	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-51	8637-8640	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-52	8641-8644	six	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-53	8645-8647	AD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[36]
46-54	8648-8656	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[36]
46-55	8657-8660	due	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-56	8661-8663	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-57	8664-8672	positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-58	8673-8678	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-59	8679-8686	testing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-60	8687-8690	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-61	8691-8706	benzodiazepines	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-62	8707-8709	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-63	8710-8713	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-64	8714-8722	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-65	8723-8726	day	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
46-66	8726-8727	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]

#Text=As a result, 24 AD patients and 20 HCs were included in the final analyses.
47-1	8728-8730	As	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
47-2	8731-8732	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
47-3	8733-8739	result	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
47-4	8739-8740	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
47-5	8741-8743	24	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
47-6	8744-8746	AD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[38]
47-7	8747-8755	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[38]
47-8	8756-8759	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
47-9	8760-8762	20	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
47-10	8763-8766	HCs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[39]
47-11	8767-8771	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
47-12	8772-8780	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
47-13	8781-8783	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
47-14	8784-8787	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
47-15	8788-8793	final	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
47-16	8794-8802	analyses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
47-17	8802-8803	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]

#Text=The included and excluded groups did not differ in demographic and clinical characteristics, suggesting the absence of selection bias due to the exclusion criteria.
48-1	8804-8807	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
48-2	8808-8816	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
48-3	8817-8820	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
48-4	8821-8829	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
48-5	8830-8836	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
48-6	8837-8840	did	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
48-7	8841-8844	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
48-8	8845-8851	differ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
48-9	8852-8854	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
48-10	8855-8866	demographic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
48-11	8867-8870	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
48-12	8871-8879	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
48-13	8880-8895	characteristics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
48-14	8895-8896	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
48-15	8897-8907	suggesting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
48-16	8908-8911	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
48-17	8912-8919	absence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
48-18	8920-8922	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
48-19	8923-8932	selection	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
48-20	8933-8937	bias	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
48-21	8938-8941	due	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
48-22	8942-8944	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
48-23	8945-8948	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
48-24	8949-8958	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
48-25	8959-8967	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
48-26	8967-8968	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]

#Text=The VU University Medical Center Ethical Review Board approved this study, and written informed consent according to the Declaration of Helsinki was obtained from all participants prior to the study.
49-1	8969-8972	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-2	8973-8975	VU	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-3	8976-8986	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-4	8987-8994	Medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-5	8995-9001	Center	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-6	9002-9009	Ethical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-7	9010-9016	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-8	9017-9022	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-9	9023-9031	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-10	9032-9036	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-11	9037-9042	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-12	9042-9043	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-13	9044-9047	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-14	9048-9055	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-15	9056-9064	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-16	9065-9072	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-17	9073-9082	according	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-18	9083-9085	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-19	9086-9089	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-20	9090-9101	Declaration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-21	9102-9104	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-22	9105-9113	Helsinki	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-23	9114-9117	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-24	9118-9126	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-25	9127-9131	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-26	9132-9135	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-27	9136-9148	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-28	9149-9154	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-29	9155-9157	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-30	9158-9161	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-31	9162-9167	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]
49-32	9167-9168	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]

#Text=Assessment of alcohol dependence characteristics
#Text=Alcohol use disorder severity was assessed using the sum score of the alcohol use disorder identification test (AUDIT) in both AD patients and HC.
50-1	9169-9179	Assessment	_
50-2	9180-9182	of	_
50-3	9183-9190	alcohol	_
50-4	9191-9201	dependence	_
50-5	9202-9217	characteristics	_
50-6	9218-9225	Alcohol	_
50-7	9226-9229	use	_
50-8	9230-9238	disorder	_
50-9	9239-9247	severity	_
50-10	9248-9251	was	_
50-11	9252-9260	assessed	_
50-12	9261-9266	using	_
50-13	9267-9270	the	_
50-14	9271-9274	sum	_
50-15	9275-9280	score	_
50-16	9281-9283	of	_
50-17	9284-9287	the	_
50-18	9288-9295	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[42]
50-19	9296-9299	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[42]
50-20	9300-9308	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[42]
50-21	9309-9323	identification	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[42]
50-22	9324-9328	test	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[42]
50-23	9329-9330	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[42]
50-24	9330-9335	AUDIT	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[42]
50-25	9335-9336	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[42]
50-26	9337-9339	in	_
50-27	9340-9344	both	_
50-28	9345-9347	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[43]
50-29	9348-9356	patients	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[43]
50-30	9357-9360	and	_
50-31	9361-9363	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[44]
50-32	9363-9364	.	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[44]

#Text=The AUDIT consists of 10 items assessing hazardous and harmful alcohol use and dependence symptoms.
51-1	9365-9368	The	_
51-2	9369-9374	AUDIT	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
51-3	9375-9383	consists	_
51-4	9384-9386	of	_
51-5	9387-9389	10	_
51-6	9390-9395	items	_
51-7	9396-9405	assessing	_
51-8	9406-9415	hazardous	_
51-9	9416-9419	and	_
51-10	9420-9427	harmful	_
51-11	9428-9435	alcohol	_
51-12	9436-9439	use	_
51-13	9440-9443	and	_
51-14	9444-9454	dependence	_
51-15	9455-9463	symptoms	_
51-16	9463-9464	.	_

#Text=Every item can be scored from 0 (no problems) to 4 (regular / large problems), resulting in a total score between 0 and 40.
52-1	9465-9470	Every	_
52-2	9471-9475	item	_
52-3	9476-9479	can	_
52-4	9480-9482	be	_
52-5	9483-9489	scored	_
52-6	9490-9494	from	_
52-7	9495-9496	0	_
52-8	9497-9498	(	_
52-9	9498-9500	no	_
52-10	9501-9509	problems	_
52-11	9509-9510	)	_
52-12	9511-9513	to	_
52-13	9514-9515	4	_
52-14	9516-9517	(	_
52-15	9517-9524	regular	_
52-16	9525-9526	/	_
52-17	9527-9532	large	_
52-18	9533-9541	problems	_
52-19	9541-9542	)	_
52-20	9542-9543	,	_
52-21	9544-9553	resulting	_
52-22	9554-9556	in	_
52-23	9557-9558	a	_
52-24	9559-9564	total	_
52-25	9565-9570	score	_
52-26	9571-9578	between	_
52-27	9579-9580	0	_
52-28	9581-9584	and	_
52-29	9585-9587	40	_
52-30	9587-9588	.	_

#Text=A score below 8 indicates no alcohol use problems, a score above 22 indicates risk for dependence.
53-1	9589-9590	A	_
53-2	9591-9596	score	_
53-3	9597-9602	below	_
53-4	9603-9604	8	_
53-5	9605-9614	indicates	_
53-6	9615-9617	no	_
53-7	9618-9625	alcohol	_
53-8	9626-9629	use	_
53-9	9630-9638	problems	_
53-10	9638-9639	,	_
53-11	9640-9641	a	_
53-12	9642-9647	score	_
53-13	9648-9653	above	_
53-14	9654-9656	22	_
53-15	9657-9666	indicates	_
53-16	9667-9671	risk	_
53-17	9672-9675	for	_
53-18	9676-9686	dependence	_
53-19	9686-9687	.	_

#Text=Disease duration in AD patients was calculated as the difference in years between age of AD onset and the last time that alcohol use disorder symptoms contributed to a DSM-IV diagnosis (in the past half year, thus current age), both obtained by the CIDI interview.
54-1	9688-9695	Disease	_
54-2	9696-9704	duration	_
54-3	9705-9707	in	_
54-4	9708-9710	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[45]
54-5	9711-9719	patients	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[45]
54-6	9720-9723	was	_
54-7	9724-9734	calculated	_
54-8	9735-9737	as	_
54-9	9738-9741	the	_
54-10	9742-9752	difference	_
54-11	9753-9755	in	_
54-12	9756-9761	years	_
54-13	9762-9769	between	_
54-14	9770-9773	age	_
54-15	9774-9776	of	_
54-16	9777-9779	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
54-17	9780-9785	onset	_
54-18	9786-9789	and	_
54-19	9790-9793	the	_
54-20	9794-9798	last	_
54-21	9799-9803	time	_
54-22	9804-9808	that	_
54-23	9809-9816	alcohol	_
54-24	9817-9820	use	_
54-25	9821-9829	disorder	_
54-26	9830-9838	symptoms	_
54-27	9839-9850	contributed	_
54-28	9851-9853	to	_
54-29	9854-9855	a	_
54-30	9856-9862	DSM-IV	_
54-31	9863-9872	diagnosis	_
54-32	9873-9874	(	_
54-33	9874-9876	in	_
54-34	9877-9880	the	_
54-35	9881-9885	past	_
54-36	9886-9890	half	_
54-37	9891-9895	year	_
54-38	9895-9896	,	_
54-39	9897-9901	thus	_
54-40	9902-9909	current	_
54-41	9910-9913	age	_
54-42	9913-9914	)	_
54-43	9914-9915	,	_
54-44	9916-9920	both	_
54-45	9921-9929	obtained	_
54-46	9930-9932	by	_
54-47	9933-9936	the	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[46]
54-48	9937-9941	CIDI	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[46]
54-49	9942-9951	interview	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[46]
54-50	9951-9952	.	_

#Text=RS-fMRI data acquisition
#Text=Magnetic resonance imaging scanning was performed at the Academic Medical Centre in Amsterdam using a 3 T Philips Intera full-Normal MR-system (Philips Medical Systems, Best, the Netherlands) with a phased array SENSE RF 8-channel head coil for radio frequency transmission and reception.
55-1	9953-9960	RS-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[47]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[48]
55-2	9961-9965	data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[47]
55-3	9966-9977	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[47]
55-4	9978-9986	Magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[49]
55-5	9987-9996	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[49]
55-6	9997-10004	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[49]
55-7	10005-10013	scanning	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[49]
55-8	10014-10017	was	_
55-9	10018-10027	performed	_
55-10	10028-10030	at	_
55-11	10031-10034	the	_
55-12	10035-10043	Academic	_
55-13	10044-10051	Medical	_
55-14	10052-10058	Centre	_
55-15	10059-10061	in	_
55-16	10062-10071	Amsterdam	_
55-17	10072-10077	using	_
55-18	10078-10079	a	_
55-19	10080-10081	3	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[50]
55-20	10082-10083	T	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[50]
55-21	10084-10091	Philips	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[50]
55-22	10092-10098	Intera	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[50]
55-23	10099-10110	full-Normal	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[50]
55-24	10111-10120	MR-system	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[50]
55-25	10121-10122	(	_
55-26	10122-10129	Philips	_
55-27	10130-10137	Medical	_
55-28	10138-10145	Systems	_
55-29	10145-10146	,	_
55-30	10147-10151	Best	_
55-31	10151-10152	,	_
55-32	10153-10156	the	_
55-33	10157-10168	Netherlands	_
55-34	10168-10169	)	_
55-35	10170-10174	with	_
55-36	10175-10176	a	_
55-37	10177-10183	phased	_
55-38	10184-10189	array	_
55-39	10190-10195	SENSE	_
55-40	10196-10198	RF	_
55-41	10199-10200	8	_
55-42	10200-10201	-	_
55-43	10201-10208	channel	_
55-44	10209-10213	head	_
55-45	10214-10218	coil	_
55-46	10219-10222	for	_
55-47	10223-10228	radio	_
55-48	10229-10238	frequency	_
55-49	10239-10251	transmission	_
55-50	10252-10255	and	_
55-51	10256-10265	reception	_
55-52	10265-10266	.	_

#Text=Three HCs were scanned under exactly the same circumstances at the Leiden University Medical Center.
56-1	10267-10272	Three	_
56-2	10273-10276	HCs	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
56-3	10277-10281	were	_
56-4	10282-10289	scanned	_
56-5	10290-10295	under	_
56-6	10296-10303	exactly	_
56-7	10304-10307	the	_
56-8	10308-10312	same	_
56-9	10313-10326	circumstances	_
56-10	10327-10329	at	_
56-11	10330-10333	the	_
56-12	10334-10340	Leiden	_
56-13	10341-10351	University	_
56-14	10352-10359	Medical	_
56-15	10360-10366	Center	_
56-16	10366-10367	.	_

#Text=RS-fMRI was acquired for 8 minutes, while participants were instructed to keep their eyes closed and not fall asleep.
57-1	10368-10375	RS-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
57-2	10376-10379	was	_
57-3	10380-10388	acquired	_
57-4	10389-10392	for	_
57-5	10393-10394	8	_
57-6	10395-10402	minutes	_
57-7	10402-10403	,	_
57-8	10404-10409	while	_
57-9	10410-10422	participants	_
57-10	10423-10427	were	_
57-11	10428-10438	instructed	_
57-12	10439-10441	to	_
57-13	10442-10446	keep	_
57-14	10447-10452	their	_
57-15	10453-10457	eyes	_
57-16	10458-10464	closed	_
57-17	10465-10468	and	_
57-18	10469-10472	not	_
57-19	10473-10477	fall	_
57-20	10478-10484	asleep	_
57-21	10484-10485	.	_

#Text=Functional blood oxygen level-dependent (BOLD) signals were acquired with a T2*-weighted gradient-echo planar imaging (EPI) sequence and a time-course series of 200 volumes (TR = 2300 ms; TE = 30 ms; matrix size = 96 × 95; voxel size = 2.29 × 2.29 × 3 mm; 35 transverse slices, positioned at an angle of 30° from the anterior-posterior commissure line).
58-1	10486-10496	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[51]
58-2	10497-10502	blood	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[51]
58-3	10503-10509	oxygen	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[51]
58-4	10510-10525	level-dependent	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[51]
58-5	10526-10527	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[51]
58-6	10527-10531	BOLD	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[51]
58-7	10531-10532	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[51]
58-8	10533-10540	signals	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[51]
58-9	10541-10545	were	_
58-10	10546-10554	acquired	_
58-11	10555-10559	with	_
58-12	10560-10561	a	_
58-13	10562-10564	T2	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[52]|http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[53]
58-14	10564-10565	*	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[52]|http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[53]
58-15	10565-10566	-	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[52]|http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[53]
58-16	10566-10574	weighted	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[52]|http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[53]
58-17	10575-10588	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[52]|http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[53]
58-18	10589-10595	planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[52]|http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[53]
58-19	10596-10603	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[52]|http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[53]
58-20	10604-10605	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[52]|http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[53]
58-21	10605-10608	EPI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[52]|http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[53]
58-22	10608-10609	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[52]|http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[53]
58-23	10610-10618	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[52]|http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[53]
58-24	10619-10622	and	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[52]
58-25	10623-10624	a	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[52]
58-26	10625-10636	time-course	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[52]
58-27	10637-10643	series	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[52]
58-28	10644-10646	of	_
58-29	10647-10650	200	_
58-30	10651-10658	volumes	_
58-31	10659-10660	(	_
58-32	10660-10662	TR	_
58-33	10663-10664	=	_
58-34	10665-10669	2300	_
58-35	10670-10672	ms	_
58-36	10672-10673	;	_
58-37	10674-10676	TE	_
58-38	10677-10678	=	_
58-39	10679-10681	30	_
58-40	10682-10684	ms	_
58-41	10684-10685	;	_
58-42	10686-10692	matrix	_
58-43	10693-10697	size	_
58-44	10698-10699	=	_
58-45	10700-10702	96	_
58-46	10703-10704	×	_
58-47	10705-10707	95	_
58-48	10707-10708	;	_
58-49	10709-10714	voxel	_
58-50	10715-10719	size	_
58-51	10720-10721	=	_
58-52	10722-10726	2.29	_
58-53	10727-10728	×	_
58-54	10729-10733	2.29	_
58-55	10734-10735	×	_
58-56	10736-10737	3	_
58-57	10738-10740	mm	_
58-58	10740-10741	;	_
58-59	10742-10744	35	_
58-60	10745-10755	transverse	_
58-61	10756-10762	slices	_
58-62	10762-10763	,	_
58-63	10764-10774	positioned	_
58-64	10775-10777	at	_
58-65	10778-10780	an	_
58-66	10781-10786	angle	_
58-67	10787-10789	of	_
58-68	10790-10792	30	_
58-69	10792-10793	°	_
58-70	10794-10798	from	_
58-71	10799-10802	the	_
58-72	10803-10821	anterior-posterior	_
58-73	10822-10832	commissure	_
58-74	10833-10837	line	_
58-75	10837-10838	)	_
58-76	10838-10839	.	_

#Text=Additionally, structural images of the whole brain were acquired using a three-dimensional gradient-echo T1-weighted sequence for anatomical reference with the EPI data (TR = 9 ms; TE = 3.6 ms; matrix size = 256 × 231; voxel size = 1 × 1 × 1 mm; slices = 170).
59-1	10840-10852	Additionally	_
59-2	10852-10853	,	_
59-3	10854-10864	structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[54]|http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[55]
59-4	10865-10871	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[54]|http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[55]
59-5	10872-10874	of	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[54]
59-6	10875-10878	the	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[54]
59-7	10879-10884	whole	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[54]
59-8	10885-10890	brain	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[54]
59-9	10891-10895	were	_
59-10	10896-10904	acquired	_
59-11	10905-10910	using	_
59-12	10911-10912	a	_
59-13	10913-10930	three-dimensional	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[56]
59-14	10931-10944	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[56]
59-15	10945-10947	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[56]
59-16	10947-10948	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[56]
59-17	10948-10956	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[56]
59-18	10957-10965	sequence	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[56]
59-19	10966-10969	for	_
59-20	10970-10980	anatomical	_
59-21	10981-10990	reference	_
59-22	10991-10995	with	_
59-23	10996-10999	the	_
59-24	11000-11003	EPI	_
59-25	11004-11008	data	_
59-26	11009-11010	(	_
59-27	11010-11012	TR	_
59-28	11013-11014	=	_
59-29	11015-11016	9	_
59-30	11017-11019	ms	_
59-31	11019-11020	;	_
59-32	11021-11023	TE	_
59-33	11024-11025	=	_
59-34	11026-11029	3.6	_
59-35	11030-11032	ms	_
59-36	11032-11033	;	_
59-37	11034-11040	matrix	_
59-38	11041-11045	size	_
59-39	11046-11047	=	_
59-40	11048-11051	256	_
59-41	11052-11053	×	_
59-42	11054-11057	231	_
59-43	11057-11058	;	_
59-44	11059-11064	voxel	_
59-45	11065-11069	size	_
59-46	11070-11071	=	_
59-47	11072-11073	1	_
59-48	11074-11075	×	_
59-49	11076-11077	1	_
59-50	11078-11079	×	_
59-51	11080-11081	1	_
59-52	11082-11084	mm	_
59-53	11084-11085	;	_
59-54	11086-11092	slices	_
59-55	11093-11094	=	_
59-56	11095-11098	170	_
59-57	11098-11099	)	_
59-58	11099-11100	.	_

#Text=RS-fMRI data preprocessing
#Text=After quality check and reorientation to the anterior– posterior commissure line in Statistical Parametric Mapping (SPM8; http://www.fil.ion.ucl.ac.uk/spm), preprocessing of the RS-fMRI data was carried out by using the MATLAB-based toolbox data processing assistant for resting-state fMRI (DPARSF) V2.3, based on SPM8 and the resting-state fMRI data analysis toolkit (http://www.restfmri.net).
60-1	11101-11108	RS-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
60-2	11109-11113	data	_
60-3	11114-11127	preprocessing	_
60-4	11128-11133	After	_
60-5	11134-11141	quality	_
60-6	11142-11147	check	_
60-7	11148-11151	and	_
60-8	11152-11165	reorientation	_
60-9	11166-11168	to	_
60-10	11169-11172	the	_
60-11	11173-11181	anterior	_
60-12	11181-11182	–	_
60-13	11183-11192	posterior	_
60-14	11193-11203	commissure	_
60-15	11204-11208	line	_
60-16	11209-11211	in	_
60-17	11212-11223	Statistical	_
60-18	11224-11234	Parametric	_
60-19	11235-11242	Mapping	_
60-20	11243-11244	(	_
60-21	11244-11248	SPM8	_
60-22	11248-11249	;	_
60-23	11250-11254	http	_
60-24	11254-11255	:	_
60-25	11255-11256	/	_
60-26	11256-11257	/	_
60-27	11257-11278	www.fil.ion.ucl.ac.uk	_
60-28	11278-11279	/	_
60-29	11279-11282	spm	_
60-30	11282-11283	)	_
60-31	11283-11284	,	_
60-32	11285-11298	preprocessing	_
60-33	11299-11301	of	_
60-34	11302-11305	the	_
60-35	11306-11313	RS-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
60-36	11314-11318	data	_
60-37	11319-11322	was	_
60-38	11323-11330	carried	_
60-39	11331-11334	out	_
60-40	11335-11337	by	_
60-41	11338-11343	using	_
60-42	11344-11347	the	_
60-43	11348-11360	MATLAB-based	_
60-44	11361-11368	toolbox	_
60-45	11369-11373	data	_
60-46	11374-11384	processing	_
60-47	11385-11394	assistant	_
60-48	11395-11398	for	_
60-49	11399-11412	resting-state	_
60-50	11413-11417	fMRI	_
60-51	11418-11419	(	_
60-52	11419-11425	DPARSF	_
60-53	11425-11426	)	_
60-54	11427-11431	V2.3	_
60-55	11431-11432	,	_
60-56	11433-11438	based	_
60-57	11439-11441	on	_
60-58	11442-11446	SPM8	_
60-59	11447-11450	and	_
60-60	11451-11454	the	_
60-61	11455-11468	resting-state	_
60-62	11469-11473	fMRI	_
60-63	11474-11478	data	_
60-64	11479-11487	analysis	_
60-65	11488-11495	toolkit	_
60-66	11496-11497	(	_
60-67	11497-11501	http	_
60-68	11501-11502	:	_
60-69	11502-11503	/	_
60-70	11503-11504	/	_
60-71	11504-11520	www.restfmri.net	_
60-72	11520-11521	)	_
60-73	11521-11522	.	_

#Text=The first four volumes of every dataset were removed to eliminate non-equilibrium effects of magnetization.
61-1	11523-11526	The	_
61-2	11527-11532	first	_
61-3	11533-11537	four	_
61-4	11538-11545	volumes	_
61-5	11546-11548	of	_
61-6	11549-11554	every	_
61-7	11555-11562	dataset	_
61-8	11563-11567	were	_
61-9	11568-11575	removed	_
61-10	11576-11578	to	_
61-11	11579-11588	eliminate	_
61-12	11589-11604	non-equilibrium	_
61-13	11605-11612	effects	_
61-14	11613-11615	of	_
61-15	11616-11629	magnetization	_
61-16	11629-11630	.	_

#Text=The following procedures were applied to the remaining 196 time points: slice timing correction, to compensate for systematic slice-dependent time shifts; realignment towards the first frame to compensate for movement artifacts; co-registration of the EPI scans to the skull-stripped T1-weighted structural scan; segmentation into grey matter (GM), white matter (WM) and cerebrospinal fluid (CSF).
62-1	11631-11634	The	_
62-2	11635-11644	following	_
62-3	11645-11655	procedures	_
62-4	11656-11660	were	_
62-5	11661-11668	applied	_
62-6	11669-11671	to	_
62-7	11672-11675	the	_
62-8	11676-11685	remaining	_
62-9	11686-11689	196	_
62-10	11690-11694	time	_
62-11	11695-11701	points	_
62-12	11701-11702	:	_
62-13	11703-11708	slice	_
62-14	11709-11715	timing	_
62-15	11716-11726	correction	_
62-16	11726-11727	,	_
62-17	11728-11730	to	_
62-18	11731-11741	compensate	_
62-19	11742-11745	for	_
62-20	11746-11756	systematic	_
62-21	11757-11772	slice-dependent	_
62-22	11773-11777	time	_
62-23	11778-11784	shifts	_
62-24	11784-11785	;	_
62-25	11786-11797	realignment	_
62-26	11798-11805	towards	_
62-27	11806-11809	the	_
62-28	11810-11815	first	_
62-29	11816-11821	frame	_
62-30	11822-11824	to	_
62-31	11825-11835	compensate	_
62-32	11836-11839	for	_
62-33	11840-11848	movement	_
62-34	11849-11858	artifacts	_
62-35	11858-11859	;	_
62-36	11860-11875	co-registration	_
62-37	11876-11878	of	_
62-38	11879-11882	the	_
62-39	11883-11886	EPI	_
62-40	11887-11892	scans	_
62-41	11893-11895	to	_
62-42	11896-11899	the	_
62-43	11900-11914	skull-stripped	_
62-44	11915-11917	T1	_
62-45	11917-11918	-	_
62-46	11918-11926	weighted	_
62-47	11927-11937	structural	_
62-48	11938-11942	scan	_
62-49	11942-11943	;	_
62-50	11944-11956	segmentation	_
62-51	11957-11961	into	_
62-52	11962-11966	grey	_
62-53	11967-11973	matter	_
62-54	11974-11975	(	_
62-55	11975-11977	GM	_
62-56	11977-11978	)	_
62-57	11978-11979	,	_
62-58	11980-11985	white	_
62-59	11986-11992	matter	_
62-60	11993-11994	(	_
62-61	11994-11996	WM	_
62-62	11996-11997	)	_
62-63	11998-12001	and	_
62-64	12002-12015	cerebrospinal	_
62-65	12016-12021	fluid	_
62-66	12022-12023	(	_
62-67	12023-12026	CSF	_
62-68	12026-12027	)	_
62-69	12027-12028	.	_

#Text=Eight nuisance signals (WM, CSF signal and six rigid-Normal motion parameters), and the global signal were regressed out to produce a residual BOLD signal.
63-1	12029-12034	Eight	_
63-2	12035-12043	nuisance	_
63-3	12044-12051	signals	_
63-4	12052-12053	(	_
63-5	12053-12055	WM	_
63-6	12055-12056	,	_
63-7	12057-12060	CSF	_
63-8	12061-12067	signal	_
63-9	12068-12071	and	_
63-10	12072-12075	six	_
63-11	12076-12088	rigid-Normal	_
63-12	12089-12095	motion	_
63-13	12096-12106	parameters	_
63-14	12106-12107	)	_
63-15	12107-12108	,	_
63-16	12109-12112	and	_
63-17	12113-12116	the	_
63-18	12117-12123	global	_
63-19	12124-12130	signal	_
63-20	12131-12135	were	_
63-21	12136-12145	regressed	_
63-22	12146-12149	out	_
63-23	12150-12152	to	_
63-24	12153-12160	produce	_
63-25	12161-12162	a	_
63-26	12163-12171	residual	_
63-27	12172-12176	BOLD	_
63-28	12177-12183	signal	_
63-29	12183-12184	.	_

#Text=Data were registered into Montreal Neurologic Institute (MNI) standard space and smoothed with a 6 mm full-width at half-maximum (FWHM) kernel.
64-1	12185-12189	Data	_
64-2	12190-12194	were	_
64-3	12195-12205	registered	_
64-4	12206-12210	into	_
64-5	12211-12219	Montreal	_
64-6	12220-12230	Neurologic	_
64-7	12231-12240	Institute	_
64-8	12241-12242	(	_
64-9	12242-12245	MNI	_
64-10	12245-12246	)	_
64-11	12247-12255	standard	_
64-12	12256-12261	space	_
64-13	12262-12265	and	_
64-14	12266-12274	smoothed	_
64-15	12275-12279	with	_
64-16	12280-12281	a	_
64-17	12282-12283	6	_
64-18	12284-12286	mm	_
64-19	12287-12297	full-width	_
64-20	12298-12300	at	_
64-21	12301-12313	half-maximum	_
64-22	12314-12315	(	_
64-23	12315-12319	FWHM	_
64-24	12319-12320	)	_
64-25	12321-12327	kernel	_
64-26	12327-12328	.	_

#Text=Low band-pass temporal filtering of less than 0.08 Hz was applied.
65-1	12329-12332	Low	_
65-2	12333-12342	band-pass	_
65-3	12343-12351	temporal	_
65-4	12352-12361	filtering	_
65-5	12362-12364	of	_
65-6	12365-12369	less	_
65-7	12370-12374	than	_
65-8	12375-12379	0.08	_
65-9	12380-12382	Hz	_
65-10	12383-12386	was	_
65-11	12387-12394	applied	_
65-12	12394-12395	.	_

#Text=For calculation of head-motion parameters, see Supporting Information.
66-1	12396-12399	For	_
66-2	12400-12411	calculation	_
66-3	12412-12414	of	_
66-4	12415-12426	head-motion	_
66-5	12427-12437	parameters	_
66-6	12437-12438	,	_
66-7	12439-12442	see	_
66-8	12443-12453	Supporting	_
66-9	12454-12465	Information	_
66-10	12465-12466	.	_

#Text=Anatomical parcellation
#Text=Parcellation of the GM maps was performed to define separate brain regions as nodes for connectivity analysis.
67-1	12467-12477	Anatomical	_
67-2	12478-12490	parcellation	_
67-3	12491-12503	Parcellation	_
67-4	12504-12506	of	_
67-5	12507-12510	the	_
67-6	12511-12513	GM	_
67-7	12514-12518	maps	_
67-8	12519-12522	was	_
67-9	12523-12532	performed	_
67-10	12533-12535	to	_
67-11	12536-12542	define	_
67-12	12543-12551	separate	_
67-13	12552-12557	brain	_
67-14	12558-12565	regions	_
67-15	12566-12568	as	_
67-16	12569-12574	nodes	_
67-17	12575-12578	for	_
67-18	12579-12591	connectivity	_
67-19	12592-12600	analysis	_
67-20	12600-12601	.	_

#Text=This was achieved using the Harvard–Oxford brain atlas based on prior anatomical information.
68-1	12602-12606	This	_
68-2	12607-12610	was	_
68-3	12611-12619	achieved	_
68-4	12620-12625	using	_
68-5	12626-12629	the	_
68-6	12630-12644	Harvard–Oxford	_
68-7	12645-12650	brain	_
68-8	12651-12656	atlas	_
68-9	12657-12662	based	_
68-10	12663-12665	on	_
68-11	12666-12671	prior	_
68-12	12672-12682	anatomical	_
68-13	12683-12694	information	_
68-14	12694-12695	.	_

#Text=In this atlas, a total of 48 cortical and eight subcortical bilateral structural areas are defined, adding up to 112 nodes.
69-1	12696-12698	In	_
69-2	12699-12703	this	_
69-3	12704-12709	atlas	_
69-4	12709-12710	,	_
69-5	12711-12712	a	_
69-6	12713-12718	total	_
69-7	12719-12721	of	_
69-8	12722-12724	48	_
69-9	12725-12733	cortical	_
69-10	12734-12737	and	_
69-11	12738-12743	eight	_
69-12	12744-12755	subcortical	_
69-13	12756-12765	bilateral	_
69-14	12766-12776	structural	_
69-15	12777-12782	areas	_
69-16	12783-12786	are	_
69-17	12787-12794	defined	_
69-18	12794-12795	,	_
69-19	12796-12802	adding	_
69-20	12803-12805	up	_
69-21	12806-12808	to	_
69-22	12809-12812	112	_
69-23	12813-12818	nodes	_
69-24	12818-12819	.	_

#Text=Although global brain network topology composed our main focus, specialized areas in the striatum were of additional a-priori interest.
70-1	12820-12828	Although	_
70-2	12829-12835	global	_
70-3	12836-12841	brain	_
70-4	12842-12849	network	_
70-5	12850-12858	topology	_
70-6	12859-12867	composed	_
70-7	12868-12871	our	_
70-8	12872-12876	main	_
70-9	12877-12882	focus	_
70-10	12882-12883	,	_
70-11	12884-12895	specialized	_
70-12	12896-12901	areas	_
70-13	12902-12904	in	_
70-14	12905-12908	the	_
70-15	12909-12917	striatum	_
70-16	12918-12922	were	_
70-17	12923-12925	of	_
70-18	12926-12936	additional	_
70-19	12937-12945	a-priori	_
70-20	12946-12954	interest	_
70-21	12954-12955	.	_

#Text=Because the anterior and posterior putamen are assumed to play a distinguishable role, especially in the framework of instrumental conditioning, we subdivided the bilateral putamen in an anterior and posterior part.
71-1	12956-12963	Because	_
71-2	12964-12967	the	_
71-3	12968-12976	anterior	_
71-4	12977-12980	and	_
71-5	12981-12990	posterior	_
71-6	12991-12998	putamen	_
71-7	12999-13002	are	_
71-8	13003-13010	assumed	_
71-9	13011-13013	to	_
71-10	13014-13018	play	_
71-11	13019-13020	a	_
71-12	13021-13036	distinguishable	_
71-13	13037-13041	role	_
71-14	13041-13042	,	_
71-15	13043-13053	especially	_
71-16	13054-13056	in	_
71-17	13057-13060	the	_
71-18	13061-13070	framework	_
71-19	13071-13073	of	_
71-20	13074-13086	instrumental	_
71-21	13087-13099	conditioning	_
71-22	13099-13100	,	_
71-23	13101-13103	we	_
71-24	13104-13114	subdivided	_
71-25	13115-13118	the	_
71-26	13119-13128	bilateral	_
71-27	13129-13136	putamen	_
71-28	13137-13139	in	_
71-29	13140-13142	an	_
71-30	13143-13151	anterior	_
71-31	13152-13155	and	_
71-32	13156-13165	posterior	_
71-33	13166-13170	part	_
71-34	13170-13171	.	_

#Text=For this, we used MRIcron & ImCalc implemented in SPM8 to split the putamen in a pre-commissural (anterior, y ≥ 0) and a post-commissural (posterior, y < 0) part.
72-1	13172-13175	For	_
72-2	13176-13180	this	_
72-3	13180-13181	,	_
72-4	13182-13184	we	_
72-5	13185-13189	used	_
72-6	13190-13197	MRIcron	_
72-7	13198-13199	&	_
72-8	13200-13206	ImCalc	_
72-9	13207-13218	implemented	_
72-10	13219-13221	in	_
72-11	13222-13226	SPM8	_
72-12	13227-13229	to	_
72-13	13230-13235	split	_
72-14	13236-13239	the	_
72-15	13240-13247	putamen	_
72-16	13248-13250	in	_
72-17	13251-13252	a	_
72-18	13253-13268	pre-commissural	_
72-19	13269-13270	(	_
72-20	13270-13278	anterior	_
72-21	13278-13279	,	_
72-22	13280-13281	y	_
72-23	13282-13283	≥	_
72-24	13284-13285	0	_
72-25	13285-13286	)	_
72-26	13287-13290	and	_
72-27	13291-13292	a	_
72-28	13293-13309	post-commissural	_
72-29	13310-13311	(	_
72-30	13311-13320	posterior	_
72-31	13320-13321	,	_
72-32	13322-13323	y	_
72-33	13324-13325	<	_
72-34	13326-13327	0	_
72-35	13327-13328	)	_
72-36	13329-13333	part	_
72-37	13333-13334	.	_

#Text=This resulted in 114 areas for final parcellation.
73-1	13335-13339	This	_
73-2	13340-13348	resulted	_
73-3	13349-13351	in	_
73-4	13352-13355	114	_
73-5	13356-13361	areas	_
73-6	13362-13365	for	_
73-7	13366-13371	final	_
73-8	13372-13384	parcellation	_
73-9	13384-13385	.	_

#Text=Regional mean time series were extracted by averaging the fMRI time series of all voxels in each of these 114 regions.
74-1	13386-13394	Regional	_
74-2	13395-13399	mean	_
74-3	13400-13404	time	_
74-4	13405-13411	series	_
74-5	13412-13416	were	_
74-6	13417-13426	extracted	_
74-7	13427-13429	by	_
74-8	13430-13439	averaging	_
74-9	13440-13443	the	_
74-10	13444-13448	fMRI	_
74-11	13449-13453	time	_
74-12	13454-13460	series	_
74-13	13461-13463	of	_
74-14	13464-13467	all	_
74-15	13468-13474	voxels	_
74-16	13475-13477	in	_
74-17	13478-13482	each	_
74-18	13483-13485	of	_
74-19	13486-13491	these	_
74-20	13492-13495	114	_
74-21	13496-13503	regions	_
74-22	13503-13504	.	_

#Text=Graph construction
#Text=The pre-processed and parcellated RS-fMRI data were analyzed using graph theory according to algorithms implemented in the brain connectivity toolbox (http://www.brain-connectivity-toolbox.net) using MATLAB 2012a (The Mathworks Inc., Natick, Massachusetts, USA).
75-1	13505-13510	Graph	_
75-2	13511-13523	construction	_
75-3	13524-13527	The	_
75-4	13528-13541	pre-processed	_
75-5	13542-13545	and	_
75-6	13546-13557	parcellated	_
75-7	13558-13565	RS-fMRI	_
75-8	13566-13570	data	_
75-9	13571-13575	were	_
75-10	13576-13584	analyzed	_
75-11	13585-13590	using	_
75-12	13591-13596	graph	_
75-13	13597-13603	theory	_
75-14	13604-13613	according	_
75-15	13614-13616	to	_
75-16	13617-13627	algorithms	_
75-17	13628-13639	implemented	_
75-18	13640-13642	in	_
75-19	13643-13646	the	_
75-20	13647-13652	brain	_
75-21	13653-13665	connectivity	_
75-22	13666-13673	toolbox	_
75-23	13674-13675	(	_
75-24	13675-13679	http	_
75-25	13679-13680	:	_
75-26	13680-13681	/	_
75-27	13681-13682	/	_
75-28	13682-13716	www.brain-connectivity-toolbox.net	_
75-29	13716-13717	)	_
75-30	13718-13723	using	_
75-31	13724-13730	MATLAB	_
75-32	13731-13736	2012a	_
75-33	13737-13738	(	_
75-34	13738-13741	The	_
75-35	13742-13751	Mathworks	_
75-36	13752-13755	Inc	_
75-37	13755-13756	.	_
75-38	13756-13757	,	_
75-39	13758-13764	Natick	_
75-40	13764-13765	,	_
75-41	13766-13779	Massachusetts	_
75-42	13779-13780	,	_
75-43	13781-13784	USA	_
75-44	13784-13785	)	_
75-45	13785-13786	.	_

#Text=A graph is a topological representation of a network consisting of nodes i, connected by links or edges a between two nodes i and j.
76-1	13787-13788	A	_
76-2	13789-13794	graph	_
76-3	13795-13797	is	_
76-4	13798-13799	a	_
76-5	13800-13811	topological	_
76-6	13812-13826	representation	_
76-7	13827-13829	of	_
76-8	13830-13831	a	_
76-9	13832-13839	network	_
76-10	13840-13850	consisting	_
76-11	13851-13853	of	_
76-12	13854-13859	nodes	_
76-13	13860-13861	i	_
76-14	13861-13862	,	_
76-15	13863-13872	connected	_
76-16	13873-13875	by	_
76-17	13876-13881	links	_
76-18	13882-13884	or	_
76-19	13885-13890	edges	_
76-20	13891-13892	a	_
76-21	13893-13900	between	_
76-22	13901-13904	two	_
76-23	13905-13910	nodes	_
76-24	13911-13912	i	_
76-25	13913-13916	and	_
76-26	13917-13918	j	_
76-27	13918-13919	.	_

#Text=A weighted undirected graph G was constructed by correlating the connections between all 114 nodes using Pearson’s correlation coefficients, resulting in a network N of 114 nodes and 114 × 113 edges.
77-1	13920-13921	A	_
77-2	13922-13930	weighted	_
77-3	13931-13941	undirected	_
77-4	13942-13947	graph	_
77-5	13948-13949	G	_
77-6	13950-13953	was	_
77-7	13954-13965	constructed	_
77-8	13966-13968	by	_
77-9	13969-13980	correlating	_
77-10	13981-13984	the	_
77-11	13985-13996	connections	_
77-12	13997-14004	between	_
77-13	14005-14008	all	_
77-14	14009-14012	114	_
77-15	14013-14018	nodes	_
77-16	14019-14024	using	_
77-17	14025-14032	Pearson	_
77-18	14032-14033	’	_
77-19	14033-14034	s	_
77-20	14035-14046	correlation	_
77-21	14047-14059	coefficients	_
77-22	14059-14060	,	_
77-23	14061-14070	resulting	_
77-24	14071-14073	in	_
77-25	14074-14075	a	_
77-26	14076-14083	network	_
77-27	14084-14085	N	_
77-28	14086-14088	of	_
77-29	14089-14092	114	_
77-30	14093-14098	nodes	_
77-31	14099-14102	and	_
77-32	14103-14106	114	_
77-33	14107-14108	×	_
77-34	14109-14112	113	_
77-35	14113-14118	edges	_
77-36	14118-14119	.	_

#Text=Edges aij between nodes had a connection weight w that was normalized, such that 0 ≤w≤ 1 for all edges aij.
78-1	14120-14125	Edges	_
78-2	14126-14129	aij	_
78-3	14130-14137	between	_
78-4	14138-14143	nodes	_
78-5	14144-14147	had	_
78-6	14148-14149	a	_
78-7	14150-14160	connection	_
78-8	14161-14167	weight	_
78-9	14168-14169	w	_
78-10	14170-14174	that	_
78-11	14175-14178	was	_
78-12	14179-14189	normalized	_
78-13	14189-14190	,	_
78-14	14191-14195	such	_
78-15	14196-14200	that	_
78-16	14201-14202	0	_
78-17	14203-14204	≤	_
78-18	14204-14205	w	_
78-19	14205-14206	≤	_
78-20	14207-14208	1	_
78-21	14209-14212	for	_
78-22	14213-14216	all	_
78-23	14217-14222	edges	_
78-24	14223-14226	aij	_
78-25	14226-14227	.	_

#Text=The 40% highest weights were retained for calculation of network characteristics in order to remove negative correlations while keeping the graph fully connected.
79-1	14228-14231	The	_
79-2	14232-14235	40%	_
79-3	14236-14243	highest	_
79-4	14244-14251	weights	_
79-5	14252-14256	were	_
79-6	14257-14265	retained	_
79-7	14266-14269	for	_
79-8	14270-14281	calculation	_
79-9	14282-14284	of	_
79-10	14285-14292	network	_
79-11	14293-14308	characteristics	_
79-12	14309-14311	in	_
79-13	14312-14317	order	_
79-14	14318-14320	to	_
79-15	14321-14327	remove	_
79-16	14328-14336	negative	_
79-17	14337-14349	correlations	_
79-18	14350-14355	while	_
79-19	14356-14363	keeping	_
79-20	14364-14367	the	_
79-21	14368-14373	graph	_
79-22	14374-14379	fully	_
79-23	14380-14389	connected	_
79-24	14389-14390	.	_

#Text=Negative correlations were discarded, because their underlying neurophysiological mechanism is still insufficiently understood (for a review see).
80-1	14391-14399	Negative	_
80-2	14400-14412	correlations	_
80-3	14413-14417	were	_
80-4	14418-14427	discarded	_
80-5	14427-14428	,	_
80-6	14429-14436	because	_
80-7	14437-14442	their	_
80-8	14443-14453	underlying	_
80-9	14454-14472	neurophysiological	_
80-10	14473-14482	mechanism	_
80-11	14483-14485	is	_
80-12	14486-14491	still	_
80-13	14492-14506	insufficiently	_
80-14	14507-14517	understood	_
80-15	14518-14519	(	_
80-16	14519-14522	for	_
80-17	14523-14524	a	_
80-18	14525-14531	review	_
80-19	14532-14535	see	_
80-20	14535-14536	)	_
80-21	14536-14537	.	_

#Text=To explore consistency of our results, we additionally performed analyses on graphs based on connection matrices with 30% and 20% highest weights, as well as unweighted graphs, by binarizing the edge weights between nodes after applying an absolute threshold of 0.25.
81-1	14538-14540	To	_
81-2	14541-14548	explore	_
81-3	14549-14560	consistency	_
81-4	14561-14563	of	_
81-5	14564-14567	our	_
81-6	14568-14575	results	_
81-7	14575-14576	,	_
81-8	14577-14579	we	_
81-9	14580-14592	additionally	_
81-10	14593-14602	performed	_
81-11	14603-14611	analyses	_
81-12	14612-14614	on	_
81-13	14615-14621	graphs	_
81-14	14622-14627	based	_
81-15	14628-14630	on	_
81-16	14631-14641	connection	_
81-17	14642-14650	matrices	_
81-18	14651-14655	with	_
81-19	14656-14659	30%	_
81-20	14660-14663	and	_
81-21	14664-14667	20%	_
81-22	14668-14675	highest	_
81-23	14676-14683	weights	_
81-24	14683-14684	,	_
81-25	14685-14687	as	_
81-26	14688-14692	well	_
81-27	14693-14695	as	_
81-28	14696-14706	unweighted	_
81-29	14707-14713	graphs	_
81-30	14713-14714	,	_
81-31	14715-14717	by	_
81-32	14718-14728	binarizing	_
81-33	14729-14732	the	_
81-34	14733-14737	edge	_
81-35	14738-14745	weights	_
81-36	14746-14753	between	_
81-37	14754-14759	nodes	_
81-38	14760-14765	after	_
81-39	14766-14774	applying	_
81-40	14775-14777	an	_
81-41	14778-14786	absolute	_
81-42	14787-14796	threshold	_
81-43	14797-14799	of	_
81-44	14800-14804	0.25	_
81-45	14804-14805	.	_

#Text=These results are reported in the Supporting Information (Tables S2 and S3).
82-1	14806-14811	These	_
82-2	14812-14819	results	_
82-3	14820-14823	are	_
82-4	14824-14832	reported	_
82-5	14833-14835	in	_
82-6	14836-14839	the	_
82-7	14840-14850	Supporting	_
82-8	14851-14862	Information	_
82-9	14863-14864	(	_
82-10	14864-14870	Tables	_
82-11	14871-14873	S2	_
82-12	14874-14877	and	_
82-13	14878-14880	S3	_
82-14	14880-14881	)	_
82-15	14881-14882	.	_

#Text=Graph topological parameters
#Text=We studied both properties of the global complex network as well as graph features of four bilateral striatal nodes (caudate nucleus, nucleus accumbens, posterior-putamen and anterior putamen) within the whole-brain network.
83-1	14883-14888	Graph	_
83-2	14889-14900	topological	_
83-3	14901-14911	parameters	_
83-4	14912-14914	We	_
83-5	14915-14922	studied	_
83-6	14923-14927	both	_
83-7	14928-14938	properties	_
83-8	14939-14941	of	_
83-9	14942-14945	the	_
83-10	14946-14952	global	_
83-11	14953-14960	complex	_
83-12	14961-14968	network	_
83-13	14969-14971	as	_
83-14	14972-14976	well	_
83-15	14977-14979	as	_
83-16	14980-14985	graph	_
83-17	14986-14994	features	_
83-18	14995-14997	of	_
83-19	14998-15002	four	_
83-20	15003-15012	bilateral	_
83-21	15013-15021	striatal	_
83-22	15022-15027	nodes	_
83-23	15028-15029	(	_
83-24	15029-15036	caudate	_
83-25	15037-15044	nucleus	_
83-26	15044-15045	,	_
83-27	15046-15053	nucleus	_
83-28	15054-15063	accumbens	_
83-29	15063-15064	,	_
83-30	15065-15082	posterior-putamen	_
83-31	15083-15086	and	_
83-32	15087-15095	anterior	_
83-33	15096-15103	putamen	_
83-34	15103-15104	)	_
83-35	15105-15111	within	_
83-36	15112-15115	the	_
83-37	15116-15127	whole-brain	_
83-38	15128-15135	network	_
83-39	15135-15136	.	_

#Text=We defined several network parameters of interest to describe the main topological characteristics of the entire graph network as well as its striatal nodes.
84-1	15137-15139	We	_
84-2	15140-15147	defined	_
84-3	15148-15155	several	_
84-4	15156-15163	network	_
84-5	15164-15174	parameters	_
84-6	15175-15177	of	_
84-7	15178-15186	interest	_
84-8	15187-15189	to	_
84-9	15190-15198	describe	_
84-10	15199-15202	the	_
84-11	15203-15207	main	_
84-12	15208-15219	topological	_
84-13	15220-15235	characteristics	_
84-14	15236-15238	of	_
84-15	15239-15242	the	_
84-16	15243-15249	entire	_
84-17	15250-15255	graph	_
84-18	15256-15263	network	_
84-19	15264-15266	as	_
84-20	15267-15271	well	_
84-21	15272-15274	as	_
84-22	15275-15278	its	_
84-23	15279-15287	striatal	_
84-24	15288-15293	nodes	_
84-25	15293-15294	.	_

#Text=These topographical parameters were derived from the connectivity toolbox as discussed by.
85-1	15295-15300	These	_
85-2	15301-15314	topographical	_
85-3	15315-15325	parameters	_
85-4	15326-15330	were	_
85-5	15331-15338	derived	_
85-6	15339-15343	from	_
85-7	15344-15347	the	_
85-8	15348-15360	connectivity	_
85-9	15361-15368	toolbox	_
85-10	15369-15371	as	_
85-11	15372-15381	discussed	_
85-12	15382-15384	by	_
85-13	15384-15385	.	_

#Text=For completeness, the equations used to calculate the global and local network topology are given in the Supporting Information methods belonging to this manuscript.
86-1	15386-15389	For	_
86-2	15390-15402	completeness	_
86-3	15402-15403	,	_
86-4	15404-15407	the	_
86-5	15408-15417	equations	_
86-6	15418-15422	used	_
86-7	15423-15425	to	_
86-8	15426-15435	calculate	_
86-9	15436-15439	the	_
86-10	15440-15446	global	_
86-11	15447-15450	and	_
86-12	15451-15456	local	_
86-13	15457-15464	network	_
86-14	15465-15473	topology	_
86-15	15474-15477	are	_
86-16	15478-15483	given	_
86-17	15484-15486	in	_
86-18	15487-15490	the	_
86-19	15491-15501	Supporting	_
86-20	15502-15513	Information	_
86-21	15514-15521	methods	_
86-22	15522-15531	belonging	_
86-23	15532-15534	to	_
86-24	15535-15539	this	_
86-25	15540-15550	manuscript	_
86-26	15550-15551	.	_

#Text=We used global efficiency (GE) as a global measure of integration.
87-1	15552-15554	We	_
87-2	15555-15559	used	_
87-3	15560-15566	global	_
87-4	15567-15577	efficiency	_
87-5	15578-15579	(	_
87-6	15579-15581	GE	_
87-7	15581-15582	)	_
87-8	15583-15585	as	_
87-9	15586-15587	a	_
87-10	15588-15594	global	_
87-11	15595-15602	measure	_
87-12	15603-15605	of	_
87-13	15606-15617	integration	_
87-14	15617-15618	.	_

#Text=GE measures how efficient the network exchanges information at the global level and can be defined as the average inverse shortest path length.
88-1	15619-15621	GE	_
88-2	15622-15630	measures	_
88-3	15631-15634	how	_
88-4	15635-15644	efficient	_
88-5	15645-15648	the	_
88-6	15649-15656	network	_
88-7	15657-15666	exchanges	_
88-8	15667-15678	information	_
88-9	15679-15681	at	_
88-10	15682-15685	the	_
88-11	15686-15692	global	_
88-12	15693-15698	level	_
88-13	15699-15702	and	_
88-14	15703-15706	can	_
88-15	15707-15709	be	_
88-16	15710-15717	defined	_
88-17	15718-15720	as	_
88-18	15721-15724	the	_
88-19	15725-15732	average	_
88-20	15733-15740	inverse	_
88-21	15741-15749	shortest	_
88-22	15750-15754	path	_
88-23	15755-15761	length	_
88-24	15761-15762	.	_

#Text=Disconnected nodes, defined to have infinite path length, have zero efficiency.
89-1	15763-15775	Disconnected	_
89-2	15776-15781	nodes	_
89-3	15781-15782	,	_
89-4	15783-15790	defined	_
89-5	15791-15793	to	_
89-6	15794-15798	have	_
89-7	15799-15807	infinite	_
89-8	15808-15812	path	_
89-9	15813-15819	length	_
89-10	15819-15820	,	_
89-11	15821-15825	have	_
89-12	15826-15830	zero	_
89-13	15831-15841	efficiency	_
89-14	15841-15842	.	_

#Text=The following local network characteristics were investigated for each individual striatal node i, as well as averaged over all 114 nodes to obtain global measures of the network N: clustering coefficient (CC), degree (D) and eigenvector centrality (EC).
90-1	15843-15846	The	_
90-2	15847-15856	following	_
90-3	15857-15862	local	_
90-4	15863-15870	network	_
90-5	15871-15886	characteristics	_
90-6	15887-15891	were	_
90-7	15892-15904	investigated	_
90-8	15905-15908	for	_
90-9	15909-15913	each	_
90-10	15914-15924	individual	_
90-11	15925-15933	striatal	_
90-12	15934-15938	node	_
90-13	15939-15940	i	_
90-14	15940-15941	,	_
90-15	15942-15944	as	_
90-16	15945-15949	well	_
90-17	15950-15952	as	_
90-18	15953-15961	averaged	_
90-19	15962-15966	over	_
90-20	15967-15970	all	_
90-21	15971-15974	114	_
90-22	15975-15980	nodes	_
90-23	15981-15983	to	_
90-24	15984-15990	obtain	_
90-25	15991-15997	global	_
90-26	15998-16006	measures	_
90-27	16007-16009	of	_
90-28	16010-16013	the	_
90-29	16014-16021	network	_
90-30	16022-16023	N	_
90-31	16023-16024	:	_
90-32	16025-16035	clustering	_
90-33	16036-16047	coefficient	_
90-34	16048-16049	(	_
90-35	16049-16051	CC	_
90-36	16051-16052	)	_
90-37	16052-16053	,	_
90-38	16054-16060	degree	_
90-39	16061-16062	(	_
90-40	16062-16063	D	_
90-41	16063-16064	)	_
90-42	16065-16068	and	_
90-43	16069-16080	eigenvector	_
90-44	16081-16091	centrality	_
90-45	16092-16093	(	_
90-46	16093-16095	EC	_
90-47	16095-16096	)	_
90-48	16096-16097	.	_

#Text=CC is a measure of segregation, defined as the fraction of triangles (3-node connections) around a node.
91-1	16098-16100	CC	_
91-2	16101-16103	is	_
91-3	16104-16105	a	_
91-4	16106-16113	measure	_
91-5	16114-16116	of	_
91-6	16117-16128	segregation	_
91-7	16128-16129	,	_
91-8	16130-16137	defined	_
91-9	16138-16140	as	_
91-10	16141-16144	the	_
91-11	16145-16153	fraction	_
91-12	16154-16156	of	_
91-13	16157-16166	triangles	_
91-14	16167-16168	(	_
91-15	16168-16169	3	_
91-16	16169-16170	-	_
91-17	16170-16174	node	_
91-18	16175-16186	connections	_
91-19	16186-16187	)	_
91-20	16188-16194	around	_
91-21	16195-16196	a	_
91-22	16197-16201	node	_
91-23	16201-16202	.	_

#Text=This is equivalent to the fraction of a node’s neighbors that are also each other’s neighbors.
92-1	16203-16207	This	_
92-2	16208-16210	is	_
92-3	16211-16221	equivalent	_
92-4	16222-16224	to	_
92-5	16225-16228	the	_
92-6	16229-16237	fraction	_
92-7	16238-16240	of	_
92-8	16241-16242	a	_
92-9	16243-16247	node	_
92-10	16247-16248	’	_
92-11	16248-16249	s	_
92-12	16250-16259	neighbors	_
92-13	16260-16264	that	_
92-14	16265-16268	are	_
92-15	16269-16273	also	_
92-16	16274-16278	each	_
92-17	16279-16284	other	_
92-18	16284-16285	’	_
92-19	16285-16286	s	_
92-20	16287-16296	neighbors	_
92-21	16296-16297	.	_

#Text=The CC per node (CCi) was averaged over the entire network, to obtain the global CC (CCN).
93-1	16298-16301	The	_
93-2	16302-16304	CC	_
93-3	16305-16308	per	_
93-4	16309-16313	node	_
93-5	16314-16315	(	_
93-6	16315-16318	CCi	_
93-7	16318-16319	)	_
93-8	16320-16323	was	_
93-9	16324-16332	averaged	_
93-10	16333-16337	over	_
93-11	16338-16341	the	_
93-12	16342-16348	entire	_
93-13	16349-16356	network	_
93-14	16356-16357	,	_
93-15	16358-16360	to	_
93-16	16361-16367	obtain	_
93-17	16368-16371	the	_
93-18	16372-16378	global	_
93-19	16379-16381	CC	_
93-20	16382-16383	(	_
93-21	16383-16386	CCN	_
93-22	16386-16387	)	_
93-23	16387-16388	.	_

#Text=D and EC are measures of centrality.
94-1	16389-16390	D	_
94-2	16391-16394	and	_
94-3	16395-16397	EC	_
94-4	16398-16401	are	_
94-5	16402-16410	measures	_
94-6	16411-16413	of	_
94-7	16414-16424	centrality	_
94-8	16424-16425	.	_

#Text=D depicts the number of links connected to a node.
95-1	16426-16427	D	_
95-2	16428-16435	depicts	_
95-3	16436-16439	the	_
95-4	16440-16446	number	_
95-5	16447-16449	of	_
95-6	16450-16455	links	_
95-7	16456-16465	connected	_
95-8	16466-16468	to	_
95-9	16469-16470	a	_
95-10	16471-16475	node	_
95-11	16475-16476	.	_

#Text=The weighted D, also called the strength, is defined as the sum of all neighboring link weights.
96-1	16477-16480	The	_
96-2	16481-16489	weighted	_
96-3	16490-16491	D	_
96-4	16491-16492	,	_
96-5	16493-16497	also	_
96-6	16498-16504	called	_
96-7	16505-16508	the	_
96-8	16509-16517	strength	_
96-9	16517-16518	,	_
96-10	16519-16521	is	_
96-11	16522-16529	defined	_
96-12	16530-16532	as	_
96-13	16533-16536	the	_
96-14	16537-16540	sum	_
96-15	16541-16543	of	_
96-16	16544-16547	all	_
96-17	16548-16559	neighboring	_
96-18	16560-16564	link	_
96-19	16565-16572	weights	_
96-20	16572-16573	.	_

#Text=The mean D of network N (DN) was calculated by averaging the nodal D (Di) and indicates the density or total wiring cost of the entire network.
97-1	16574-16577	The	_
97-2	16578-16582	mean	_
97-3	16583-16584	D	_
97-4	16585-16587	of	_
97-5	16588-16595	network	_
97-6	16596-16597	N	_
97-7	16598-16599	(	_
97-8	16599-16601	DN	_
97-9	16601-16602	)	_
97-10	16603-16606	was	_
97-11	16607-16617	calculated	_
97-12	16618-16620	by	_
97-13	16621-16630	averaging	_
97-14	16631-16634	the	_
97-15	16635-16640	nodal	_
97-16	16641-16642	D	_
97-17	16643-16644	(	_
97-18	16644-16646	Di	_
97-19	16646-16647	)	_
97-20	16648-16651	and	_
97-21	16652-16661	indicates	_
97-22	16662-16665	the	_
97-23	16666-16673	density	_
97-24	16674-16676	or	_
97-25	16677-16682	total	_
97-26	16683-16689	wiring	_
97-27	16690-16694	cost	_
97-28	16695-16697	of	_
97-29	16698-16701	the	_
97-30	16702-16708	entire	_
97-31	16709-16716	network	_
97-32	16716-16717	.	_

#Text=The EC is a measure of the influence of a node in a network.
98-1	16718-16721	The	_
98-2	16722-16724	EC	_
98-3	16725-16727	is	_
98-4	16728-16729	a	_
98-5	16730-16737	measure	_
98-6	16738-16740	of	_
98-7	16741-16744	the	_
98-8	16745-16754	influence	_
98-9	16755-16757	of	_
98-10	16758-16759	a	_
98-11	16760-16764	node	_
98-12	16765-16767	in	_
98-13	16768-16769	a	_
98-14	16770-16777	network	_
98-15	16777-16778	.	_

#Text=Basically, a node with a high EC has connections with nodes that themselves have a strong connection with many other nodes that are central within the network.
99-1	16779-16788	Basically	_
99-2	16788-16789	,	_
99-3	16790-16791	a	_
99-4	16792-16796	node	_
99-5	16797-16801	with	_
99-6	16802-16803	a	_
99-7	16804-16808	high	_
99-8	16809-16811	EC	_
99-9	16812-16815	has	_
99-10	16816-16827	connections	_
99-11	16828-16832	with	_
99-12	16833-16838	nodes	_
99-13	16839-16843	that	_
99-14	16844-16854	themselves	_
99-15	16855-16859	have	_
99-16	16860-16861	a	_
99-17	16862-16868	strong	_
99-18	16869-16879	connection	_
99-19	16880-16884	with	_
99-20	16885-16889	many	_
99-21	16890-16895	other	_
99-22	16896-16901	nodes	_
99-23	16902-16906	that	_
99-24	16907-16910	are	_
99-25	16911-16918	central	_
99-26	16919-16925	within	_
99-27	16926-16929	the	_
99-28	16930-16937	network	_
99-29	16937-16938	.	_

#Text=It takes into account the entire pattern of the network and is therefore an important addition to the degree centrality.
100-1	16939-16941	It	_
100-2	16942-16947	takes	_
100-3	16948-16952	into	_
100-4	16953-16960	account	_
100-5	16961-16964	the	_
100-6	16965-16971	entire	_
100-7	16972-16979	pattern	_
100-8	16980-16982	of	_
100-9	16983-16986	the	_
100-10	16987-16994	network	_
100-11	16995-16998	and	_
100-12	16999-17001	is	_
100-13	17002-17011	therefore	_
100-14	17012-17014	an	_
100-15	17015-17024	important	_
100-16	17025-17033	addition	_
100-17	17034-17036	to	_
100-18	17037-17040	the	_
100-19	17041-17047	degree	_
100-20	17048-17058	centrality	_
100-21	17058-17059	.	_

#Text=EC is thought to be a more adequate measurement of local centrality than the often used betweenness centrality parameter.
101-1	17060-17062	EC	_
101-2	17063-17065	is	_
101-3	17066-17073	thought	_
101-4	17074-17076	to	_
101-5	17077-17079	be	_
101-6	17080-17081	a	_
101-7	17082-17086	more	_
101-8	17087-17095	adequate	_
101-9	17096-17107	measurement	_
101-10	17108-17110	of	_
101-11	17111-17116	local	_
101-12	17117-17127	centrality	_
101-13	17128-17132	than	_
101-14	17133-17136	the	_
101-15	17137-17142	often	_
101-16	17143-17147	used	_
101-17	17148-17159	betweenness	_
101-18	17160-17170	centrality	_
101-19	17171-17180	parameter	_
101-20	17180-17181	.	_

#Text=Global EC (ECN) was again the global average of nodal EC (ECi), calculated the same way as global CCN and DN.
102-1	17182-17188	Global	_
102-2	17189-17191	EC	_
102-3	17192-17193	(	_
102-4	17193-17196	ECN	_
102-5	17196-17197	)	_
102-6	17198-17201	was	_
102-7	17202-17207	again	_
102-8	17208-17211	the	_
102-9	17212-17218	global	_
102-10	17219-17226	average	_
102-11	17227-17229	of	_
102-12	17230-17235	nodal	_
102-13	17236-17238	EC	_
102-14	17239-17240	(	_
102-15	17240-17243	ECi	_
102-16	17243-17244	)	_
102-17	17244-17245	,	_
102-18	17246-17256	calculated	_
102-19	17257-17260	the	_
102-20	17261-17265	same	_
102-21	17266-17269	way	_
102-22	17270-17272	as	_
102-23	17273-17279	global	_
102-24	17280-17283	CCN	_
102-25	17284-17287	and	_
102-26	17288-17290	DN	_
102-27	17290-17291	.	_

#Text=Statistical analyses
#Text=Demographic and clinical characteristics were analyzed using IBM SPSS Statistics 20 (IBM, New York, NY, USA) using independent samples t-test and non-parametric Kruskal–Wallis for continuous variables, and χ2 tests for categorical variables.
103-1	17292-17303	Statistical	_
103-2	17304-17312	analyses	_
103-3	17313-17324	Demographic	_
103-4	17325-17328	and	_
103-5	17329-17337	clinical	_
103-6	17338-17353	characteristics	_
103-7	17354-17358	were	_
103-8	17359-17367	analyzed	_
103-9	17368-17373	using	_
103-10	17374-17377	IBM	_
103-11	17378-17382	SPSS	_
103-12	17383-17393	Statistics	_
103-13	17394-17396	20	_
103-14	17397-17398	(	_
103-15	17398-17401	IBM	_
103-16	17401-17402	,	_
103-17	17403-17406	New	_
103-18	17407-17411	York	_
103-19	17411-17412	,	_
103-20	17413-17415	NY	_
103-21	17415-17416	,	_
103-22	17417-17420	USA	_
103-23	17420-17421	)	_
103-24	17422-17427	using	_
103-25	17428-17439	independent	_
103-26	17440-17447	samples	_
103-27	17448-17454	t-test	_
103-28	17455-17458	and	_
103-29	17459-17473	non-parametric	_
103-30	17474-17488	Kruskal–Wallis	_
103-31	17489-17492	for	_
103-32	17493-17503	continuous	_
103-33	17504-17513	variables	_
103-34	17513-17514	,	_
103-35	17515-17518	and	_
103-36	17519-17521	χ2	_
103-37	17522-17527	tests	_
103-38	17528-17531	for	_
103-39	17532-17543	categorical	_
103-40	17544-17553	variables	_
103-41	17553-17554	.	_

#Text=Within the AD group, associations were examined using bivariate correlation analyses.
104-1	17555-17561	Within	_
104-2	17562-17565	the	_
104-3	17566-17568	AD	_
104-4	17569-17574	group	_
104-5	17574-17575	,	_
104-6	17576-17588	associations	_
104-7	17589-17593	were	_
104-8	17594-17602	examined	_
104-9	17603-17608	using	_
104-10	17609-17618	bivariate	_
104-11	17619-17630	correlation	_
104-12	17631-17639	analyses	_
104-13	17639-17640	.	_

#Text=All network characteristics were normally distributed, and thus, parametric tests were used to test for between group differences and within group associations.
105-1	17641-17644	All	_
105-2	17645-17652	network	_
105-3	17653-17668	characteristics	_
105-4	17669-17673	were	_
105-5	17674-17682	normally	_
105-6	17683-17694	distributed	_
105-7	17694-17695	,	_
105-8	17696-17699	and	_
105-9	17700-17704	thus	_
105-10	17704-17705	,	_
105-11	17706-17716	parametric	_
105-12	17717-17722	tests	_
105-13	17723-17727	were	_
105-14	17728-17732	used	_
105-15	17733-17735	to	_
105-16	17736-17740	test	_
105-17	17741-17744	for	_
105-18	17745-17752	between	_
105-19	17753-17758	group	_
105-20	17759-17770	differences	_
105-21	17771-17774	and	_
105-22	17775-17781	within	_
105-23	17782-17787	group	_
105-24	17788-17800	associations	_
105-25	17800-17801	.	_

#Text=All individual network characteristics (GE, CC, D and EC), obtained from the correlation matrix, were compared between the AD patients and HCs, and associated with AD duration (in years) and severity (total AUDIT score) within the AD group using multiple linear regressions, and considered significant at P < 0.05 two-sided.
106-1	17802-17805	All	_
106-2	17806-17816	individual	_
106-3	17817-17824	network	_
106-4	17825-17840	characteristics	_
106-5	17841-17842	(	_
106-6	17842-17844	GE	_
106-7	17844-17845	,	_
106-8	17846-17848	CC	_
106-9	17848-17849	,	_
106-10	17850-17851	D	_
106-11	17852-17855	and	_
106-12	17856-17858	EC	_
106-13	17858-17859	)	_
106-14	17859-17860	,	_
106-15	17861-17869	obtained	_
106-16	17870-17874	from	_
106-17	17875-17878	the	_
106-18	17879-17890	correlation	_
106-19	17891-17897	matrix	_
106-20	17897-17898	,	_
106-21	17899-17903	were	_
106-22	17904-17912	compared	_
106-23	17913-17920	between	_
106-24	17921-17924	the	_
106-25	17925-17927	AD	_
106-26	17928-17936	patients	_
106-27	17937-17940	and	_
106-28	17941-17944	HCs	_
106-29	17944-17945	,	_
106-30	17946-17949	and	_
106-31	17950-17960	associated	_
106-32	17961-17965	with	_
106-33	17966-17968	AD	_
106-34	17969-17977	duration	_
106-35	17978-17979	(	_
106-36	17979-17981	in	_
106-37	17982-17987	years	_
106-38	17987-17988	)	_
106-39	17989-17992	and	_
106-40	17993-18001	severity	_
106-41	18002-18003	(	_
106-42	18003-18008	total	_
106-43	18009-18014	AUDIT	_
106-44	18015-18020	score	_
106-45	18020-18021	)	_
106-46	18022-18028	within	_
106-47	18029-18032	the	_
106-48	18033-18035	AD	_
106-49	18036-18041	group	_
106-50	18042-18047	using	_
106-51	18048-18056	multiple	_
106-52	18057-18063	linear	_
106-53	18064-18075	regressions	_
106-54	18075-18076	,	_
106-55	18077-18080	and	_
106-56	18081-18091	considered	_
106-57	18092-18103	significant	_
106-58	18104-18106	at	_
106-59	18107-18108	P	_
106-60	18109-18110	<	_
106-61	18111-18115	0.05	_
106-62	18116-18125	two-sided	_
106-63	18125-18126	.	_

#Text=Alcohol use was also assessed in HCs using the AUDIT questionnaire, albeit showing significantly lower scores and less variance (i.e. a bottom effect).
107-1	18127-18134	Alcohol	_
107-2	18135-18138	use	_
107-3	18139-18142	was	_
107-4	18143-18147	also	_
107-5	18148-18156	assessed	_
107-6	18157-18159	in	_
107-7	18160-18163	HCs	_
107-8	18164-18169	using	_
107-9	18170-18173	the	_
107-10	18174-18179	AUDIT	_
107-11	18180-18193	questionnaire	_
107-12	18193-18194	,	_
107-13	18195-18201	albeit	_
107-14	18202-18209	showing	_
107-15	18210-18223	significantly	_
107-16	18224-18229	lower	_
107-17	18230-18236	scores	_
107-18	18237-18240	and	_
107-19	18241-18245	less	_
107-20	18246-18254	variance	_
107-21	18255-18256	(	_
107-22	18256-18259	i.e	_
107-23	18259-18260	.	_
107-24	18261-18262	a	_
107-25	18263-18269	bottom	_
107-26	18270-18276	effect	_
107-27	18276-18277	)	_
107-28	18277-18278	.	_

#Text=We additionally examined whether an association between alcohol use (AUDIT score) and network topology as seen in the AD group was specific for the patient sample, or could be generalized to a non-alcoholic population.
108-1	18279-18281	We	_
108-2	18282-18294	additionally	_
108-3	18295-18303	examined	_
108-4	18304-18311	whether	_
108-5	18312-18314	an	_
108-6	18315-18326	association	_
108-7	18327-18334	between	_
108-8	18335-18342	alcohol	_
108-9	18343-18346	use	_
108-10	18347-18348	(	_
108-11	18348-18353	AUDIT	_
108-12	18354-18359	score	_
108-13	18359-18360	)	_
108-14	18361-18364	and	_
108-15	18365-18372	network	_
108-16	18373-18381	topology	_
108-17	18382-18384	as	_
108-18	18385-18389	seen	_
108-19	18390-18392	in	_
108-20	18393-18396	the	_
108-21	18397-18399	AD	_
108-22	18400-18405	group	_
108-23	18406-18409	was	_
108-24	18410-18418	specific	_
108-25	18419-18422	for	_
108-26	18423-18426	the	_
108-27	18427-18434	patient	_
108-28	18435-18441	sample	_
108-29	18441-18442	,	_
108-30	18443-18445	or	_
108-31	18446-18451	could	_
108-32	18452-18454	be	_
108-33	18455-18466	generalized	_
108-34	18467-18469	to	_
108-35	18470-18471	a	_
108-36	18472-18485	non-alcoholic	_
108-37	18486-18496	population	_
108-38	18496-18497	.	_

#Text=Mean head motion, age and gender were added as covariates to all analyses.
109-1	18498-18502	Mean	_
109-2	18503-18507	head	_
109-3	18508-18514	motion	_
109-4	18514-18515	,	_
109-5	18516-18519	age	_
109-6	18520-18523	and	_
109-7	18524-18530	gender	_
109-8	18531-18535	were	_
109-9	18536-18541	added	_
109-10	18542-18544	as	_
109-11	18545-18555	covariates	_
109-12	18556-18558	to	_
109-13	18559-18562	all	_
109-14	18563-18571	analyses	_
109-15	18571-18572	.	_

#Text=The significance level for all demographic/clinical and network ANOVA and correlational analyses was set to P < 0.05.
110-1	18573-18576	The	_
110-2	18577-18589	significance	_
110-3	18590-18595	level	_
110-4	18596-18599	for	_
110-5	18600-18603	all	_
110-6	18604-18615	demographic	_
110-7	18615-18616	/	_
110-8	18616-18624	clinical	_
110-9	18625-18628	and	_
110-10	18629-18636	network	_
110-11	18637-18642	ANOVA	_
110-12	18643-18646	and	_
110-13	18647-18660	correlational	_
110-14	18661-18669	analyses	_
110-15	18670-18673	was	_
110-16	18674-18677	set	_
110-17	18678-18680	to	_
110-18	18681-18682	P	_
110-19	18683-18684	<	_
110-20	18685-18689	0.05	_
110-21	18689-18690	.	_

#Text=We post hoc tested for the influence of smoking and depression symptoms, as groups differed on these characteristics, for total gray matter volume obtained from the T1 scan after segmentation using Ged Ridgway’s VBM script ‘get_totals.m’ in MATLAB (http://www0.cs.ucl.ac.uk/staff/G.Ridgway/vbm/get_totals.m), and for abstinence duration in the within patient group analyses.
111-1	18691-18693	We	_
111-2	18694-18698	post	_
111-3	18699-18702	hoc	_
111-4	18703-18709	tested	_
111-5	18710-18713	for	_
111-6	18714-18717	the	_
111-7	18718-18727	influence	_
111-8	18728-18730	of	_
111-9	18731-18738	smoking	_
111-10	18739-18742	and	_
111-11	18743-18753	depression	_
111-12	18754-18762	symptoms	_
111-13	18762-18763	,	_
111-14	18764-18766	as	_
111-15	18767-18773	groups	_
111-16	18774-18782	differed	_
111-17	18783-18785	on	_
111-18	18786-18791	these	_
111-19	18792-18807	characteristics	_
111-20	18807-18808	,	_
111-21	18809-18812	for	_
111-22	18813-18818	total	_
111-23	18819-18823	gray	_
111-24	18824-18830	matter	_
111-25	18831-18837	volume	_
111-26	18838-18846	obtained	_
111-27	18847-18851	from	_
111-28	18852-18855	the	_
111-29	18856-18858	T1	_
111-30	18859-18863	scan	_
111-31	18864-18869	after	_
111-32	18870-18882	segmentation	_
111-33	18883-18888	using	_
111-34	18889-18892	Ged	_
111-35	18893-18900	Ridgway	_
111-36	18900-18901	’	_
111-37	18901-18902	s	_
111-38	18903-18906	VBM	_
111-39	18907-18913	script	_
111-40	18914-18915	‘	_
111-41	18915-18927	get_totals.m	_
111-42	18927-18928	’	_
111-43	18929-18931	in	_
111-44	18932-18938	MATLAB	_
111-45	18939-18940	(	_
111-46	18940-18944	http	_
111-47	18944-18945	:	_
111-48	18945-18946	/	_
111-49	18946-18947	/	_
111-50	18947-18951	www0	_
111-51	18951-18952	.	_
111-52	18952-18964	cs.ucl.ac.uk	_
111-53	18964-18965	/	_
111-54	18965-18970	staff	_
111-55	18970-18971	/	_
111-56	18971-18980	G.Ridgway	_
111-57	18980-18981	/	_
111-58	18981-18984	vbm	_
111-59	18984-18985	/	_
111-60	18985-18997	get_totals.m	_
111-61	18997-18998	)	_
111-62	18998-18999	,	_
111-63	19000-19003	and	_
111-64	19004-19007	for	_
111-65	19008-19018	abstinence	_
111-66	19019-19027	duration	_
111-67	19028-19030	in	_
111-68	19031-19034	the	_
111-69	19035-19041	within	_
111-70	19042-19049	patient	_
111-71	19050-19055	group	_
111-72	19056-19064	analyses	_
111-73	19064-19065	.	_

#Text=RESULTS
#Text=Sample characteristics
#Text=The two groups were matched on age, gender, education and handedness.
112-1	19066-19073	RESULTS	_
112-2	19074-19080	Sample	_
112-3	19081-19096	characteristics	_
112-4	19097-19100	The	_
112-5	19101-19104	two	_
112-6	19105-19111	groups	_
112-7	19112-19116	were	_
112-8	19117-19124	matched	_
112-9	19125-19127	on	_
112-10	19128-19131	age	_
112-11	19131-19132	,	_
112-12	19133-19139	gender	_
112-13	19139-19140	,	_
112-14	19141-19150	education	_
112-15	19151-19154	and	_
112-16	19155-19165	handedness	_
112-17	19165-19166	.	_

#Text=As expected, the AD group had more severe alcohol use problems (total AUDIT score) than the HC group (t = 24.221, P < 0.001).
113-1	19167-19169	As	_
113-2	19170-19178	expected	_
113-3	19178-19179	,	_
113-4	19180-19183	the	_
113-5	19184-19186	AD	_
113-6	19187-19192	group	_
113-7	19193-19196	had	_
113-8	19197-19201	more	_
113-9	19202-19208	severe	_
113-10	19209-19216	alcohol	_
113-11	19217-19220	use	_
113-12	19221-19229	problems	_
113-13	19230-19231	(	_
113-14	19231-19236	total	_
113-15	19237-19242	AUDIT	_
113-16	19243-19248	score	_
113-17	19248-19249	)	_
113-18	19250-19254	than	_
113-19	19255-19258	the	_
113-20	19259-19261	HC	_
113-21	19262-19267	group	_
113-22	19268-19269	(	_
113-23	19269-19270	t	_
113-24	19271-19272	=	_
113-25	19273-19279	24.221	_
113-26	19279-19280	,	_
113-27	19281-19282	P	_
113-28	19283-19284	<	_
113-29	19285-19290	0.001	_
113-30	19290-19291	)	_
113-31	19291-19292	.	_

#Text=The AD group also contained more smokers (χ2 = 12.156, P < 0.001) and reported more depressive symptoms (U = 137.5, P = 0.016) than the HC group.
114-1	19293-19296	The	_
114-2	19297-19299	AD	_
114-3	19300-19305	group	_
114-4	19306-19310	also	_
114-5	19311-19320	contained	_
114-6	19321-19325	more	_
114-7	19326-19333	smokers	_
114-8	19334-19335	(	_
114-9	19335-19337	χ2	_
114-10	19338-19339	=	_
114-11	19340-19346	12.156	_
114-12	19346-19347	,	_
114-13	19348-19349	P	_
114-14	19350-19351	<	_
114-15	19352-19357	0.001	_
114-16	19357-19358	)	_
114-17	19359-19362	and	_
114-18	19363-19371	reported	_
114-19	19372-19376	more	_
114-20	19377-19387	depressive	_
114-21	19388-19396	symptoms	_
114-22	19397-19398	(	_
114-23	19398-19399	U	_
114-24	19400-19401	=	_
114-25	19402-19407	137.5	_
114-26	19407-19408	,	_
114-27	19409-19410	P	_
114-28	19411-19412	=	_
114-29	19413-19418	0.016	_
114-30	19418-19419	)	_
114-31	19420-19424	than	_
114-32	19425-19428	the	_
114-33	19429-19431	HC	_
114-34	19432-19437	group	_
114-35	19437-19438	.	_

#Text=Groups did not differ regarding mean head motion during scanning and total GM volume.
115-1	19439-19445	Groups	_
115-2	19446-19449	did	_
115-3	19450-19453	not	_
115-4	19454-19460	differ	_
115-5	19461-19470	regarding	_
115-6	19471-19475	mean	_
115-7	19476-19480	head	_
115-8	19481-19487	motion	_
115-9	19488-19494	during	_
115-10	19495-19503	scanning	_
115-11	19504-19507	and	_
115-12	19508-19513	total	_
115-13	19514-19516	GM	_
115-14	19517-19523	volume	_
115-15	19523-19524	.	_

#Text=See Table 1 for sample characteristics.
116-1	19525-19528	See	_
116-2	19529-19534	Table	_
116-3	19535-19536	1	_
116-4	19537-19540	for	_
116-5	19541-19547	sample	_
116-6	19548-19563	characteristics	_
116-7	19563-19564	.	_

#Text=Alcohol dependence severity and duration were moderately correlated within the AD group (R = 0.509, P = 0.011).
117-1	19565-19572	Alcohol	_
117-2	19573-19583	dependence	_
117-3	19584-19592	severity	_
117-4	19593-19596	and	_
117-5	19597-19605	duration	_
117-6	19606-19610	were	_
117-7	19611-19621	moderately	_
117-8	19622-19632	correlated	_
117-9	19633-19639	within	_
117-10	19640-19643	the	_
117-11	19644-19646	AD	_
117-12	19647-19652	group	_
117-13	19653-19654	(	_
117-14	19654-19655	R	_
117-15	19656-19657	=	_
117-16	19658-19663	0.509	_
117-17	19663-19664	,	_
117-18	19665-19666	P	_
117-19	19667-19668	=	_
117-20	19669-19674	0.011	_
117-21	19674-19675	)	_
117-22	19675-19676	.	_

#Text=AD severity and duration were not correlated with smoking behavior (number of cigarettes smoked per day) (severity: R = 0.187, P = 0.383; duration: R = −0.170, P = 0.427).
118-1	19677-19679	AD	_
118-2	19680-19688	severity	_
118-3	19689-19692	and	_
118-4	19693-19701	duration	_
118-5	19702-19706	were	_
118-6	19707-19710	not	_
118-7	19711-19721	correlated	_
118-8	19722-19726	with	_
118-9	19727-19734	smoking	_
118-10	19735-19743	behavior	_
118-11	19744-19745	(	_
118-12	19745-19751	number	_
118-13	19752-19754	of	_
118-14	19755-19765	cigarettes	_
118-15	19766-19772	smoked	_
118-16	19773-19776	per	_
118-17	19777-19780	day	_
118-18	19780-19781	)	_
118-19	19782-19783	(	_
118-20	19783-19791	severity	_
118-21	19791-19792	:	_
118-22	19793-19794	R	_
118-23	19795-19796	=	_
118-24	19797-19802	0.187	_
118-25	19802-19803	,	_
118-26	19804-19805	P	_
118-27	19806-19807	=	_
118-28	19808-19813	0.383	_
118-29	19813-19814	;	_
118-30	19815-19823	duration	_
118-31	19823-19824	:	_
118-32	19825-19826	R	_
118-33	19827-19828	=	_
118-34	19829-19830	−	_
118-35	19830-19835	0.170	_
118-36	19835-19836	,	_
118-37	19837-19838	P	_
118-38	19839-19840	=	_
118-39	19841-19846	0.427	_
118-40	19846-19847	)	_
118-41	19847-19848	.	_

#Text=AD severity showed a moderately high positive correlation with abstinence duration (R = 0.571, P = 0.004) and a moderately high inverse correlation with total GM volume (R = −0.560, P = 0.004), whereas AD duration did not.
119-1	19849-19851	AD	_
119-2	19852-19860	severity	_
119-3	19861-19867	showed	_
119-4	19868-19869	a	_
119-5	19870-19880	moderately	_
119-6	19881-19885	high	_
119-7	19886-19894	positive	_
119-8	19895-19906	correlation	_
119-9	19907-19911	with	_
119-10	19912-19922	abstinence	_
119-11	19923-19931	duration	_
119-12	19932-19933	(	_
119-13	19933-19934	R	_
119-14	19935-19936	=	_
119-15	19937-19942	0.571	_
119-16	19942-19943	,	_
119-17	19944-19945	P	_
119-18	19946-19947	=	_
119-19	19948-19953	0.004	_
119-20	19953-19954	)	_
119-21	19955-19958	and	_
119-22	19959-19960	a	_
119-23	19961-19971	moderately	_
119-24	19972-19976	high	_
119-25	19977-19984	inverse	_
119-26	19985-19996	correlation	_
119-27	19997-20001	with	_
119-28	20002-20007	total	_
119-29	20008-20010	GM	_
119-30	20011-20017	volume	_
119-31	20018-20019	(	_
119-32	20019-20020	R	_
119-33	20021-20022	=	_
119-34	20023-20024	−	_
119-35	20024-20029	0.560	_
119-36	20029-20030	,	_
119-37	20031-20032	P	_
119-38	20033-20034	=	_
119-39	20035-20040	0.004	_
119-40	20040-20041	)	_
119-41	20041-20042	,	_
119-42	20043-20050	whereas	_
119-43	20051-20053	AD	_
119-44	20054-20062	duration	_
119-45	20063-20066	did	_
119-46	20067-20070	not	_
119-47	20070-20071	.	_

#Text=Complex network analyses
#Text=Group comparisons: AD versus HC
#Text=Global brain network topology (described by GE, CCN, DN and ECN) for the AD and the HC group was not significantly different, as illustrated in Fig. 1.
120-1	20072-20079	Complex	_
120-2	20080-20087	network	_
120-3	20088-20096	analyses	_
120-4	20097-20102	Group	_
120-5	20103-20114	comparisons	_
120-6	20114-20115	:	_
120-7	20116-20118	AD	_
120-8	20119-20125	versus	_
120-9	20126-20128	HC	_
120-10	20129-20135	Global	_
120-11	20136-20141	brain	_
120-12	20142-20149	network	_
120-13	20150-20158	topology	_
120-14	20159-20160	(	_
120-15	20160-20169	described	_
120-16	20170-20172	by	_
120-17	20173-20175	GE	_
120-18	20175-20176	,	_
120-19	20177-20180	CCN	_
120-20	20180-20181	,	_
120-21	20182-20184	DN	_
120-22	20185-20188	and	_
120-23	20189-20192	ECN	_
120-24	20192-20193	)	_
120-25	20194-20197	for	_
120-26	20198-20201	the	_
120-27	20202-20204	AD	_
120-28	20205-20208	and	_
120-29	20209-20212	the	_
120-30	20213-20215	HC	_
120-31	20216-20221	group	_
120-32	20222-20225	was	_
120-33	20226-20229	not	_
120-34	20230-20243	significantly	_
120-35	20244-20253	different	_
120-36	20253-20254	,	_
120-37	20255-20257	as	_
120-38	20258-20269	illustrated	_
120-39	20270-20272	in	_
120-40	20273-20276	Fig	_
120-41	20276-20277	.	_
120-42	20278-20279	1	_
120-43	20279-20280	.	_

#Text=There were also no group differences in the local network characteristics (CCi, Di, ECi) of the striatal nodes.
121-1	20281-20286	There	_
121-2	20287-20291	were	_
121-3	20292-20296	also	_
121-4	20297-20299	no	_
121-5	20300-20305	group	_
121-6	20306-20317	differences	_
121-7	20318-20320	in	_
121-8	20321-20324	the	_
121-9	20325-20330	local	_
121-10	20331-20338	network	_
121-11	20339-20354	characteristics	_
121-12	20355-20356	(	_
121-13	20356-20359	CCi	_
121-14	20359-20360	,	_
121-15	20361-20363	Di	_
121-16	20363-20364	,	_
121-17	20365-20368	ECi	_
121-18	20368-20369	)	_
121-19	20370-20372	of	_
121-20	20373-20376	the	_
121-21	20377-20385	striatal	_
121-22	20386-20391	nodes	_
121-23	20391-20392	.	_

#Text=Alcohol dependence characteristics
#Text=Severity of alcohol use
#Text=Higher AD severity was associated with lower CCN (r2 = 0.2992, P = 0.0493), and a marginally (0.1 > P > 0.05) lower GE (r2 = 0.2819, P = 0.0646) and DN (r2 = 0.2722, P = 0.0752), but AD severity was not associated with ECN (r2 = 0.1535, P = 0.5434) (Fig. 2a).
122-1	20393-20400	Alcohol	_
122-2	20401-20411	dependence	_
122-3	20412-20427	characteristics	_
122-4	20428-20436	Severity	_
122-5	20437-20439	of	_
122-6	20440-20447	alcohol	_
122-7	20448-20451	use	_
122-8	20452-20458	Higher	_
122-9	20459-20461	AD	_
122-10	20462-20470	severity	_
122-11	20471-20474	was	_
122-12	20475-20485	associated	_
122-13	20486-20490	with	_
122-14	20491-20496	lower	_
122-15	20497-20500	CCN	_
122-16	20501-20502	(	_
122-17	20502-20504	r2	_
122-18	20505-20506	=	_
122-19	20507-20513	0.2992	_
122-20	20513-20514	,	_
122-21	20515-20516	P	_
122-22	20517-20518	=	_
122-23	20519-20525	0.0493	_
122-24	20525-20526	)	_
122-25	20526-20527	,	_
122-26	20528-20531	and	_
122-27	20532-20533	a	_
122-28	20534-20544	marginally	_
122-29	20545-20546	(	_
122-30	20546-20549	0.1	_
122-31	20550-20551	>	_
122-32	20552-20553	P	_
122-33	20554-20555	>	_
122-34	20556-20560	0.05	_
122-35	20560-20561	)	_
122-36	20562-20567	lower	_
122-37	20568-20570	GE	_
122-38	20571-20572	(	_
122-39	20572-20574	r2	_
122-40	20575-20576	=	_
122-41	20577-20583	0.2819	_
122-42	20583-20584	,	_
122-43	20585-20586	P	_
122-44	20587-20588	=	_
122-45	20589-20595	0.0646	_
122-46	20595-20596	)	_
122-47	20597-20600	and	_
122-48	20601-20603	DN	_
122-49	20604-20605	(	_
122-50	20605-20607	r2	_
122-51	20608-20609	=	_
122-52	20610-20616	0.2722	_
122-53	20616-20617	,	_
122-54	20618-20619	P	_
122-55	20620-20621	=	_
122-56	20622-20628	0.0752	_
122-57	20628-20629	)	_
122-58	20629-20630	,	_
122-59	20631-20634	but	_
122-60	20635-20637	AD	_
122-61	20638-20646	severity	_
122-62	20647-20650	was	_
122-63	20651-20654	not	_
122-64	20655-20665	associated	_
122-65	20666-20670	with	_
122-66	20671-20674	ECN	_
122-67	20675-20676	(	_
122-68	20676-20678	r2	_
122-69	20679-20680	=	_
122-70	20681-20687	0.1535	_
122-71	20687-20688	,	_
122-72	20689-20690	P	_
122-73	20691-20692	=	_
122-74	20693-20699	0.5434	_
122-75	20699-20700	)	_
122-76	20701-20702	(	_
122-77	20702-20705	Fig	_
122-78	20705-20706	.	_
122-79	20707-20709	2a	_
122-80	20709-20710	)	_
122-81	20710-20711	.	_

#Text=Within the striatum, higher AD severity was associated with reduced CCi in the left caudate nucleus (r2 = 0.3477, P = 0.0226) (Fig. 3a), but this effect seemed inconsistent when using a variety of thresholded graphs (see Supporting Information Table S3).
123-1	20712-20718	Within	_
123-2	20719-20722	the	_
123-3	20723-20731	striatum	_
123-4	20731-20732	,	_
123-5	20733-20739	higher	_
123-6	20740-20742	AD	_
123-7	20743-20751	severity	_
123-8	20752-20755	was	_
123-9	20756-20766	associated	_
123-10	20767-20771	with	_
123-11	20772-20779	reduced	_
123-12	20780-20783	CCi	_
123-13	20784-20786	in	_
123-14	20787-20790	the	_
123-15	20791-20795	left	_
123-16	20796-20803	caudate	_
123-17	20804-20811	nucleus	_
123-18	20812-20813	(	_
123-19	20813-20815	r2	_
123-20	20816-20817	=	_
123-21	20818-20824	0.3477	_
123-22	20824-20825	,	_
123-23	20826-20827	P	_
123-24	20828-20829	=	_
123-25	20830-20836	0.0226	_
123-26	20836-20837	)	_
123-27	20838-20839	(	_
123-28	20839-20842	Fig	_
123-29	20842-20843	.	_
123-30	20844-20846	3a	_
123-31	20846-20847	)	_
123-32	20847-20848	,	_
123-33	20849-20852	but	_
123-34	20853-20857	this	_
123-35	20858-20864	effect	_
123-36	20865-20871	seemed	_
123-37	20872-20884	inconsistent	_
123-38	20885-20889	when	_
123-39	20890-20895	using	_
123-40	20896-20897	a	_
123-41	20898-20905	variety	_
123-42	20906-20908	of	_
123-43	20909-20920	thresholded	_
123-44	20921-20927	graphs	_
123-45	20928-20929	(	_
123-46	20929-20932	see	_
123-47	20933-20943	Supporting	_
123-48	20944-20955	Information	_
123-49	20956-20961	Table	_
123-50	20962-20964	S3	_
123-51	20964-20965	)	_
123-52	20965-20966	.	_

#Text=Because total AUDIT score was also available from the HC group (M = 4.00, SD = 3.03), we additionally examined if within a non-alcohol dependent sample, a similar association was detectable between alcohol use disorder characteristics and network topology.
124-1	20967-20974	Because	_
124-2	20975-20980	total	_
124-3	20981-20986	AUDIT	_
124-4	20987-20992	score	_
124-5	20993-20996	was	_
124-6	20997-21001	also	_
124-7	21002-21011	available	_
124-8	21012-21016	from	_
124-9	21017-21020	the	_
124-10	21021-21023	HC	_
124-11	21024-21029	group	_
124-12	21030-21031	(	_
124-13	21031-21032	M	_
124-14	21033-21034	=	_
124-15	21035-21039	4.00	_
124-16	21039-21040	,	_
124-17	21041-21043	SD	_
124-18	21044-21045	=	_
124-19	21046-21050	3.03	_
124-20	21050-21051	)	_
124-21	21051-21052	,	_
124-22	21053-21055	we	_
124-23	21056-21068	additionally	_
124-24	21069-21077	examined	_
124-25	21078-21080	if	_
124-26	21081-21087	within	_
124-27	21088-21089	a	_
124-28	21090-21101	non-alcohol	_
124-29	21102-21111	dependent	_
124-30	21112-21118	sample	_
124-31	21118-21119	,	_
124-32	21120-21121	a	_
124-33	21122-21129	similar	_
124-34	21130-21141	association	_
124-35	21142-21145	was	_
124-36	21146-21156	detectable	_
124-37	21157-21164	between	_
124-38	21165-21172	alcohol	_
124-39	21173-21176	use	_
124-40	21177-21185	disorder	_
124-41	21186-21201	characteristics	_
124-42	21202-21205	and	_
124-43	21206-21213	network	_
124-44	21214-21222	topology	_
124-45	21222-21223	.	_

#Text=We, however, did not show an effect of drinking severity on whole-brain network topology in HCs (all Ps > 0.5).
125-1	21224-21226	We	_
125-2	21226-21227	,	_
125-3	21228-21235	however	_
125-4	21235-21236	,	_
125-5	21237-21240	did	_
125-6	21241-21244	not	_
125-7	21245-21249	show	_
125-8	21250-21252	an	_
125-9	21253-21259	effect	_
125-10	21260-21262	of	_
125-11	21263-21271	drinking	_
125-12	21272-21280	severity	_
125-13	21281-21283	on	_
125-14	21284-21295	whole-brain	_
125-15	21296-21303	network	_
125-16	21304-21312	topology	_
125-17	21313-21315	in	_
125-18	21316-21319	HCs	_
125-19	21320-21321	(	_
125-20	21321-21324	all	_
125-21	21325-21327	Ps	_
125-22	21328-21329	>	_
125-23	21330-21333	0.5	_
125-24	21333-21334	)	_
125-25	21334-21335	.	_

#Text=Duration of alcohol dependence
#Text=Longer AD duration was associated with lower GE (r2 = 0.4789, Ps = 0.0119), DN (r2 = 0.4864, P = 0.0102), and CCN (r2 = 0.5158, P = 0.0056) in the whole-brain network, but AD duration was not associated with ECN (r2 = 0.2745, P = 0.6592) (Fig. 2b).
126-1	21336-21344	Duration	_
126-2	21345-21347	of	_
126-3	21348-21355	alcohol	_
126-4	21356-21366	dependence	_
126-5	21367-21373	Longer	_
126-6	21374-21376	AD	_
126-7	21377-21385	duration	_
126-8	21386-21389	was	_
126-9	21390-21400	associated	_
126-10	21401-21405	with	_
126-11	21406-21411	lower	_
126-12	21412-21414	GE	_
126-13	21415-21416	(	_
126-14	21416-21418	r2	_
126-15	21419-21420	=	_
126-16	21421-21427	0.4789	_
126-17	21427-21428	,	_
126-18	21429-21431	Ps	_
126-19	21432-21433	=	_
126-20	21434-21440	0.0119	_
126-21	21440-21441	)	_
126-22	21441-21442	,	_
126-23	21443-21445	DN	_
126-24	21446-21447	(	_
126-25	21447-21449	r2	_
126-26	21450-21451	=	_
126-27	21452-21458	0.4864	_
126-28	21458-21459	,	_
126-29	21460-21461	P	_
126-30	21462-21463	=	_
126-31	21464-21470	0.0102	_
126-32	21470-21471	)	_
126-33	21471-21472	,	_
126-34	21473-21476	and	_
126-35	21477-21480	CCN	_
126-36	21481-21482	(	_
126-37	21482-21484	r2	_
126-38	21485-21486	=	_
126-39	21487-21493	0.5158	_
126-40	21493-21494	,	_
126-41	21495-21496	P	_
126-42	21497-21498	=	_
126-43	21499-21505	0.0056	_
126-44	21505-21506	)	_
126-45	21507-21509	in	_
126-46	21510-21513	the	_
126-47	21514-21525	whole-brain	_
126-48	21526-21533	network	_
126-49	21533-21534	,	_
126-50	21535-21538	but	_
126-51	21539-21541	AD	_
126-52	21542-21550	duration	_
126-53	21551-21554	was	_
126-54	21555-21558	not	_
126-55	21559-21569	associated	_
126-56	21570-21574	with	_
126-57	21575-21578	ECN	_
126-58	21579-21580	(	_
126-59	21580-21582	r2	_
126-60	21583-21584	=	_
126-61	21585-21591	0.2745	_
126-62	21591-21592	,	_
126-63	21593-21594	P	_
126-64	21595-21596	=	_
126-65	21597-21603	0.6592	_
126-66	21603-21604	)	_
126-67	21605-21606	(	_
126-68	21606-21609	Fig	_
126-69	21609-21610	.	_
126-70	21611-21613	2b	_
126-71	21613-21614	)	_
126-72	21614-21615	.	_

#Text=Within the striatum, longer AD duration was associated with lower CCi and Di in the bilateral caudate nucleus (CCi: Left: r2 = 0.4197, P = 0.0374; Right: r2 = 0.4502, P = 0.0210; Di: Left: r2 = 0.4091, P = 0.0456; Right: r2 = 0.4246, P = 0.0342) and with lower CCi in the left putamen and right anterior putamen (anterior, Left: r2 = 0.4061, P = 0.0482; Right: r2 = 0.4272, P = 0.0325; posterior, Left: r2 = 0.4077, P = 0.0468).
127-1	21616-21622	Within	_
127-2	21623-21626	the	_
127-3	21627-21635	striatum	_
127-4	21635-21636	,	_
127-5	21637-21643	longer	_
127-6	21644-21646	AD	_
127-7	21647-21655	duration	_
127-8	21656-21659	was	_
127-9	21660-21670	associated	_
127-10	21671-21675	with	_
127-11	21676-21681	lower	_
127-12	21682-21685	CCi	_
127-13	21686-21689	and	_
127-14	21690-21692	Di	_
127-15	21693-21695	in	_
127-16	21696-21699	the	_
127-17	21700-21709	bilateral	_
127-18	21710-21717	caudate	_
127-19	21718-21725	nucleus	_
127-20	21726-21727	(	_
127-21	21727-21730	CCi	_
127-22	21730-21731	:	_
127-23	21732-21736	Left	_
127-24	21736-21737	:	_
127-25	21738-21740	r2	_
127-26	21741-21742	=	_
127-27	21743-21749	0.4197	_
127-28	21749-21750	,	_
127-29	21751-21752	P	_
127-30	21753-21754	=	_
127-31	21755-21761	0.0374	_
127-32	21761-21762	;	_
127-33	21763-21768	Right	_
127-34	21768-21769	:	_
127-35	21770-21772	r2	_
127-36	21773-21774	=	_
127-37	21775-21781	0.4502	_
127-38	21781-21782	,	_
127-39	21783-21784	P	_
127-40	21785-21786	=	_
127-41	21787-21793	0.0210	_
127-42	21793-21794	;	_
127-43	21795-21797	Di	_
127-44	21797-21798	:	_
127-45	21799-21803	Left	_
127-46	21803-21804	:	_
127-47	21805-21807	r2	_
127-48	21808-21809	=	_
127-49	21810-21816	0.4091	_
127-50	21816-21817	,	_
127-51	21818-21819	P	_
127-52	21820-21821	=	_
127-53	21822-21828	0.0456	_
127-54	21828-21829	;	_
127-55	21830-21835	Right	_
127-56	21835-21836	:	_
127-57	21837-21839	r2	_
127-58	21840-21841	=	_
127-59	21842-21848	0.4246	_
127-60	21848-21849	,	_
127-61	21850-21851	P	_
127-62	21852-21853	=	_
127-63	21854-21860	0.0342	_
127-64	21860-21861	)	_
127-65	21862-21865	and	_
127-66	21866-21870	with	_
127-67	21871-21876	lower	_
127-68	21877-21880	CCi	_
127-69	21881-21883	in	_
127-70	21884-21887	the	_
127-71	21888-21892	left	_
127-72	21893-21900	putamen	_
127-73	21901-21904	and	_
127-74	21905-21910	right	_
127-75	21911-21919	anterior	_
127-76	21920-21927	putamen	_
127-77	21928-21929	(	_
127-78	21929-21937	anterior	_
127-79	21937-21938	,	_
127-80	21939-21943	Left	_
127-81	21943-21944	:	_
127-82	21945-21947	r2	_
127-83	21948-21949	=	_
127-84	21950-21956	0.4061	_
127-85	21956-21957	,	_
127-86	21958-21959	P	_
127-87	21960-21961	=	_
127-88	21962-21968	0.0482	_
127-89	21968-21969	;	_
127-90	21970-21975	Right	_
127-91	21975-21976	:	_
127-92	21977-21979	r2	_
127-93	21980-21981	=	_
127-94	21982-21988	0.4272	_
127-95	21988-21989	,	_
127-96	21990-21991	P	_
127-97	21992-21993	=	_
127-98	21994-22000	0.0325	_
127-99	22000-22001	;	_
127-100	22002-22011	posterior	_
127-101	22011-22012	,	_
127-102	22013-22017	Left	_
127-103	22017-22018	:	_
127-104	22019-22021	r2	_
127-105	22022-22023	=	_
127-106	22024-22030	0.4077	_
127-107	22030-22031	,	_
127-108	22032-22033	P	_
127-109	22034-22035	=	_
127-110	22036-22042	0.0468	_
127-111	22042-22043	)	_
127-112	22043-22044	.	_

#Text=In contrast, longer AD duration was associated with higher ECi in the left posterior putamen (r2 = 0.4577, P = 0.0188).
128-1	22045-22047	In	_
128-2	22048-22056	contrast	_
128-3	22056-22057	,	_
128-4	22058-22064	longer	_
128-5	22065-22067	AD	_
128-6	22068-22076	duration	_
128-7	22077-22080	was	_
128-8	22081-22091	associated	_
128-9	22092-22096	with	_
128-10	22097-22103	higher	_
128-11	22104-22107	ECi	_
128-12	22108-22110	in	_
128-13	22111-22114	the	_
128-14	22115-22119	left	_
128-15	22120-22129	posterior	_
128-16	22130-22137	putamen	_
128-17	22138-22139	(	_
128-18	22139-22141	r2	_
128-19	22142-22143	=	_
128-20	22144-22150	0.4577	_
128-21	22150-22151	,	_
128-22	22152-22153	P	_
128-23	22154-22155	=	_
128-24	22156-22162	0.0188	_
128-25	22162-22163	)	_
128-26	22163-22164	.	_

#Text=These results are depicted in Fig. 3b.
129-1	22165-22170	These	_
129-2	22171-22178	results	_
129-3	22179-22182	are	_
129-4	22183-22191	depicted	_
129-5	22192-22194	in	_
129-6	22195-22198	Fig	_
129-7	22198-22199	.	_
129-8	22200-22202	3b	_
129-9	22202-22203	.	_

#Text=It should be noted that the effects in the striatum did not survive any correction for the multiple tests performed on four separate bilateral nodes.
130-1	22204-22206	It	_
130-2	22207-22213	should	_
130-3	22214-22216	be	_
130-4	22217-22222	noted	_
130-5	22223-22227	that	_
130-6	22228-22231	the	_
130-7	22232-22239	effects	_
130-8	22240-22242	in	_
130-9	22243-22246	the	_
130-10	22247-22255	striatum	_
130-11	22256-22259	did	_
130-12	22260-22263	not	_
130-13	22264-22271	survive	_
130-14	22272-22275	any	_
130-15	22276-22286	correction	_
130-16	22287-22290	for	_
130-17	22291-22294	the	_
130-18	22295-22303	multiple	_
130-19	22304-22309	tests	_
130-20	22310-22319	performed	_
130-21	22320-22322	on	_
130-22	22323-22327	four	_
130-23	22328-22336	separate	_
130-24	22337-22346	bilateral	_
130-25	22347-22352	nodes	_
130-26	22352-22353	.	_

#Text=Confounding variables
#Text=The within-group associations between AD characteristics (severity and duration) and network topology could have been confounded by clinical characteristics, such as the number of cigarettes smoked per day, depression symptoms according to the BDI and abstinence duration before the study.
131-1	22354-22365	Confounding	_
131-2	22366-22375	variables	_
131-3	22376-22379	The	_
131-4	22380-22392	within-group	_
131-5	22393-22405	associations	_
131-6	22406-22413	between	_
131-7	22414-22416	AD	_
131-8	22417-22432	characteristics	_
131-9	22433-22434	(	_
131-10	22434-22442	severity	_
131-11	22443-22446	and	_
131-12	22447-22455	duration	_
131-13	22455-22456	)	_
131-14	22457-22460	and	_
131-15	22461-22468	network	_
131-16	22469-22477	topology	_
131-17	22478-22483	could	_
131-18	22484-22488	have	_
131-19	22489-22493	been	_
131-20	22494-22504	confounded	_
131-21	22505-22507	by	_
131-22	22508-22516	clinical	_
131-23	22517-22532	characteristics	_
131-24	22532-22533	,	_
131-25	22534-22538	such	_
131-26	22539-22541	as	_
131-27	22542-22545	the	_
131-28	22546-22552	number	_
131-29	22553-22555	of	_
131-30	22556-22566	cigarettes	_
131-31	22567-22573	smoked	_
131-32	22574-22577	per	_
131-33	22578-22581	day	_
131-34	22581-22582	,	_
131-35	22583-22593	depression	_
131-36	22594-22602	symptoms	_
131-37	22603-22612	according	_
131-38	22613-22615	to	_
131-39	22616-22619	the	_
131-40	22620-22623	BDI	_
131-41	22624-22627	and	_
131-42	22628-22638	abstinence	_
131-43	22639-22647	duration	_
131-44	22648-22654	before	_
131-45	22655-22658	the	_
131-46	22659-22664	study	_
131-47	22664-22665	.	_

#Text=Therefore, we performed additional within AD-group regression analyses between these potential confounders and the general and local network characteristics.
132-1	22666-22675	Therefore	_
132-2	22675-22676	,	_
132-3	22677-22679	we	_
132-4	22680-22689	performed	_
132-5	22690-22700	additional	_
132-6	22701-22707	within	_
132-7	22708-22716	AD-group	_
132-8	22717-22727	regression	_
132-9	22728-22736	analyses	_
132-10	22737-22744	between	_
132-11	22745-22750	these	_
132-12	22751-22760	potential	_
132-13	22761-22772	confounders	_
132-14	22773-22776	and	_
132-15	22777-22780	the	_
132-16	22781-22788	general	_
132-17	22789-22792	and	_
132-18	22793-22798	local	_
132-19	22799-22806	network	_
132-20	22807-22822	characteristics	_
132-21	22822-22823	.	_

#Text=Smoking, depression, and abstinence duration were not associated (Ps > 0.2) with whole-brain network topology, and abstinence duration was also not associated with striatal network topology.
133-1	22824-22831	Smoking	_
133-2	22831-22832	,	_
133-3	22833-22843	depression	_
133-4	22843-22844	,	_
133-5	22845-22848	and	_
133-6	22849-22859	abstinence	_
133-7	22860-22868	duration	_
133-8	22869-22873	were	_
133-9	22874-22877	not	_
133-10	22878-22888	associated	_
133-11	22889-22890	(	_
133-12	22890-22892	Ps	_
133-13	22893-22894	>	_
133-14	22895-22898	0.2	_
133-15	22898-22899	)	_
133-16	22900-22904	with	_
133-17	22905-22916	whole-brain	_
133-18	22917-22924	network	_
133-19	22925-22933	topology	_
133-20	22933-22934	,	_
133-21	22935-22938	and	_
133-22	22939-22949	abstinence	_
133-23	22950-22958	duration	_
133-24	22959-22962	was	_
133-25	22963-22967	also	_
133-26	22968-22971	not	_
133-27	22972-22982	associated	_
133-28	22983-22987	with	_
133-29	22988-22996	striatal	_
133-30	22997-23004	network	_
133-31	23005-23013	topology	_
133-32	23013-23014	.	_

#Text=However, the number of cigarettes per day was associated with higher Di in the left posterior putamen (r2 = 0.2883, P = 0.0365), whereas a higher depression score was associated with lower Di in the right anterior putamen (r2 = 0.2685, P = 0.0306).
134-1	23015-23022	However	_
134-2	23022-23023	,	_
134-3	23024-23027	the	_
134-4	23028-23034	number	_
134-5	23035-23037	of	_
134-6	23038-23048	cigarettes	_
134-7	23049-23052	per	_
134-8	23053-23056	day	_
134-9	23057-23060	was	_
134-10	23061-23071	associated	_
134-11	23072-23076	with	_
134-12	23077-23083	higher	_
134-13	23084-23086	Di	_
134-14	23087-23089	in	_
134-15	23090-23093	the	_
134-16	23094-23098	left	_
134-17	23099-23108	posterior	_
134-18	23109-23116	putamen	_
134-19	23117-23118	(	_
134-20	23118-23120	r2	_
134-21	23121-23122	=	_
134-22	23123-23129	0.2883	_
134-23	23129-23130	,	_
134-24	23131-23132	P	_
134-25	23133-23134	=	_
134-26	23135-23141	0.0365	_
134-27	23141-23142	)	_
134-28	23142-23143	,	_
134-29	23144-23151	whereas	_
134-30	23152-23153	a	_
134-31	23154-23160	higher	_
134-32	23161-23171	depression	_
134-33	23172-23177	score	_
134-34	23178-23181	was	_
134-35	23182-23192	associated	_
134-36	23193-23197	with	_
134-37	23198-23203	lower	_
134-38	23204-23206	Di	_
134-39	23207-23209	in	_
134-40	23210-23213	the	_
134-41	23214-23219	right	_
134-42	23220-23228	anterior	_
134-43	23229-23236	putamen	_
134-44	23237-23238	(	_
134-45	23238-23240	r2	_
134-46	23241-23242	=	_
134-47	23243-23249	0.2685	_
134-48	23249-23250	,	_
134-49	23251-23252	P	_
134-50	23253-23254	=	_
134-51	23255-23261	0.0306	_
134-52	23261-23262	)	_
134-53	23262-23263	.	_

#Text=A higher depression score was associated with higher ECi in the right caudate (r2 = 0.4802, P < 0.001) and lower ECi in the left posterior putamen (r2 = 0.3185, P = 0.0144).
135-1	23264-23265	A	_
135-2	23266-23272	higher	_
135-3	23273-23283	depression	_
135-4	23284-23289	score	_
135-5	23290-23293	was	_
135-6	23294-23304	associated	_
135-7	23305-23309	with	_
135-8	23310-23316	higher	_
135-9	23317-23320	ECi	_
135-10	23321-23323	in	_
135-11	23324-23327	the	_
135-12	23328-23333	right	_
135-13	23334-23341	caudate	_
135-14	23342-23343	(	_
135-15	23343-23345	r2	_
135-16	23346-23347	=	_
135-17	23348-23354	0.4802	_
135-18	23354-23355	,	_
135-19	23356-23357	P	_
135-20	23358-23359	<	_
135-21	23360-23365	0.001	_
135-22	23365-23366	)	_
135-23	23367-23370	and	_
135-24	23371-23376	lower	_
135-25	23377-23380	ECi	_
135-26	23381-23383	in	_
135-27	23384-23387	the	_
135-28	23388-23392	left	_
135-29	23393-23402	posterior	_
135-30	23403-23410	putamen	_
135-31	23411-23412	(	_
135-32	23412-23414	r2	_
135-33	23415-23416	=	_
135-34	23417-23423	0.3185	_
135-35	23423-23424	,	_
135-36	23425-23426	P	_
135-37	23427-23428	=	_
135-38	23429-23435	0.0144	_
135-39	23435-23436	)	_
135-40	23436-23437	.	_

#Text=None of these associations of striatal topology with smoking and depression overlapped with the associations that we found between AD characteristics (severity and duration) and the topology within the striatum.
136-1	23438-23442	None	_
136-2	23443-23445	of	_
136-3	23446-23451	these	_
136-4	23452-23464	associations	_
136-5	23465-23467	of	_
136-6	23468-23476	striatal	_
136-7	23477-23485	topology	_
136-8	23486-23490	with	_
136-9	23491-23498	smoking	_
136-10	23499-23502	and	_
136-11	23503-23513	depression	_
136-12	23514-23524	overlapped	_
136-13	23525-23529	with	_
136-14	23530-23533	the	_
136-15	23534-23546	associations	_
136-16	23547-23551	that	_
136-17	23552-23554	we	_
136-18	23555-23560	found	_
136-19	23561-23568	between	_
136-20	23569-23571	AD	_
136-21	23572-23587	characteristics	_
136-22	23588-23589	(	_
136-23	23589-23597	severity	_
136-24	23598-23601	and	_
136-25	23602-23610	duration	_
136-26	23610-23611	)	_
136-27	23612-23615	and	_
136-28	23616-23619	the	_
136-29	23620-23628	topology	_
136-30	23629-23635	within	_
136-31	23636-23639	the	_
136-32	23640-23648	striatum	_
136-33	23648-23649	.	_

#Text=However, to directly test whether the reported associations between striatal topology and AD characteristics (severity and duration) were influenced by smoking and/or depression, we subsequently performed multiple regression analyses with AD characteristics (duration and severity), smoking, and depression as the independent variables and striatal nodal topology parameters (CCi, Di and ECi) of the bilateral caudate and anterior putamen and the left posterior putamen as dependent variables.
137-1	23650-23657	However	_
137-2	23657-23658	,	_
137-3	23659-23661	to	_
137-4	23662-23670	directly	_
137-5	23671-23675	test	_
137-6	23676-23683	whether	_
137-7	23684-23687	the	_
137-8	23688-23696	reported	_
137-9	23697-23709	associations	_
137-10	23710-23717	between	_
137-11	23718-23726	striatal	_
137-12	23727-23735	topology	_
137-13	23736-23739	and	_
137-14	23740-23742	AD	_
137-15	23743-23758	characteristics	_
137-16	23759-23760	(	_
137-17	23760-23768	severity	_
137-18	23769-23772	and	_
137-19	23773-23781	duration	_
137-20	23781-23782	)	_
137-21	23783-23787	were	_
137-22	23788-23798	influenced	_
137-23	23799-23801	by	_
137-24	23802-23809	smoking	_
137-25	23810-23813	and	_
137-26	23813-23814	/	_
137-27	23814-23816	or	_
137-28	23817-23827	depression	_
137-29	23827-23828	,	_
137-30	23829-23831	we	_
137-31	23832-23844	subsequently	_
137-32	23845-23854	performed	_
137-33	23855-23863	multiple	_
137-34	23864-23874	regression	_
137-35	23875-23883	analyses	_
137-36	23884-23888	with	_
137-37	23889-23891	AD	_
137-38	23892-23907	characteristics	_
137-39	23908-23909	(	_
137-40	23909-23917	duration	_
137-41	23918-23921	and	_
137-42	23922-23930	severity	_
137-43	23930-23931	)	_
137-44	23931-23932	,	_
137-45	23933-23940	smoking	_
137-46	23940-23941	,	_
137-47	23942-23945	and	_
137-48	23946-23956	depression	_
137-49	23957-23959	as	_
137-50	23960-23963	the	_
137-51	23964-23975	independent	_
137-52	23976-23985	variables	_
137-53	23986-23989	and	_
137-54	23990-23998	striatal	_
137-55	23999-24004	nodal	_
137-56	24005-24013	topology	_
137-57	24014-24024	parameters	_
137-58	24025-24026	(	_
137-59	24026-24029	CCi	_
137-60	24029-24030	,	_
137-61	24031-24033	Di	_
137-62	24034-24037	and	_
137-63	24038-24041	ECi	_
137-64	24041-24042	)	_
137-65	24043-24045	of	_
137-66	24046-24049	the	_
137-67	24050-24059	bilateral	_
137-68	24060-24067	caudate	_
137-69	24068-24071	and	_
137-70	24072-24080	anterior	_
137-71	24081-24088	putamen	_
137-72	24089-24092	and	_
137-73	24093-24096	the	_
137-74	24097-24101	left	_
137-75	24102-24111	posterior	_
137-76	24112-24119	putamen	_
137-77	24120-24122	as	_
137-78	24123-24132	dependent	_
137-79	24133-24142	variables	_
137-80	24142-24143	.	_

#Text=This did not influence the changes in network topology in the striatal areas as reported above (all Ps < 0.05).
138-1	24144-24148	This	_
138-2	24149-24152	did	_
138-3	24153-24156	not	_
138-4	24157-24166	influence	_
138-5	24167-24170	the	_
138-6	24171-24178	changes	_
138-7	24179-24181	in	_
138-8	24182-24189	network	_
138-9	24190-24198	topology	_
138-10	24199-24201	in	_
138-11	24202-24205	the	_
138-12	24206-24214	striatal	_
138-13	24215-24220	areas	_
138-14	24221-24223	as	_
138-15	24224-24232	reported	_
138-16	24233-24238	above	_
138-17	24239-24240	(	_
138-18	24240-24243	all	_
138-19	24244-24246	Ps	_
138-20	24247-24248	<	_
138-21	24249-24253	0.05	_
138-22	24253-24254	)	_
138-23	24254-24255	.	_

#Text=Alcohol dependence is generally known to be associated with decreased GM volumes, either as a predisposition or a consequence of the neurotoxic effects of alcohol.
139-1	24256-24263	Alcohol	_
139-2	24264-24274	dependence	_
139-3	24275-24277	is	_
139-4	24278-24287	generally	_
139-5	24288-24293	known	_
139-6	24294-24296	to	_
139-7	24297-24299	be	_
139-8	24300-24310	associated	_
139-9	24311-24315	with	_
139-10	24316-24325	decreased	_
139-11	24326-24328	GM	_
139-12	24329-24336	volumes	_
139-13	24336-24337	,	_
139-14	24338-24344	either	_
139-15	24345-24347	as	_
139-16	24348-24349	a	_
139-17	24350-24364	predisposition	_
139-18	24365-24367	or	_
139-19	24368-24369	a	_
139-20	24370-24381	consequence	_
139-21	24382-24384	of	_
139-22	24385-24388	the	_
139-23	24389-24399	neurotoxic	_
139-24	24400-24407	effects	_
139-25	24408-24410	of	_
139-26	24411-24418	alcohol	_
139-27	24418-24419	.	_

#Text=Moreover, in this study, total GM volume showed an inverse correlation with AD severity (but not duration) (R = −0.560, P = 0.004).
140-1	24420-24428	Moreover	_
140-2	24428-24429	,	_
140-3	24430-24432	in	_
140-4	24433-24437	this	_
140-5	24438-24443	study	_
140-6	24443-24444	,	_
140-7	24445-24450	total	_
140-8	24451-24453	GM	_
140-9	24454-24460	volume	_
140-10	24461-24467	showed	_
140-11	24468-24470	an	_
140-12	24471-24478	inverse	_
140-13	24479-24490	correlation	_
140-14	24491-24495	with	_
140-15	24496-24498	AD	_
140-16	24499-24507	severity	_
140-17	24508-24509	(	_
140-18	24509-24512	but	_
140-19	24513-24516	not	_
140-20	24517-24525	duration	_
140-21	24525-24526	)	_
140-22	24527-24528	(	_
140-23	24528-24529	R	_
140-24	24530-24531	=	_
140-25	24532-24533	−	_
140-26	24533-24538	0.560	_
140-27	24538-24539	,	_
140-28	24540-24541	P	_
140-29	24542-24543	=	_
140-30	24544-24549	0.004	_
140-31	24549-24550	)	_
140-32	24550-24551	.	_

#Text=This may have influenced our results on the relation between AD severity with global and local network characteristics.
141-1	24552-24556	This	_
141-2	24557-24560	may	_
141-3	24561-24565	have	_
141-4	24566-24576	influenced	_
141-5	24577-24580	our	_
141-6	24581-24588	results	_
141-7	24589-24591	on	_
141-8	24592-24595	the	_
141-9	24596-24604	relation	_
141-10	24605-24612	between	_
141-11	24613-24615	AD	_
141-12	24616-24624	severity	_
141-13	24625-24629	with	_
141-14	24630-24636	global	_
141-15	24637-24640	and	_
141-16	24641-24646	local	_
141-17	24647-24654	network	_
141-18	24655-24670	characteristics	_
141-19	24670-24671	.	_

#Text=Therefore, we included total GM volume as an additional covariate to all between group and within group analyses.
142-1	24672-24681	Therefore	_
142-2	24681-24682	,	_
142-3	24683-24685	we	_
142-4	24686-24694	included	_
142-5	24695-24700	total	_
142-6	24701-24703	GM	_
142-7	24704-24710	volume	_
142-8	24711-24713	as	_
142-9	24714-24716	an	_
142-10	24717-24727	additional	_
142-11	24728-24737	covariate	_
142-12	24738-24740	to	_
142-13	24741-24744	all	_
142-14	24745-24752	between	_
142-15	24753-24758	group	_
142-16	24759-24762	and	_
142-17	24763-24769	within	_
142-18	24770-24775	group	_
142-19	24776-24784	analyses	_
142-20	24784-24785	.	_

#Text=GM volume correction did not affect the comparison of topology network characteristics between the AD and the HC group, which remained non-significant.
143-1	24786-24788	GM	_
143-2	24789-24795	volume	_
143-3	24796-24806	correction	_
143-4	24807-24810	did	_
143-5	24811-24814	not	_
143-6	24815-24821	affect	_
143-7	24822-24825	the	_
143-8	24826-24836	comparison	_
143-9	24837-24839	of	_
143-10	24840-24848	topology	_
143-11	24849-24856	network	_
143-12	24857-24872	characteristics	_
143-13	24873-24880	between	_
143-14	24881-24884	the	_
143-15	24885-24887	AD	_
143-16	24888-24891	and	_
143-17	24892-24895	the	_
143-18	24896-24898	HC	_
143-19	24899-24904	group	_
143-20	24904-24905	,	_
143-21	24906-24911	which	_
143-22	24912-24920	remained	_
143-23	24921-24936	non-significant	_
143-24	24936-24937	.	_

#Text=Within the AD group, the global network characteristics were still significantly lower in patients with longer AD duration (CCN: P = 0.0072; DN: P = 0.0129; GE: P = 0.0146), whereas the inverse relation between AD severity and CCN became trendwise significant (r2 = 0.4867, P = 0.0750).
144-1	24938-24944	Within	_
144-2	24945-24948	the	_
144-3	24949-24951	AD	_
144-4	24952-24957	group	_
144-5	24957-24958	,	_
144-6	24959-24962	the	_
144-7	24963-24969	global	_
144-8	24970-24977	network	_
144-9	24978-24993	characteristics	_
144-10	24994-24998	were	_
144-11	24999-25004	still	_
144-12	25005-25018	significantly	_
144-13	25019-25024	lower	_
144-14	25025-25027	in	_
144-15	25028-25036	patients	_
144-16	25037-25041	with	_
144-17	25042-25048	longer	_
144-18	25049-25051	AD	_
144-19	25052-25060	duration	_
144-20	25061-25062	(	_
144-21	25062-25065	CCN	_
144-22	25065-25066	:	_
144-23	25067-25068	P	_
144-24	25069-25070	=	_
144-25	25071-25077	0.0072	_
144-26	25077-25078	;	_
144-27	25079-25081	DN	_
144-28	25081-25082	:	_
144-29	25083-25084	P	_
144-30	25085-25086	=	_
144-31	25087-25093	0.0129	_
144-32	25093-25094	;	_
144-33	25095-25097	GE	_
144-34	25097-25098	:	_
144-35	25099-25100	P	_
144-36	25101-25102	=	_
144-37	25103-25109	0.0146	_
144-38	25109-25110	)	_
144-39	25110-25111	,	_
144-40	25112-25119	whereas	_
144-41	25120-25123	the	_
144-42	25124-25131	inverse	_
144-43	25132-25140	relation	_
144-44	25141-25148	between	_
144-45	25149-25151	AD	_
144-46	25152-25160	severity	_
144-47	25161-25164	and	_
144-48	25165-25168	CCN	_
144-49	25169-25175	became	_
144-50	25176-25185	trendwise	_
144-51	25186-25197	significant	_
144-52	25198-25199	(	_
144-53	25199-25201	r2	_
144-54	25202-25203	=	_
144-55	25204-25210	0.4867	_
144-56	25210-25211	,	_
144-57	25212-25213	P	_
144-58	25214-25215	=	_
144-59	25216-25222	0.0750	_
144-60	25222-25223	)	_
144-61	25223-25224	.	_

#Text=When adding total GM volume as a covariate to the striatal analyses most of the original results remained significant: higher AD severity was still associated with lower CCi in the left caudate nucleus (P = 0.0472), and longer AD duration was still associated with lower CCi in the bilateral caudate nucleus (Left: P = 0.0443; Right: P = 0.0251) and left anterior putamen (P = 0.0367), with lower Di in the right caudate nucleus (P = 0.0414), and with higher ECi in left posterior putamen (P = 0.0174).
145-1	25225-25229	When	_
145-2	25230-25236	adding	_
145-3	25237-25242	total	_
145-4	25243-25245	GM	_
145-5	25246-25252	volume	_
145-6	25253-25255	as	_
145-7	25256-25257	a	_
145-8	25258-25267	covariate	_
145-9	25268-25270	to	_
145-10	25271-25274	the	_
145-11	25275-25283	striatal	_
145-12	25284-25292	analyses	_
145-13	25293-25297	most	_
145-14	25298-25300	of	_
145-15	25301-25304	the	_
145-16	25305-25313	original	_
145-17	25314-25321	results	_
145-18	25322-25330	remained	_
145-19	25331-25342	significant	_
145-20	25342-25343	:	_
145-21	25344-25350	higher	_
145-22	25351-25353	AD	_
145-23	25354-25362	severity	_
145-24	25363-25366	was	_
145-25	25367-25372	still	_
145-26	25373-25383	associated	_
145-27	25384-25388	with	_
145-28	25389-25394	lower	_
145-29	25395-25398	CCi	_
145-30	25399-25401	in	_
145-31	25402-25405	the	_
145-32	25406-25410	left	_
145-33	25411-25418	caudate	_
145-34	25419-25426	nucleus	_
145-35	25427-25428	(	_
145-36	25428-25429	P	_
145-37	25430-25431	=	_
145-38	25432-25438	0.0472	_
145-39	25438-25439	)	_
145-40	25439-25440	,	_
145-41	25441-25444	and	_
145-42	25445-25451	longer	_
145-43	25452-25454	AD	_
145-44	25455-25463	duration	_
145-45	25464-25467	was	_
145-46	25468-25473	still	_
145-47	25474-25484	associated	_
145-48	25485-25489	with	_
145-49	25490-25495	lower	_
145-50	25496-25499	CCi	_
145-51	25500-25502	in	_
145-52	25503-25506	the	_
145-53	25507-25516	bilateral	_
145-54	25517-25524	caudate	_
145-55	25525-25532	nucleus	_
145-56	25533-25534	(	_
145-57	25534-25538	Left	_
145-58	25538-25539	:	_
145-59	25540-25541	P	_
145-60	25542-25543	=	_
145-61	25544-25550	0.0443	_
145-62	25550-25551	;	_
145-63	25552-25557	Right	_
145-64	25557-25558	:	_
145-65	25559-25560	P	_
145-66	25561-25562	=	_
145-67	25563-25569	0.0251	_
145-68	25569-25570	)	_
145-69	25571-25574	and	_
145-70	25575-25579	left	_
145-71	25580-25588	anterior	_
145-72	25589-25596	putamen	_
145-73	25597-25598	(	_
145-74	25598-25599	P	_
145-75	25600-25601	=	_
145-76	25602-25608	0.0367	_
145-77	25608-25609	)	_
145-78	25609-25610	,	_
145-79	25611-25615	with	_
145-80	25616-25621	lower	_
145-81	25622-25624	Di	_
145-82	25625-25627	in	_
145-83	25628-25631	the	_
145-84	25632-25637	right	_
145-85	25638-25645	caudate	_
145-86	25646-25653	nucleus	_
145-87	25654-25655	(	_
145-88	25655-25656	P	_
145-89	25657-25658	=	_
145-90	25659-25665	0.0414	_
145-91	25665-25666	)	_
145-92	25666-25667	,	_
145-93	25668-25671	and	_
145-94	25672-25676	with	_
145-95	25677-25683	higher	_
145-96	25684-25687	ECi	_
145-97	25688-25690	in	_
145-98	25691-25695	left	_
145-99	25696-25705	posterior	_
145-100	25706-25713	putamen	_
145-101	25714-25715	(	_
145-102	25715-25716	P	_
145-103	25717-25718	=	_
145-104	25719-25725	0.0174	_
145-105	25725-25726	)	_
145-106	25726-25727	.	_

#Text=DISCUSSION
#Text=The brain network topology of AD patients does not significantly differ from that of HCs.
146-1	25728-25738	DISCUSSION	_
146-2	25739-25742	The	_
146-3	25743-25748	brain	_
146-4	25749-25756	network	_
146-5	25757-25765	topology	_
146-6	25766-25768	of	_
146-7	25769-25771	AD	_
146-8	25772-25780	patients	_
146-9	25781-25785	does	_
146-10	25786-25789	not	_
146-11	25790-25803	significantly	_
146-12	25804-25810	differ	_
146-13	25811-25815	from	_
146-14	25816-25820	that	_
146-15	25821-25823	of	_
146-16	25824-25827	HCs	_
146-17	25827-25828	.	_

#Text=However, within the group of AD patients, longer AD duration is strongly associated with reduced global brain network integrity (global efficiency, degree and clustering coefficient), whereas alcohol use severity is moderately associated with reduced clustering coefficient in AD patients.
147-1	25829-25836	However	_
147-2	25836-25837	,	_
147-3	25838-25844	within	_
147-4	25845-25848	the	_
147-5	25849-25854	group	_
147-6	25855-25857	of	_
147-7	25858-25860	AD	_
147-8	25861-25869	patients	_
147-9	25869-25870	,	_
147-10	25871-25877	longer	_
147-11	25878-25880	AD	_
147-12	25881-25889	duration	_
147-13	25890-25892	is	_
147-14	25893-25901	strongly	_
147-15	25902-25912	associated	_
147-16	25913-25917	with	_
147-17	25918-25925	reduced	_
147-18	25926-25932	global	_
147-19	25933-25938	brain	_
147-20	25939-25946	network	_
147-21	25947-25956	integrity	_
147-22	25957-25958	(	_
147-23	25958-25964	global	_
147-24	25965-25975	efficiency	_
147-25	25975-25976	,	_
147-26	25977-25983	degree	_
147-27	25984-25987	and	_
147-28	25988-25998	clustering	_
147-29	25999-26010	coefficient	_
147-30	26010-26011	)	_
147-31	26011-26012	,	_
147-32	26013-26020	whereas	_
147-33	26021-26028	alcohol	_
147-34	26029-26032	use	_
147-35	26033-26041	severity	_
147-36	26042-26044	is	_
147-37	26045-26055	moderately	_
147-38	26056-26066	associated	_
147-39	26067-26071	with	_
147-40	26072-26079	reduced	_
147-41	26080-26090	clustering	_
147-42	26091-26102	coefficient	_
147-43	26103-26105	in	_
147-44	26106-26108	AD	_
147-45	26109-26117	patients	_
147-46	26117-26118	.	_

#Text=Within the striatal nodes, AD duration is associated with lower efficiency (clustering coefficient, degree) of the ventromedial and anterior striatum (caudate nucleus, anterior putamen); an association that was also visible, but less consistent, with AD severity.
148-1	26119-26125	Within	_
148-2	26126-26129	the	_
148-3	26130-26138	striatal	_
148-4	26139-26144	nodes	_
148-5	26144-26145	,	_
148-6	26146-26148	AD	_
148-7	26149-26157	duration	_
148-8	26158-26160	is	_
148-9	26161-26171	associated	_
148-10	26172-26176	with	_
148-11	26177-26182	lower	_
148-12	26183-26193	efficiency	_
148-13	26194-26195	(	_
148-14	26195-26205	clustering	_
148-15	26206-26217	coefficient	_
148-16	26217-26218	,	_
148-17	26219-26225	degree	_
148-18	26225-26226	)	_
148-19	26227-26229	of	_
148-20	26230-26233	the	_
148-21	26234-26246	ventromedial	_
148-22	26247-26250	and	_
148-23	26251-26259	anterior	_
148-24	26260-26268	striatum	_
148-25	26269-26270	(	_
148-26	26270-26277	caudate	_
148-27	26278-26285	nucleus	_
148-28	26285-26286	,	_
148-29	26287-26295	anterior	_
148-30	26296-26303	putamen	_
148-31	26303-26304	)	_
148-32	26304-26305	;	_
148-33	26306-26308	an	_
148-34	26309-26320	association	_
148-35	26321-26325	that	_
148-36	26326-26329	was	_
148-37	26330-26334	also	_
148-38	26335-26342	visible	_
148-39	26342-26343	,	_
148-40	26344-26347	but	_
148-41	26348-26352	less	_
148-42	26353-26363	consistent	_
148-43	26363-26364	,	_
148-44	26365-26369	with	_
148-45	26370-26372	AD	_
148-46	26373-26381	severity	_
148-47	26381-26382	.	_

#Text=These results indicate that AD chronicity is associated with whole-brain network changes: the resting brain functions less efficiently with longer AD duration.
149-1	26383-26388	These	_
149-2	26389-26396	results	_
149-3	26397-26405	indicate	_
149-4	26406-26410	that	_
149-5	26411-26413	AD	_
149-6	26414-26424	chronicity	_
149-7	26425-26427	is	_
149-8	26428-26438	associated	_
149-9	26439-26443	with	_
149-10	26444-26455	whole-brain	_
149-11	26456-26463	network	_
149-12	26464-26471	changes	_
149-13	26471-26472	:	_
149-14	26473-26476	the	_
149-15	26477-26484	resting	_
149-16	26485-26490	brain	_
149-17	26491-26500	functions	_
149-18	26501-26505	less	_
149-19	26506-26517	efficiently	_
149-20	26518-26522	with	_
149-21	26523-26529	longer	_
149-22	26530-26532	AD	_
149-23	26533-26541	duration	_
149-24	26541-26542	.	_

#Text=Reduced global network efficiency adversely affects cognition, including intelligence.
150-1	26543-26550	Reduced	_
150-2	26551-26557	global	_
150-3	26558-26565	network	_
150-4	26566-26576	efficiency	_
150-5	26577-26586	adversely	_
150-6	26587-26594	affects	_
150-7	26595-26604	cognition	_
150-8	26604-26605	,	_
150-9	26606-26615	including	_
150-10	26616-26628	intelligence	_
150-11	26628-26629	.	_

#Text=It is therefore conceivable that these network changes in AD are partly responsible for cognitive dysfunctions reported in addicted patients.
151-1	26630-26632	It	_
151-2	26633-26635	is	_
151-3	26636-26645	therefore	_
151-4	26646-26657	conceivable	_
151-5	26658-26662	that	_
151-6	26663-26668	these	_
151-7	26669-26676	network	_
151-8	26677-26684	changes	_
151-9	26685-26687	in	_
151-10	26688-26690	AD	_
151-11	26691-26694	are	_
151-12	26695-26701	partly	_
151-13	26702-26713	responsible	_
151-14	26714-26717	for	_
151-15	26718-26727	cognitive	_
151-16	26728-26740	dysfunctions	_
151-17	26741-26749	reported	_
151-18	26750-26752	in	_
151-19	26753-26761	addicted	_
151-20	26762-26770	patients	_
151-21	26770-26771	.	_

#Text=Interestingly, local topology in the striatum also seemed associated with AD characteristics.
152-1	26772-26785	Interestingly	_
152-2	26785-26786	,	_
152-3	26787-26792	local	_
152-4	26793-26801	topology	_
152-5	26802-26804	in	_
152-6	26805-26808	the	_
152-7	26809-26817	striatum	_
152-8	26818-26822	also	_
152-9	26823-26829	seemed	_
152-10	26830-26840	associated	_
152-11	26841-26845	with	_
152-12	26846-26848	AD	_
152-13	26849-26864	characteristics	_
152-14	26864-26865	.	_

#Text=Reduced efficiency with longer AD duration in anterior striatum (caudate nucleus and anterior putamen), thought to be involved in goal-directed behavior, is consistent with prior evidence of reduced anterior putamen activation in alcohol dependent patients during goal-directed behavior.
153-1	26866-26873	Reduced	_
153-2	26874-26884	efficiency	_
153-3	26885-26889	with	_
153-4	26890-26896	longer	_
153-5	26897-26899	AD	_
153-6	26900-26908	duration	_
153-7	26909-26911	in	_
153-8	26912-26920	anterior	_
153-9	26921-26929	striatum	_
153-10	26930-26931	(	_
153-11	26931-26938	caudate	_
153-12	26939-26946	nucleus	_
153-13	26947-26950	and	_
153-14	26951-26959	anterior	_
153-15	26960-26967	putamen	_
153-16	26967-26968	)	_
153-17	26968-26969	,	_
153-18	26970-26977	thought	_
153-19	26978-26980	to	_
153-20	26981-26983	be	_
153-21	26984-26992	involved	_
153-22	26993-26995	in	_
153-23	26996-27009	goal-directed	_
153-24	27010-27018	behavior	_
153-25	27018-27019	,	_
153-26	27020-27022	is	_
153-27	27023-27033	consistent	_
153-28	27034-27038	with	_
153-29	27039-27044	prior	_
153-30	27045-27053	evidence	_
153-31	27054-27056	of	_
153-32	27057-27064	reduced	_
153-33	27065-27073	anterior	_
153-34	27074-27081	putamen	_
153-35	27082-27092	activation	_
153-36	27093-27095	in	_
153-37	27096-27103	alcohol	_
153-38	27104-27113	dependent	_
153-39	27114-27122	patients	_
153-40	27123-27129	during	_
153-41	27130-27143	goal-directed	_
153-42	27144-27152	behavior	_
153-43	27152-27153	.	_

#Text=We also see a putative increase in network centrality of the posterior putamen with longer AD duration, an area known for its involvement in habitual actions.
154-1	27154-27156	We	_
154-2	27157-27161	also	_
154-3	27162-27165	see	_
154-4	27166-27167	a	_
154-5	27168-27176	putative	_
154-6	27177-27185	increase	_
154-7	27186-27188	in	_
154-8	27189-27196	network	_
154-9	27197-27207	centrality	_
154-10	27208-27210	of	_
154-11	27211-27214	the	_
154-12	27215-27224	posterior	_
154-13	27225-27232	putamen	_
154-14	27233-27237	with	_
154-15	27238-27244	longer	_
154-16	27245-27247	AD	_
154-17	27248-27256	duration	_
154-18	27256-27257	,	_
154-19	27258-27260	an	_
154-20	27261-27265	area	_
154-21	27266-27271	known	_
154-22	27272-27275	for	_
154-23	27276-27279	its	_
154-24	27280-27291	involvement	_
154-25	27292-27294	in	_
154-26	27295-27303	habitual	_
154-27	27304-27311	actions	_
154-28	27311-27312	.	_

#Text=This finding could match the notion of a negative spiral towards maladaptive habitual drug taking in addiction-vulnerable animals and human addiction, such as AD (for reviews, see:).
155-1	27313-27317	This	_
155-2	27318-27325	finding	_
155-3	27326-27331	could	_
155-4	27332-27337	match	_
155-5	27338-27341	the	_
155-6	27342-27348	notion	_
155-7	27349-27351	of	_
155-8	27352-27353	a	_
155-9	27354-27362	negative	_
155-10	27363-27369	spiral	_
155-11	27370-27377	towards	_
155-12	27378-27389	maladaptive	_
155-13	27390-27398	habitual	_
155-14	27399-27403	drug	_
155-15	27404-27410	taking	_
155-16	27411-27413	in	_
155-17	27414-27434	addiction-vulnerable	_
155-18	27435-27442	animals	_
155-19	27443-27446	and	_
155-20	27447-27452	human	_
155-21	27453-27462	addiction	_
155-22	27462-27463	,	_
155-23	27464-27468	such	_
155-24	27469-27471	as	_
155-25	27472-27474	AD	_
155-26	27475-27476	(	_
155-27	27476-27479	for	_
155-28	27480-27487	reviews	_
155-29	27487-27488	,	_
155-30	27489-27492	see	_
155-31	27492-27493	:	_
155-32	27493-27494	)	_
155-33	27494-27495	.	_

#Text=Using task-related functional MRI, we earlier showed increased posterior putamen involvement during cuereactivity and instrumental learning with prolonged AD duration.
156-1	27496-27501	Using	_
156-2	27502-27514	task-related	_
156-3	27515-27525	functional	_
156-4	27526-27529	MRI	_
156-5	27529-27530	,	_
156-6	27531-27533	we	_
156-7	27534-27541	earlier	_
156-8	27542-27548	showed	_
156-9	27549-27558	increased	_
156-10	27559-27568	posterior	_
156-11	27569-27576	putamen	_
156-12	27577-27588	involvement	_
156-13	27589-27595	during	_
156-14	27596-27609	cuereactivity	_
156-15	27610-27613	and	_
156-16	27614-27626	instrumental	_
156-17	27627-27635	learning	_
156-18	27636-27640	with	_
156-19	27641-27650	prolonged	_
156-20	27651-27653	AD	_
156-21	27654-27662	duration	_
156-22	27662-27663	.	_

#Text=It should be noted that in the current study, contrary to the consistent topology changes in whole-brain network, caudate and anterior putamen, topology changes in the striatum associated with AD severity, and changes in the posterior putamen with AD duration were inconsistent when exploring a broader range of thresholds of the weighted graph (see Table S 3).
157-1	27664-27666	It	_
157-2	27667-27673	should	_
157-3	27674-27676	be	_
157-4	27677-27682	noted	_
157-5	27683-27687	that	_
157-6	27688-27690	in	_
157-7	27691-27694	the	_
157-8	27695-27702	current	_
157-9	27703-27708	study	_
157-10	27708-27709	,	_
157-11	27710-27718	contrary	_
157-12	27719-27721	to	_
157-13	27722-27725	the	_
157-14	27726-27736	consistent	_
157-15	27737-27745	topology	_
157-16	27746-27753	changes	_
157-17	27754-27756	in	_
157-18	27757-27768	whole-brain	_
157-19	27769-27776	network	_
157-20	27776-27777	,	_
157-21	27778-27785	caudate	_
157-22	27786-27789	and	_
157-23	27790-27798	anterior	_
157-24	27799-27806	putamen	_
157-25	27806-27807	,	_
157-26	27808-27816	topology	_
157-27	27817-27824	changes	_
157-28	27825-27827	in	_
157-29	27828-27831	the	_
157-30	27832-27840	striatum	_
157-31	27841-27851	associated	_
157-32	27852-27856	with	_
157-33	27857-27859	AD	_
157-34	27860-27868	severity	_
157-35	27868-27869	,	_
157-36	27870-27873	and	_
157-37	27874-27881	changes	_
157-38	27882-27884	in	_
157-39	27885-27888	the	_
157-40	27889-27898	posterior	_
157-41	27899-27906	putamen	_
157-42	27907-27911	with	_
157-43	27912-27914	AD	_
157-44	27915-27923	duration	_
157-45	27924-27928	were	_
157-46	27929-27941	inconsistent	_
157-47	27942-27946	when	_
157-48	27947-27956	exploring	_
157-49	27957-27958	a	_
157-50	27959-27966	broader	_
157-51	27967-27972	range	_
157-52	27973-27975	of	_
157-53	27976-27986	thresholds	_
157-54	27987-27989	of	_
157-55	27990-27993	the	_
157-56	27994-28002	weighted	_
157-57	28003-28008	graph	_
157-58	28009-28010	(	_
157-59	28010-28013	see	_
157-60	28014-28019	Table	_
157-61	28020-28021	S	_
157-62	28022-28023	3	_
157-63	28023-28024	)	_
157-64	28024-28025	.	_

#Text=Moreover, these local effects were not corrected for the multiple tests performed in the four bilateral striatal nodes.
158-1	28026-28034	Moreover	_
158-2	28034-28035	,	_
158-3	28036-28041	these	_
158-4	28042-28047	local	_
158-5	28048-28055	effects	_
158-6	28056-28060	were	_
158-7	28061-28064	not	_
158-8	28065-28074	corrected	_
158-9	28075-28078	for	_
158-10	28079-28082	the	_
158-11	28083-28091	multiple	_
158-12	28092-28097	tests	_
158-13	28098-28107	performed	_
158-14	28108-28110	in	_
158-15	28111-28114	the	_
158-16	28115-28119	four	_
158-17	28120-28129	bilateral	_
158-18	28130-28138	striatal	_
158-19	28139-28144	nodes	_
158-20	28144-28145	.	_

#Text=Network efficiency reduction with longer AD duration could indicate direct drinking-related toxic effects on the complex brain network.
159-1	28146-28153	Network	_
159-2	28154-28164	efficiency	_
159-3	28165-28174	reduction	_
159-4	28175-28179	with	_
159-5	28180-28186	longer	_
159-6	28187-28189	AD	_
159-7	28190-28198	duration	_
159-8	28199-28204	could	_
159-9	28205-28213	indicate	_
159-10	28214-28220	direct	_
159-11	28221-28237	drinking-related	_
159-12	28238-28243	toxic	_
159-13	28244-28251	effects	_
159-14	28252-28254	on	_
159-15	28255-28258	the	_
159-16	28259-28266	complex	_
159-17	28267-28272	brain	_
159-18	28273-28280	network	_
159-19	28280-28281	.	_

#Text=However, a study in pathological gambling, a non-substance dependence, found comparable reductions in brain network efficiency with longer disease duration.
160-1	28282-28289	However	_
160-2	28289-28290	,	_
160-3	28291-28292	a	_
160-4	28293-28298	study	_
160-5	28299-28301	in	_
160-6	28302-28314	pathological	_
160-7	28315-28323	gambling	_
160-8	28323-28324	,	_
160-9	28325-28326	a	_
160-10	28327-28340	non-substance	_
160-11	28341-28351	dependence	_
160-12	28351-28352	,	_
160-13	28353-28358	found	_
160-14	28359-28369	comparable	_
160-15	28370-28380	reductions	_
160-16	28381-28383	in	_
160-17	28384-28389	brain	_
160-18	28390-28397	network	_
160-19	28398-28408	efficiency	_
160-20	28409-28413	with	_
160-21	28414-28420	longer	_
160-22	28421-28428	disease	_
160-23	28429-28437	duration	_
160-24	28437-28438	.	_

#Text=This suggests either a non-toxic influence of maladaptive behavior on the brain network, or a predisposition for network inefficiency before onset of the disorder.
161-1	28439-28443	This	_
161-2	28444-28452	suggests	_
161-3	28453-28459	either	_
161-4	28460-28461	a	_
161-5	28462-28471	non-toxic	_
161-6	28472-28481	influence	_
161-7	28482-28484	of	_
161-8	28485-28496	maladaptive	_
161-9	28497-28505	behavior	_
161-10	28506-28508	on	_
161-11	28509-28512	the	_
161-12	28513-28518	brain	_
161-13	28519-28526	network	_
161-14	28526-28527	,	_
161-15	28528-28530	or	_
161-16	28531-28532	a	_
161-17	28533-28547	predisposition	_
161-18	28548-28551	for	_
161-19	28552-28559	network	_
161-20	28560-28572	inefficiency	_
161-21	28573-28579	before	_
161-22	28580-28585	onset	_
161-23	28586-28588	of	_
161-24	28589-28592	the	_
161-25	28593-28601	disorder	_
161-26	28601-28602	.	_

#Text=Nonetheless, because of the cross-sectional nature of our study, we can only infer that the observed lower efficiency is associated with a longer drinking history.
162-1	28603-28614	Nonetheless	_
162-2	28614-28615	,	_
162-3	28616-28623	because	_
162-4	28624-28626	of	_
162-5	28627-28630	the	_
162-6	28631-28646	cross-sectional	_
162-7	28647-28653	nature	_
162-8	28654-28656	of	_
162-9	28657-28660	our	_
162-10	28661-28666	study	_
162-11	28666-28667	,	_
162-12	28668-28670	we	_
162-13	28671-28674	can	_
162-14	28675-28679	only	_
162-15	28680-28685	infer	_
162-16	28686-28690	that	_
162-17	28691-28694	the	_
162-18	28695-28703	observed	_
162-19	28704-28709	lower	_
162-20	28710-28720	efficiency	_
162-21	28721-28723	is	_
162-22	28724-28734	associated	_
162-23	28735-28739	with	_
162-24	28740-28741	a	_
162-25	28742-28748	longer	_
162-26	28749-28757	drinking	_
162-27	28758-28765	history	_
162-28	28765-28766	.	_

#Text=Longitudinal studies are desirable to replicate and elaborate on our findings.
163-1	28767-28779	Longitudinal	_
163-2	28780-28787	studies	_
163-3	28788-28791	are	_
163-4	28792-28801	desirable	_
163-5	28802-28804	to	_
163-6	28805-28814	replicate	_
163-7	28815-28818	and	_
163-8	28819-28828	elaborate	_
163-9	28829-28831	on	_
163-10	28832-28835	our	_
163-11	28836-28844	findings	_
163-12	28844-28845	.	_

#Text=We did not find an effect of smoking on the brain network topology.
164-1	28846-28848	We	_
164-2	28849-28852	did	_
164-3	28853-28856	not	_
164-4	28857-28861	find	_
164-5	28862-28864	an	_
164-6	28865-28871	effect	_
164-7	28872-28874	of	_
164-8	28875-28882	smoking	_
164-9	28883-28885	on	_
164-10	28886-28889	the	_
164-11	28890-28895	brain	_
164-12	28896-28903	network	_
164-13	28904-28912	topology	_
164-14	28912-28913	.	_

#Text=Although it has been shown that smoking affects specialized functional brain networks during rest in AD patients, our results are in agreement with findings that the complex brain network analyzed by using graph theory does not differ between smokers and non-smokers.
165-1	28914-28922	Although	_
165-2	28923-28925	it	_
165-3	28926-28929	has	_
165-4	28930-28934	been	_
165-5	28935-28940	shown	_
165-6	28941-28945	that	_
165-7	28946-28953	smoking	_
165-8	28954-28961	affects	_
165-9	28962-28973	specialized	_
165-10	28974-28984	functional	_
165-11	28985-28990	brain	_
165-12	28991-28999	networks	_
165-13	29000-29006	during	_
165-14	29007-29011	rest	_
165-15	29012-29014	in	_
165-16	29015-29017	AD	_
165-17	29018-29026	patients	_
165-18	29026-29027	,	_
165-19	29028-29031	our	_
165-20	29032-29039	results	_
165-21	29040-29043	are	_
165-22	29044-29046	in	_
165-23	29047-29056	agreement	_
165-24	29057-29061	with	_
165-25	29062-29070	findings	_
165-26	29071-29075	that	_
165-27	29076-29079	the	_
165-28	29080-29087	complex	_
165-29	29088-29093	brain	_
165-30	29094-29101	network	_
165-31	29102-29110	analyzed	_
165-32	29111-29113	by	_
165-33	29114-29119	using	_
165-34	29120-29125	graph	_
165-35	29126-29132	theory	_
165-36	29133-29137	does	_
165-37	29138-29141	not	_
165-38	29142-29148	differ	_
165-39	29149-29156	between	_
165-40	29157-29164	smokers	_
165-41	29165-29168	and	_
165-42	29169-29180	non-smokers	_
165-43	29180-29181	.	_

#Text=In contrast to our expectations, we did not find differences in global network topology between AD patients and HC.
166-1	29182-29184	In	_
166-2	29185-29193	contrast	_
166-3	29194-29196	to	_
166-4	29197-29200	our	_
166-5	29201-29213	expectations	_
166-6	29213-29214	,	_
166-7	29215-29217	we	_
166-8	29218-29221	did	_
166-9	29222-29225	not	_
166-10	29226-29230	find	_
166-11	29231-29242	differences	_
166-12	29243-29245	in	_
166-13	29246-29252	global	_
166-14	29253-29260	network	_
166-15	29261-29269	topology	_
166-16	29270-29277	between	_
166-17	29278-29280	AD	_
166-18	29281-29289	patients	_
166-19	29290-29293	and	_
166-20	29294-29296	HC	_
166-21	29296-29297	.	_

#Text=Some local network characteristics outside the striatum only differed between groups when considered at an uncorrected threshold (see Supporting Information Table S1).
167-1	29298-29302	Some	_
167-2	29303-29308	local	_
167-3	29309-29316	network	_
167-4	29317-29332	characteristics	_
167-5	29333-29340	outside	_
167-6	29341-29344	the	_
167-7	29345-29353	striatum	_
167-8	29354-29358	only	_
167-9	29359-29367	differed	_
167-10	29368-29375	between	_
167-11	29376-29382	groups	_
167-12	29383-29387	when	_
167-13	29388-29398	considered	_
167-14	29399-29401	at	_
167-15	29402-29404	an	_
167-16	29405-29416	uncorrected	_
167-17	29417-29426	threshold	_
167-18	29427-29428	(	_
167-19	29428-29431	see	_
167-20	29432-29442	Supporting	_
167-21	29443-29454	Information	_
167-22	29455-29460	Table	_
167-23	29461-29463	S1	_
167-24	29463-29464	)	_
167-25	29464-29465	.	_

#Text=The lack of group differences is especially surprising considering the here shown association between network topology and AD characteristics.
168-1	29466-29469	The	_
168-2	29470-29474	lack	_
168-3	29475-29477	of	_
168-4	29478-29483	group	_
168-5	29484-29495	differences	_
168-6	29496-29498	is	_
168-7	29499-29509	especially	_
168-8	29510-29520	surprising	_
168-9	29521-29532	considering	_
168-10	29533-29536	the	_
168-11	29537-29541	here	_
168-12	29542-29547	shown	_
168-13	29548-29559	association	_
168-14	29560-29567	between	_
168-15	29568-29575	network	_
168-16	29576-29584	topology	_
168-17	29585-29588	and	_
168-18	29589-29591	AD	_
168-19	29592-29607	characteristics	_
168-20	29607-29608	.	_

#Text=The fact that a large portion of our AD sample was recruited from a population-based cohort, which did not primarily seek help for alcohol-related problems, might contribute to this.
169-1	29609-29612	The	_
169-2	29613-29617	fact	_
169-3	29618-29622	that	_
169-4	29623-29624	a	_
169-5	29625-29630	large	_
169-6	29631-29638	portion	_
169-7	29639-29641	of	_
169-8	29642-29645	our	_
169-9	29646-29648	AD	_
169-10	29649-29655	sample	_
169-11	29656-29659	was	_
169-12	29660-29669	recruited	_
169-13	29670-29674	from	_
169-14	29675-29676	a	_
169-15	29677-29693	population-based	_
169-16	29694-29700	cohort	_
169-17	29700-29701	,	_
169-18	29702-29707	which	_
169-19	29708-29711	did	_
169-20	29712-29715	not	_
169-21	29716-29725	primarily	_
169-22	29726-29730	seek	_
169-23	29731-29735	help	_
169-24	29736-29739	for	_
169-25	29740-29755	alcohol-related	_
169-26	29756-29764	problems	_
169-27	29764-29765	,	_
169-28	29766-29771	might	_
169-29	29772-29782	contribute	_
169-30	29783-29785	to	_
169-31	29786-29790	this	_
169-32	29790-29791	.	_

#Text=This has namely led to the inclusion of a heteroge-neous AD sample with some minimally severe AD patients producing a weak contrast between the AD and the HC groups.
170-1	29792-29796	This	_
170-2	29797-29800	has	_
170-3	29801-29807	namely	_
170-4	29808-29811	led	_
170-5	29812-29814	to	_
170-6	29815-29818	the	_
170-7	29819-29828	inclusion	_
170-8	29829-29831	of	_
170-9	29832-29833	a	_
170-10	29834-29848	heteroge-neous	_
170-11	29849-29851	AD	_
170-12	29852-29858	sample	_
170-13	29859-29863	with	_
170-14	29864-29868	some	_
170-15	29869-29878	minimally	_
170-16	29879-29885	severe	_
170-17	29886-29888	AD	_
170-18	29889-29897	patients	_
170-19	29898-29907	producing	_
170-20	29908-29909	a	_
170-21	29910-29914	weak	_
170-22	29915-29923	contrast	_
170-23	29924-29931	between	_
170-24	29932-29935	the	_
170-25	29936-29938	AD	_
170-26	29939-29942	and	_
170-27	29943-29946	the	_
170-28	29947-29949	HC	_
170-29	29950-29956	groups	_
170-30	29956-29957	.	_

#Text=To further explore this, we post hoc split the AD group based on median AUDIT score to compare the most severe patients with HC, see Supporting Information Text S1.
171-1	29958-29960	To	_
171-2	29961-29968	further	_
171-3	29969-29976	explore	_
171-4	29977-29981	this	_
171-5	29981-29982	,	_
171-6	29983-29985	we	_
171-7	29986-29990	post	_
171-8	29991-29994	hoc	_
171-9	29995-30000	split	_
171-10	30001-30004	the	_
171-11	30005-30007	AD	_
171-12	30008-30013	group	_
171-13	30014-30019	based	_
171-14	30020-30022	on	_
171-15	30023-30029	median	_
171-16	30030-30035	AUDIT	_
171-17	30036-30041	score	_
171-18	30042-30044	to	_
171-19	30045-30052	compare	_
171-20	30053-30056	the	_
171-21	30057-30061	most	_
171-22	30062-30068	severe	_
171-23	30069-30077	patients	_
171-24	30078-30082	with	_
171-25	30083-30085	HC	_
171-26	30085-30086	,	_
171-27	30087-30090	see	_
171-28	30091-30101	Supporting	_
171-29	30102-30113	Information	_
171-30	30114-30118	Text	_
171-31	30119-30121	S1	_
171-32	30121-30122	.	_

#Text=This does indicate a deviation from ‘healthy’ in more severe AD patients with an AUDIT score above the clinical cut-off (AUDIT score: 20) for risk of dependence.
172-1	30123-30127	This	_
172-2	30128-30132	does	_
172-3	30133-30141	indicate	_
172-4	30142-30143	a	_
172-5	30144-30153	deviation	_
172-6	30154-30158	from	_
172-7	30159-30160	‘	_
172-8	30160-30167	healthy	_
172-9	30167-30168	’	_
172-10	30169-30171	in	_
172-11	30172-30176	more	_
172-12	30177-30183	severe	_
172-13	30184-30186	AD	_
172-14	30187-30195	patients	_
172-15	30196-30200	with	_
172-16	30201-30203	an	_
172-17	30204-30209	AUDIT	_
172-18	30210-30215	score	_
172-19	30216-30221	above	_
172-20	30222-30225	the	_
172-21	30226-30234	clinical	_
172-22	30235-30242	cut-off	_
172-23	30243-30244	(	_
172-24	30244-30249	AUDIT	_
172-25	30250-30255	score	_
172-26	30255-30256	:	_
172-27	30257-30259	20	_
172-28	30259-30260	)	_
172-29	30261-30264	for	_
172-30	30265-30269	risk	_
172-31	30270-30272	of	_
172-32	30273-30283	dependence	_
172-33	30283-30284	.	_

#Text=However, considering the smaller subsample (n = 12) of this exploratory analysis, and the weak effects on global topology, this should be interpreted with caution.
173-1	30285-30292	However	_
173-2	30292-30293	,	_
173-3	30294-30305	considering	_
173-4	30306-30309	the	_
173-5	30310-30317	smaller	_
173-6	30318-30327	subsample	_
173-7	30328-30329	(	_
173-8	30329-30330	n	_
173-9	30331-30332	=	_
173-10	30333-30335	12	_
173-11	30335-30336	)	_
173-12	30337-30339	of	_
173-13	30340-30344	this	_
173-14	30345-30356	exploratory	_
173-15	30357-30365	analysis	_
173-16	30365-30366	,	_
173-17	30367-30370	and	_
173-18	30371-30374	the	_
173-19	30375-30379	weak	_
173-20	30380-30387	effects	_
173-21	30388-30390	on	_
173-22	30391-30397	global	_
173-23	30398-30406	topology	_
173-24	30406-30407	,	_
173-25	30408-30412	this	_
173-26	30413-30419	should	_
173-27	30420-30422	be	_
173-28	30423-30434	interpreted	_
173-29	30435-30439	with	_
173-30	30440-30447	caution	_
173-31	30447-30448	.	_

#Text=Notably, other studies using graph analysis in behavioral addictions similarly failed to show a difference in global network topology with HCs, while also showing disease-associated effects within the patient samples.
174-1	30449-30456	Notably	_
174-2	30456-30457	,	_
174-3	30458-30463	other	_
174-4	30464-30471	studies	_
174-5	30472-30477	using	_
174-6	30478-30483	graph	_
174-7	30484-30492	analysis	_
174-8	30493-30495	in	_
174-9	30496-30506	behavioral	_
174-10	30507-30517	addictions	_
174-11	30518-30527	similarly	_
174-12	30528-30534	failed	_
174-13	30535-30537	to	_
174-14	30538-30542	show	_
174-15	30543-30544	a	_
174-16	30545-30555	difference	_
174-17	30556-30558	in	_
174-18	30559-30565	global	_
174-19	30566-30573	network	_
174-20	30574-30582	topology	_
174-21	30583-30587	with	_
174-22	30588-30591	HCs	_
174-23	30591-30592	,	_
174-24	30593-30598	while	_
174-25	30599-30603	also	_
174-26	30604-30611	showing	_
174-27	30612-30630	disease-associated	_
174-28	30631-30638	effects	_
174-29	30639-30645	within	_
174-30	30646-30649	the	_
174-31	30650-30657	patient	_
174-32	30658-30665	samples	_
174-33	30665-30666	.	_

#Text=This demonstrates the prominence of heterogeneity within categorical Psychiatric diagnoses and contributes to the popular idea that dimensional neurobiological constructs are desirable in Psychiatry as a guideline to define disease-related mechanisms and to predict treatment response, rather than the rigid boundaries of symptom-based categories.
175-1	30667-30671	This	_
175-2	30672-30684	demonstrates	_
175-3	30685-30688	the	_
175-4	30689-30699	prominence	_
175-5	30700-30702	of	_
175-6	30703-30716	heterogeneity	_
175-7	30717-30723	within	_
175-8	30724-30735	categorical	_
175-9	30736-30747	Psychiatric	_
175-10	30748-30757	diagnoses	_
175-11	30758-30761	and	_
175-12	30762-30773	contributes	_
175-13	30774-30776	to	_
175-14	30777-30780	the	_
175-15	30781-30788	popular	_
175-16	30789-30793	idea	_
175-17	30794-30798	that	_
175-18	30799-30810	dimensional	_
175-19	30811-30826	neurobiological	_
175-20	30827-30837	constructs	_
175-21	30838-30841	are	_
175-22	30842-30851	desirable	_
175-23	30852-30854	in	_
175-24	30855-30865	Psychiatry	_
175-25	30866-30868	as	_
175-26	30869-30870	a	_
175-27	30871-30880	guideline	_
175-28	30881-30883	to	_
175-29	30884-30890	define	_
175-30	30891-30906	disease-related	_
175-31	30907-30917	mechanisms	_
175-32	30918-30921	and	_
175-33	30922-30924	to	_
175-34	30925-30932	predict	_
175-35	30933-30942	treatment	_
175-36	30943-30951	response	_
175-37	30951-30952	,	_
175-38	30953-30959	rather	_
175-39	30960-30964	than	_
175-40	30965-30968	the	_
175-41	30969-30974	rigid	_
175-42	30975-30985	boundaries	_
175-43	30986-30988	of	_
175-44	30989-31002	symptom-based	_
175-45	31003-31013	categories	_
175-46	31013-31014	.	_

#Text=Our focus was on the stationary functional brain network.
176-1	31015-31018	Our	_
176-2	31019-31024	focus	_
176-3	31025-31028	was	_
176-4	31029-31031	on	_
176-5	31032-31035	the	_
176-6	31036-31046	stationary	_
176-7	31047-31057	functional	_
176-8	31058-31063	brain	_
176-9	31064-31071	network	_
176-10	31071-31072	.	_

#Text=An interesting new direction in resting-state research is the exploration of dynamic reconfiguration of connectivity, which may yield more insight into the processes that take place within the functional network on a finer time scale.
177-1	31073-31075	An	_
177-2	31076-31087	interesting	_
177-3	31088-31091	new	_
177-4	31092-31101	direction	_
177-5	31102-31104	in	_
177-6	31105-31118	resting-state	_
177-7	31119-31127	research	_
177-8	31128-31130	is	_
177-9	31131-31134	the	_
177-10	31135-31146	exploration	_
177-11	31147-31149	of	_
177-12	31150-31157	dynamic	_
177-13	31158-31173	reconfiguration	_
177-14	31174-31176	of	_
177-15	31177-31189	connectivity	_
177-16	31189-31190	,	_
177-17	31191-31196	which	_
177-18	31197-31200	may	_
177-19	31201-31206	yield	_
177-20	31207-31211	more	_
177-21	31212-31219	insight	_
177-22	31220-31224	into	_
177-23	31225-31228	the	_
177-24	31229-31238	processes	_
177-25	31239-31243	that	_
177-26	31244-31248	take	_
177-27	31249-31254	place	_
177-28	31255-31261	within	_
177-29	31262-31265	the	_
177-30	31266-31276	functional	_
177-31	31277-31284	network	_
177-32	31285-31287	on	_
177-33	31288-31289	a	_
177-34	31290-31295	finer	_
177-35	31296-31300	time	_
177-36	31301-31306	scale	_
177-37	31306-31307	.	_

#Text=This could also give further insights into the dynamic state of the diseased brain, such as in several Psychiatric disorders.
178-1	31308-31312	This	_
178-2	31313-31318	could	_
178-3	31319-31323	also	_
178-4	31324-31328	give	_
178-5	31329-31336	further	_
178-6	31337-31345	insights	_
178-7	31346-31350	into	_
178-8	31351-31354	the	_
178-9	31355-31362	dynamic	_
178-10	31363-31368	state	_
178-11	31369-31371	of	_
178-12	31372-31375	the	_
178-13	31376-31384	diseased	_
178-14	31385-31390	brain	_
178-15	31390-31391	,	_
178-16	31392-31396	such	_
178-17	31397-31399	as	_
178-18	31400-31402	in	_
178-19	31403-31410	several	_
178-20	31411-31422	Psychiatric	_
178-21	31423-31432	disorders	_
178-22	31432-31433	.	_

#Text=Altered topology in the alcoholics’ brain could be targeted for the treatment of chronic AD, for example by applying non-invasive techniques including transcranial magnetic stimulation, which has been shown to successfully manipulate whole-brain networks.
179-1	31434-31441	Altered	_
179-2	31442-31450	topology	_
179-3	31451-31453	in	_
179-4	31454-31457	the	_
179-5	31458-31468	alcoholics	_
179-6	31468-31469	’	_
179-7	31470-31475	brain	_
179-8	31476-31481	could	_
179-9	31482-31484	be	_
179-10	31485-31493	targeted	_
179-11	31494-31497	for	_
179-12	31498-31501	the	_
179-13	31502-31511	treatment	_
179-14	31512-31514	of	_
179-15	31515-31522	chronic	_
179-16	31523-31525	AD	_
179-17	31525-31526	,	_
179-18	31527-31530	for	_
179-19	31531-31538	example	_
179-20	31539-31541	by	_
179-21	31542-31550	applying	_
179-22	31551-31563	non-invasive	_
179-23	31564-31574	techniques	_
179-24	31575-31584	including	_
179-25	31585-31597	transcranial	_
179-26	31598-31606	magnetic	_
179-27	31607-31618	stimulation	_
179-28	31618-31619	,	_
179-29	31620-31625	which	_
179-30	31626-31629	has	_
179-31	31630-31634	been	_
179-32	31635-31640	shown	_
179-33	31641-31643	to	_
179-34	31644-31656	successfully	_
179-35	31657-31667	manipulate	_
179-36	31668-31679	whole-brain	_
179-37	31680-31688	networks	_
179-38	31688-31689	.	_

#Text=Although more invasive, deep brain stimulation may also rebalance altered disease-related brain networks by specifically targeting deeper subcortical hubs (e.g. striatum).
180-1	31690-31698	Although	_
180-2	31699-31703	more	_
180-3	31704-31712	invasive	_
180-4	31712-31713	,	_
180-5	31714-31718	deep	_
180-6	31719-31724	brain	_
180-7	31725-31736	stimulation	_
180-8	31737-31740	may	_
180-9	31741-31745	also	_
180-10	31746-31755	rebalance	_
180-11	31756-31763	altered	_
180-12	31764-31779	disease-related	_
180-13	31780-31785	brain	_
180-14	31786-31794	networks	_
180-15	31795-31797	by	_
180-16	31798-31810	specifically	_
180-17	31811-31820	targeting	_
180-18	31821-31827	deeper	_
180-19	31828-31839	subcortical	_
180-20	31840-31844	hubs	_
180-21	31845-31846	(	_
180-22	31846-31849	e.g	_
180-23	31849-31850	.	_
180-24	31851-31859	striatum	_
180-25	31859-31860	)	_
180-26	31860-31861	.	_

#Text=The nucleus accumbens, a ventral part of the striatum and center to the reward system, has already been shown to be a promising target of deep brain stimulation to treat addictions.
181-1	31862-31865	The	_
181-2	31866-31873	nucleus	_
181-3	31874-31883	accumbens	_
181-4	31883-31884	,	_
181-5	31885-31886	a	_
181-6	31887-31894	ventral	_
181-7	31895-31899	part	_
181-8	31900-31902	of	_
181-9	31903-31906	the	_
181-10	31907-31915	striatum	_
181-11	31916-31919	and	_
181-12	31920-31926	center	_
181-13	31927-31929	to	_
181-14	31930-31933	the	_
181-15	31934-31940	reward	_
181-16	31941-31947	system	_
181-17	31947-31948	,	_
181-18	31949-31952	has	_
181-19	31953-31960	already	_
181-20	31961-31965	been	_
181-21	31966-31971	shown	_
181-22	31972-31974	to	_
181-23	31975-31977	be	_
181-24	31978-31979	a	_
181-25	31980-31989	promising	_
181-26	31990-31996	target	_
181-27	31997-31999	of	_
181-28	32000-32004	deep	_
181-29	32005-32010	brain	_
181-30	32011-32022	stimulation	_
181-31	32023-32025	to	_
181-32	32026-32031	treat	_
181-33	32032-32042	addictions	_
181-34	32042-32043	.	_

#Text=In conclusion, by using a graph-theoretical approach, this study shows that prolonged alcohol dependence is associated with decreased global brain network efficiency and less anterior striatal segregation.
182-1	32044-32046	In	_
182-2	32047-32057	conclusion	_
182-3	32057-32058	,	_
182-4	32059-32061	by	_
182-5	32062-32067	using	_
182-6	32068-32069	a	_
182-7	32070-32087	graph-theoretical	_
182-8	32088-32096	approach	_
182-9	32096-32097	,	_
182-10	32098-32102	this	_
182-11	32103-32108	study	_
182-12	32109-32114	shows	_
182-13	32115-32119	that	_
182-14	32120-32129	prolonged	_
182-15	32130-32137	alcohol	_
182-16	32138-32148	dependence	_
182-17	32149-32151	is	_
182-18	32152-32162	associated	_
182-19	32163-32167	with	_
182-20	32168-32177	decreased	_
182-21	32178-32184	global	_
182-22	32185-32190	brain	_
182-23	32191-32198	network	_
182-24	32199-32209	efficiency	_
182-25	32210-32213	and	_
182-26	32214-32218	less	_
182-27	32219-32227	anterior	_
182-28	32228-32236	striatal	_
182-29	32237-32248	segregation	_
182-30	32248-32249	.	_

#Text=Decreased global network integration and local segregation could be a key candidate for the future treatment of alcohol use disorders.
183-1	32250-32259	Decreased	_
183-2	32260-32266	global	_
183-3	32267-32274	network	_
183-4	32275-32286	integration	_
183-5	32287-32290	and	_
183-6	32291-32296	local	_
183-7	32297-32308	segregation	_
183-8	32309-32314	could	_
183-9	32315-32317	be	_
183-10	32318-32319	a	_
183-11	32320-32323	key	_
183-12	32324-32333	candidate	_
183-13	32334-32337	for	_
183-14	32338-32341	the	_
183-15	32342-32348	future	_
183-16	32349-32358	treatment	_
183-17	32359-32361	of	_
183-18	32362-32369	alcohol	_
183-19	32370-32373	use	_
183-20	32374-32383	disorders	_
183-21	32383-32384	.	_

#Text=Supplementary Material
#Text=Authors Contribution
#Text=ZS, DJV, WVDB, BWJHP and LD were responsible for the study concept and design.
184-1	32385-32398	Supplementary	_
184-2	32399-32407	Material	_
184-3	32408-32415	Authors	_
184-4	32416-32428	Contribution	_
184-5	32429-32431	ZS	_
184-6	32431-32432	,	_
184-7	32433-32436	DJV	_
184-8	32436-32437	,	_
184-9	32438-32442	WVDB	_
184-10	32442-32443	,	_
184-11	32444-32449	BWJHP	_
184-12	32450-32453	and	_
184-13	32454-32456	LD	_
184-14	32457-32461	were	_
184-15	32462-32473	responsible	_
184-16	32474-32477	for	_
184-17	32478-32481	the	_
184-18	32482-32487	study	_
184-19	32488-32495	concept	_
184-20	32496-32499	and	_
184-21	32500-32506	design	_
184-22	32506-32507	.	_

#Text=ZS acquired data.
185-1	32508-32510	ZS	_
185-2	32511-32519	acquired	_
185-3	32520-32524	data	_
185-4	32524-32525	.	_

#Text=ZS and LD performed analyses.
186-1	32526-32528	ZS	_
186-2	32529-32532	and	_
186-3	32533-32535	LD	_
186-4	32536-32545	performed	_
186-5	32546-32554	analyses	_
186-6	32554-32555	.	_

#Text=ZS, SS and LD interpreted the findings.
187-1	32556-32558	ZS	_
187-2	32558-32559	,	_
187-3	32560-32562	SS	_
187-4	32563-32566	and	_
187-5	32567-32569	LD	_
187-6	32570-32581	interpreted	_
187-7	32582-32585	the	_
187-8	32586-32594	findings	_
187-9	32594-32595	.	_

#Text=ZS drafted the manuscript.
188-1	32596-32598	ZS	_
188-2	32599-32606	drafted	_
188-3	32607-32610	the	_
188-4	32611-32621	manuscript	_
188-5	32621-32622	.	_

#Text=SS, DJV, WVDB, BWJHP and LD provided critical revision of the manuscript for important intellectual content.
189-1	32623-32625	SS	_
189-2	32625-32626	,	_
189-3	32627-32630	DJV	_
189-4	32630-32631	,	_
189-5	32632-32636	WVDB	_
189-6	32636-32637	,	_
189-7	32638-32643	BWJHP	_
189-8	32644-32647	and	_
189-9	32648-32650	LD	_
189-10	32651-32659	provided	_
189-11	32660-32668	critical	_
189-12	32669-32677	revision	_
189-13	32678-32680	of	_
189-14	32681-32684	the	_
189-15	32685-32695	manuscript	_
189-16	32696-32699	for	_
189-17	32700-32709	important	_
189-18	32710-32722	intellectual	_
189-19	32723-32730	content	_
189-20	32730-32731	.	_

#Text=All authors critically reviewed content and approved final version for publication.
190-1	32732-32735	All	_
190-2	32736-32743	authors	_
190-3	32744-32754	critically	_
190-4	32755-32763	reviewed	_
190-5	32764-32771	content	_
190-6	32772-32775	and	_
190-7	32776-32784	approved	_
190-8	32785-32790	final	_
190-9	32791-32798	version	_
190-10	32799-32802	for	_
190-11	32803-32814	publication	_
190-12	32814-32815	.	_

#Text=SUPPORTING INFORMATION
#Text=Additional Supporting Information may be found in the online version of this article at the publisher's web-site.
191-1	32816-32826	SUPPORTING	_
191-2	32827-32838	INFORMATION	_
191-3	32839-32849	Additional	_
191-4	32850-32860	Supporting	_
191-5	32861-32872	Information	_
191-6	32873-32876	may	_
191-7	32877-32879	be	_
191-8	32880-32885	found	_
191-9	32886-32888	in	_
191-10	32889-32892	the	_
191-11	32893-32899	online	_
191-12	32900-32907	version	_
191-13	32908-32910	of	_
191-14	32911-32915	this	_
191-15	32916-32923	article	_
191-16	32924-32926	at	_
191-17	32927-32930	the	_
191-18	32931-32942	publisher's	_
191-19	32943-32951	web-site	_
191-20	32951-32952	.	_

#Text=References
#Text=Semi-Automatic Parcellation of the Corpus Striatum
#Text=
#Text=The role of default network deactivation in cognition and disease
#Text=Early detection of harmful alcohol consumption: comparison of clinical, laboratory, and self-report screening procedures
#Text=Habitual alcohol seeking: Modeling the transition from casual drinking to addiction
#Text=Human brain networks in health and disease
#Text=Investigations into resting-state connectivity using independent component analysis
#Text=Complex networks: Structure and dynamics
#Text=Some unique properties of eigenvector centrality
#Text=The efficiency of functional brain networks does not differ between smokers and non-smokers
#Text=Brain connectivity: an opening window into addiction
#Text=DPARSF: A MATLAB Toolbox for ‘Pipeline’ Data Analysis of Resting-State fMRI
#Text=Uncertainty-based competition between prefrontal and dorsolateral striatal systems for behavioral control
#Text=Neural network alterations underlie cognitive deficits in brain tumor patients
#Text=An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest
#Text=Dissociated multimodal hubs and seizures in temporal lobe epilepsy
#Text=Cognition is related to resting-state small-world network topology: an magnetoencephalographic study
#Text=Review.
192-1	32953-32963	References	_
192-2	32964-32978	Semi-Automatic	_
192-3	32979-32991	Parcellation	_
192-4	32992-32994	of	_
192-5	32995-32998	the	_
192-6	32999-33005	Corpus	_
192-7	33006-33014	Striatum	_
192-8	33016-33019	The	_
192-9	33020-33024	role	_
192-10	33025-33027	of	_
192-11	33028-33035	default	_
192-12	33036-33043	network	_
192-13	33044-33056	deactivation	_
192-14	33057-33059	in	_
192-15	33060-33069	cognition	_
192-16	33070-33073	and	_
192-17	33074-33081	disease	_
192-18	33082-33087	Early	_
192-19	33088-33097	detection	_
192-20	33098-33100	of	_
192-21	33101-33108	harmful	_
192-22	33109-33116	alcohol	_
192-23	33117-33128	consumption	_
192-24	33128-33129	:	_
192-25	33130-33140	comparison	_
192-26	33141-33143	of	_
192-27	33144-33152	clinical	_
192-28	33152-33153	,	_
192-29	33154-33164	laboratory	_
192-30	33164-33165	,	_
192-31	33166-33169	and	_
192-32	33170-33181	self-report	_
192-33	33182-33191	screening	_
192-34	33192-33202	procedures	_
192-35	33203-33211	Habitual	_
192-36	33212-33219	alcohol	_
192-37	33220-33227	seeking	_
192-38	33227-33228	:	_
192-39	33229-33237	Modeling	_
192-40	33238-33241	the	_
192-41	33242-33252	transition	_
192-42	33253-33257	from	_
192-43	33258-33264	casual	_
192-44	33265-33273	drinking	_
192-45	33274-33276	to	_
192-46	33277-33286	addiction	_
192-47	33287-33292	Human	_
192-48	33293-33298	brain	_
192-49	33299-33307	networks	_
192-50	33308-33310	in	_
192-51	33311-33317	health	_
192-52	33318-33321	and	_
192-53	33322-33329	disease	_
192-54	33330-33344	Investigations	_
192-55	33345-33349	into	_
192-56	33350-33363	resting-state	_
192-57	33364-33376	connectivity	_
192-58	33377-33382	using	_
192-59	33383-33394	independent	_
192-60	33395-33404	component	_
192-61	33405-33413	analysis	_
192-62	33414-33421	Complex	_
192-63	33422-33430	networks	_
192-64	33430-33431	:	_
192-65	33432-33441	Structure	_
192-66	33442-33445	and	_
192-67	33446-33454	dynamics	_
192-68	33455-33459	Some	_
192-69	33460-33466	unique	_
192-70	33467-33477	properties	_
192-71	33478-33480	of	_
192-72	33481-33492	eigenvector	_
192-73	33493-33503	centrality	_
192-74	33504-33507	The	_
192-75	33508-33518	efficiency	_
192-76	33519-33521	of	_
192-77	33522-33532	functional	_
192-78	33533-33538	brain	_
192-79	33539-33547	networks	_
192-80	33548-33552	does	_
192-81	33553-33556	not	_
192-82	33557-33563	differ	_
192-83	33564-33571	between	_
192-84	33572-33579	smokers	_
192-85	33580-33583	and	_
192-86	33584-33595	non-smokers	_
192-87	33596-33601	Brain	_
192-88	33602-33614	connectivity	_
192-89	33614-33615	:	_
192-90	33616-33618	an	_
192-91	33619-33626	opening	_
192-92	33627-33633	window	_
192-93	33634-33638	into	_
192-94	33639-33648	addiction	_
192-95	33649-33655	DPARSF	_
192-96	33655-33656	:	_
192-97	33657-33658	A	_
192-98	33659-33665	MATLAB	_
192-99	33666-33673	Toolbox	_
192-100	33674-33677	for	_
192-101	33678-33679	‘	_
192-102	33679-33687	Pipeline	_
192-103	33687-33688	’	_
192-104	33689-33693	Data	_
192-105	33694-33702	Analysis	_
192-106	33703-33705	of	_
192-107	33706-33719	Resting-State	_
192-108	33720-33724	fMRI	_
192-109	33725-33742	Uncertainty-based	_
192-110	33743-33754	competition	_
192-111	33755-33762	between	_
192-112	33763-33773	prefrontal	_
192-113	33774-33777	and	_
192-114	33778-33790	dorsolateral	_
192-115	33791-33799	striatal	_
192-116	33800-33807	systems	_
192-117	33808-33811	for	_
192-118	33812-33822	behavioral	_
192-119	33823-33830	control	_
192-120	33831-33837	Neural	_
192-121	33838-33845	network	_
192-122	33846-33857	alterations	_
192-123	33858-33866	underlie	_
192-124	33867-33876	cognitive	_
192-125	33877-33885	deficits	_
192-126	33886-33888	in	_
192-127	33889-33894	brain	_
192-128	33895-33900	tumor	_
192-129	33901-33909	patients	_
192-130	33910-33912	An	_
192-131	33913-33922	automated	_
192-132	33923-33931	labeling	_
192-133	33932-33938	system	_
192-134	33939-33942	for	_
192-135	33943-33954	subdividing	_
192-136	33955-33958	the	_
192-137	33959-33964	human	_
192-138	33965-33973	cerebral	_
192-139	33974-33980	cortex	_
192-140	33981-33983	on	_
192-141	33984-33987	MRI	_
192-142	33988-33993	scans	_
192-143	33994-33998	into	_
192-144	33999-34004	gyral	_
192-145	34005-34010	based	_
192-146	34011-34018	regions	_
192-147	34019-34021	of	_
192-148	34022-34030	interest	_
192-149	34031-34042	Dissociated	_
192-150	34043-34053	multimodal	_
192-151	34054-34058	hubs	_
192-152	34059-34062	and	_
192-153	34063-34071	seizures	_
192-154	34072-34074	in	_
192-155	34075-34083	temporal	_
192-156	34084-34088	lobe	_
192-157	34089-34097	epilepsy	_
192-158	34098-34107	Cognition	_
192-159	34108-34110	is	_
192-160	34111-34118	related	_
192-161	34119-34121	to	_
192-162	34122-34135	resting-state	_
192-163	34136-34147	small-world	_
192-164	34148-34155	network	_
192-165	34156-34164	topology	_
192-166	34164-34165	:	_
192-167	34166-34168	an	_
192-168	34169-34192	magnetoencephalographic	_
192-169	34193-34198	study	_
192-170	34199-34205	Review	_
192-171	34205-34206	.	_

#Text=Neural mechanisms underlying the vulnerability to develop compulsive drug-seeking habits and addiction
#Text=Neural systems of reinforcement for drug addiction: from actions to habits to compulsion
#Text=Measuring and manipulating brain connectivity with resting state functional connectivity magnetic resonance imaging (fcMRI) and transcranial magnetic stimulation (TMS)
#Text=Dynamic causal modelling
#Text=The neurocircuitry of impaired insight in drug addiction
#Text=Efficiency of functional brain networks and intellectual performance
#Text=Coupling mechanism and significance of the BOLD signal: a status report
#Text=Drug-related decrease in neuropsy-chological functions of abstinent drug users
#Text=Neural networks in psychiatry
#Text=The NIMH Research Domain Criteria (RDoC) Project: precision medicine for psychiatry
#Text=Behavioral endophenotypes of drug addiction: Etiological insights from neuroimaging studies
#Text=Neurocircuitry of addiction.
193-1	34207-34213	Neural	_
193-2	34214-34224	mechanisms	_
193-3	34225-34235	underlying	_
193-4	34236-34239	the	_
193-5	34240-34253	vulnerability	_
193-6	34254-34256	to	_
193-7	34257-34264	develop	_
193-8	34265-34275	compulsive	_
193-9	34276-34288	drug-seeking	_
193-10	34289-34295	habits	_
193-11	34296-34299	and	_
193-12	34300-34309	addiction	_
193-13	34310-34316	Neural	_
193-14	34317-34324	systems	_
193-15	34325-34327	of	_
193-16	34328-34341	reinforcement	_
193-17	34342-34345	for	_
193-18	34346-34350	drug	_
193-19	34351-34360	addiction	_
193-20	34360-34361	:	_
193-21	34362-34366	from	_
193-22	34367-34374	actions	_
193-23	34375-34377	to	_
193-24	34378-34384	habits	_
193-25	34385-34387	to	_
193-26	34388-34398	compulsion	_
193-27	34399-34408	Measuring	_
193-28	34409-34412	and	_
193-29	34413-34425	manipulating	_
193-30	34426-34431	brain	_
193-31	34432-34444	connectivity	_
193-32	34445-34449	with	_
193-33	34450-34457	resting	_
193-34	34458-34463	state	_
193-35	34464-34474	functional	_
193-36	34475-34487	connectivity	_
193-37	34488-34496	magnetic	_
193-38	34497-34506	resonance	_
193-39	34507-34514	imaging	_
193-40	34515-34516	(	_
193-41	34516-34521	fcMRI	_
193-42	34521-34522	)	_
193-43	34523-34526	and	_
193-44	34527-34539	transcranial	_
193-45	34540-34548	magnetic	_
193-46	34549-34560	stimulation	_
193-47	34561-34562	(	_
193-48	34562-34565	TMS	_
193-49	34565-34566	)	_
193-50	34567-34574	Dynamic	_
193-51	34575-34581	causal	_
193-52	34582-34591	modelling	_
193-53	34592-34595	The	_
193-54	34596-34610	neurocircuitry	_
193-55	34611-34613	of	_
193-56	34614-34622	impaired	_
193-57	34623-34630	insight	_
193-58	34631-34633	in	_
193-59	34634-34638	drug	_
193-60	34639-34648	addiction	_
193-61	34649-34659	Efficiency	_
193-62	34660-34662	of	_
193-63	34663-34673	functional	_
193-64	34674-34679	brain	_
193-65	34680-34688	networks	_
193-66	34689-34692	and	_
193-67	34693-34705	intellectual	_
193-68	34706-34717	performance	_
193-69	34718-34726	Coupling	_
193-70	34727-34736	mechanism	_
193-71	34737-34740	and	_
193-72	34741-34753	significance	_
193-73	34754-34756	of	_
193-74	34757-34760	the	_
193-75	34761-34765	BOLD	_
193-76	34766-34772	signal	_
193-77	34772-34773	:	_
193-78	34774-34775	a	_
193-79	34776-34782	status	_
193-80	34783-34789	report	_
193-81	34790-34802	Drug-related	_
193-82	34803-34811	decrease	_
193-83	34812-34814	in	_
193-84	34815-34834	neuropsy-chological	_
193-85	34835-34844	functions	_
193-86	34845-34847	of	_
193-87	34848-34857	abstinent	_
193-88	34858-34862	drug	_
193-89	34863-34868	users	_
193-90	34869-34875	Neural	_
193-91	34876-34884	networks	_
193-92	34885-34887	in	_
193-93	34888-34898	psychiatry	_
193-94	34899-34902	The	_
193-95	34903-34907	NIMH	_
193-96	34908-34916	Research	_
193-97	34917-34923	Domain	_
193-98	34924-34932	Criteria	_
193-99	34933-34934	(	_
193-100	34934-34938	RDoC	_
193-101	34938-34939	)	_
193-102	34940-34947	Project	_
193-103	34947-34948	:	_
193-104	34949-34958	precision	_
193-105	34959-34967	medicine	_
193-106	34968-34971	for	_
193-107	34972-34982	psychiatry	_
193-108	34983-34993	Behavioral	_
193-109	34994-35008	endophenotypes	_
193-110	35009-35011	of	_
193-111	35012-35016	drug	_
193-112	35017-35026	addiction	_
193-113	35026-35027	:	_
193-114	35028-35039	Etiological	_
193-115	35040-35048	insights	_
193-116	35049-35053	from	_
193-117	35054-35066	neuroimaging	_
193-118	35067-35074	studies	_
193-119	35075-35089	Neurocircuitry	_
193-120	35090-35092	of	_
193-121	35093-35102	addiction	_
193-122	35102-35103	.	_

#Text=Nature Publishing Group
#Text=Balancing the brain: resting state networks and deep brain stimulation
#Text=Behavioral interpretations of intrinsic connectivity networks
#Text=Eigenvector centrality mapping for analyzing connectivity patterns in fMRI data of the human brain
#Text=Deep brain stimulation in addiction: a review of potential brain targets
#Text=Electrophysiological signatures of resting state networks in the human brain
#Text=The Resting Brain of Alcoholics
#Text=Habit formation: Implications for alcoholism research
#Text=Mental health in Dutch adolescents: a TRAILS report on prevalence, severity, age of onset, continuity and co-morbidity of DSM disorders
#Text=The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods
#Text=The Composite International Diagnostic Interview.
194-1	35104-35110	Nature	_
194-2	35111-35121	Publishing	_
194-3	35122-35127	Group	_
194-4	35128-35137	Balancing	_
194-5	35138-35141	the	_
194-6	35142-35147	brain	_
194-7	35147-35148	:	_
194-8	35149-35156	resting	_
194-9	35157-35162	state	_
194-10	35163-35171	networks	_
194-11	35172-35175	and	_
194-12	35176-35180	deep	_
194-13	35181-35186	brain	_
194-14	35187-35198	stimulation	_
194-15	35199-35209	Behavioral	_
194-16	35210-35225	interpretations	_
194-17	35226-35228	of	_
194-18	35229-35238	intrinsic	_
194-19	35239-35251	connectivity	_
194-20	35252-35260	networks	_
194-21	35261-35272	Eigenvector	_
194-22	35273-35283	centrality	_
194-23	35284-35291	mapping	_
194-24	35292-35295	for	_
194-25	35296-35305	analyzing	_
194-26	35306-35318	connectivity	_
194-27	35319-35327	patterns	_
194-28	35328-35330	in	_
194-29	35331-35335	fMRI	_
194-30	35336-35340	data	_
194-31	35341-35343	of	_
194-32	35344-35347	the	_
194-33	35348-35353	human	_
194-34	35354-35359	brain	_
194-35	35360-35364	Deep	_
194-36	35365-35370	brain	_
194-37	35371-35382	stimulation	_
194-38	35383-35385	in	_
194-39	35386-35395	addiction	_
194-40	35395-35396	:	_
194-41	35397-35398	a	_
194-42	35399-35405	review	_
194-43	35406-35408	of	_
194-44	35409-35418	potential	_
194-45	35419-35424	brain	_
194-46	35425-35432	targets	_
194-47	35433-35453	Electrophysiological	_
194-48	35454-35464	signatures	_
194-49	35465-35467	of	_
194-50	35468-35475	resting	_
194-51	35476-35481	state	_
194-52	35482-35490	networks	_
194-53	35491-35493	in	_
194-54	35494-35497	the	_
194-55	35498-35503	human	_
194-56	35504-35509	brain	_
194-57	35510-35513	The	_
194-58	35514-35521	Resting	_
194-59	35522-35527	Brain	_
194-60	35528-35530	of	_
194-61	35531-35541	Alcoholics	_
194-62	35542-35547	Habit	_
194-63	35548-35557	formation	_
194-64	35557-35558	:	_
194-65	35559-35571	Implications	_
194-66	35572-35575	for	_
194-67	35576-35586	alcoholism	_
194-68	35587-35595	research	_
194-69	35596-35602	Mental	_
194-70	35603-35609	health	_
194-71	35610-35612	in	_
194-72	35613-35618	Dutch	_
194-73	35619-35630	adolescents	_
194-74	35630-35631	:	_
194-75	35632-35633	a	_
194-76	35634-35640	TRAILS	_
194-77	35641-35647	report	_
194-78	35648-35650	on	_
194-79	35651-35661	prevalence	_
194-80	35661-35662	,	_
194-81	35663-35671	severity	_
194-82	35671-35672	,	_
194-83	35673-35676	age	_
194-84	35677-35679	of	_
194-85	35680-35685	onset	_
194-86	35685-35686	,	_
194-87	35687-35697	continuity	_
194-88	35698-35701	and	_
194-89	35702-35714	co-morbidity	_
194-90	35715-35717	of	_
194-91	35718-35721	DSM	_
194-92	35722-35731	disorders	_
194-93	35732-35735	The	_
194-94	35736-35747	Netherlands	_
194-95	35748-35753	Study	_
194-96	35754-35756	of	_
194-97	35757-35767	Depression	_
194-98	35768-35771	and	_
194-99	35772-35779	Anxiety	_
194-100	35780-35781	(	_
194-101	35781-35786	NESDA	_
194-102	35786-35787	)	_
194-103	35787-35788	:	_
194-104	35789-35798	rationale	_
194-105	35798-35799	,	_
194-106	35800-35810	objectives	_
194-107	35811-35814	and	_
194-108	35815-35822	methods	_
194-109	35823-35826	The	_
194-110	35827-35836	Composite	_
194-111	35837-35850	International	_
194-112	35851-35861	Diagnostic	_
194-113	35862-35871	Interview	_
194-114	35871-35872	.	_

#Text=An epidemiologic Instrument suitable for use in conjunction with different diagnostic systems and in different cultures
#Text=Complex network measures of brain connectivity: uses and interpretations
#Text=Modafinil modulates restingstate functional network connectivity and cognitive control in alcohol-dependent patients
#Text=Recovery of neurocognitive functions following sustained abstinence after substance dependence and implications for treatment
#Text=Neuronal Reward and Decision Signals: From Theories to Data
#Text=The resting brain: Unconstrained yet reliable
#Text=Cue reactivity is associated with duration and severity of alcohol dependence: an fMRI study
#Text=Behavioral and neuroimaging evidence for overreliance on habit learning in alcohol-dependent patients
#Text=The human connectome: A structural description of the human brain
#Text=Network analysis of intrinsic functional brain connectivity in Alzheimer’s disease
#Text=Calculating consequences: brain systems that encode the causal effects of actions
#Text=Striatocortical pathway dysfunction in addiction and obesity: differences and similarities
#Text=A specific role for posterior dorsolateral striatum in human habit learning
#Text=Abnormalities of functional brain networks in pathological gambling: a graph-theoretical approach
#Text=The Brain on Drugs: From Reward to Addiction
#Text=Addiction circuitry in the human brain
#Text=Initial, habitual and compulsive alcohol use is characterized by a shift of cue processing from ventral to dorsal striatum
#Text=A hyper-connected but less efficient small-world network in the substance-dependent brain
#Text=Disrupted Brain Functional Network in Internet Addiction Disorder: A Resting-State Functional Magnetic Resonance Imaging Study
#Text=Corticostriatal connectivity underlies individual differences in the balance between habitual and goal-directed action control
#Text=The role of the dorsomedial striatum in instrumental conditioning
#Text=Group comparisons on whole-brain network characteristics.
195-1	35873-35875	An	_
195-2	35876-35889	epidemiologic	_
195-3	35890-35900	Instrument	_
195-4	35901-35909	suitable	_
195-5	35910-35913	for	_
195-6	35914-35917	use	_
195-7	35918-35920	in	_
195-8	35921-35932	conjunction	_
195-9	35933-35937	with	_
195-10	35938-35947	different	_
195-11	35948-35958	diagnostic	_
195-12	35959-35966	systems	_
195-13	35967-35970	and	_
195-14	35971-35973	in	_
195-15	35974-35983	different	_
195-16	35984-35992	cultures	_
195-17	35993-36000	Complex	_
195-18	36001-36008	network	_
195-19	36009-36017	measures	_
195-20	36018-36020	of	_
195-21	36021-36026	brain	_
195-22	36027-36039	connectivity	_
195-23	36039-36040	:	_
195-24	36041-36045	uses	_
195-25	36046-36049	and	_
195-26	36050-36065	interpretations	_
195-27	36066-36075	Modafinil	_
195-28	36076-36085	modulates	_
195-29	36086-36098	restingstate	_
195-30	36099-36109	functional	_
195-31	36110-36117	network	_
195-32	36118-36130	connectivity	_
195-33	36131-36134	and	_
195-34	36135-36144	cognitive	_
195-35	36145-36152	control	_
195-36	36153-36155	in	_
195-37	36156-36173	alcohol-dependent	_
195-38	36174-36182	patients	_
195-39	36183-36191	Recovery	_
195-40	36192-36194	of	_
195-41	36195-36209	neurocognitive	_
195-42	36210-36219	functions	_
195-43	36220-36229	following	_
195-44	36230-36239	sustained	_
195-45	36240-36250	abstinence	_
195-46	36251-36256	after	_
195-47	36257-36266	substance	_
195-48	36267-36277	dependence	_
195-49	36278-36281	and	_
195-50	36282-36294	implications	_
195-51	36295-36298	for	_
195-52	36299-36308	treatment	_
195-53	36309-36317	Neuronal	_
195-54	36318-36324	Reward	_
195-55	36325-36328	and	_
195-56	36329-36337	Decision	_
195-57	36338-36345	Signals	_
195-58	36345-36346	:	_
195-59	36347-36351	From	_
195-60	36352-36360	Theories	_
195-61	36361-36363	to	_
195-62	36364-36368	Data	_
195-63	36369-36372	The	_
195-64	36373-36380	resting	_
195-65	36381-36386	brain	_
195-66	36386-36387	:	_
195-67	36388-36401	Unconstrained	_
195-68	36402-36405	yet	_
195-69	36406-36414	reliable	_
195-70	36415-36418	Cue	_
195-71	36419-36429	reactivity	_
195-72	36430-36432	is	_
195-73	36433-36443	associated	_
195-74	36444-36448	with	_
195-75	36449-36457	duration	_
195-76	36458-36461	and	_
195-77	36462-36470	severity	_
195-78	36471-36473	of	_
195-79	36474-36481	alcohol	_
195-80	36482-36492	dependence	_
195-81	36492-36493	:	_
195-82	36494-36496	an	_
195-83	36497-36501	fMRI	_
195-84	36502-36507	study	_
195-85	36508-36518	Behavioral	_
195-86	36519-36522	and	_
195-87	36523-36535	neuroimaging	_
195-88	36536-36544	evidence	_
195-89	36545-36548	for	_
195-90	36549-36561	overreliance	_
195-91	36562-36564	on	_
195-92	36565-36570	habit	_
195-93	36571-36579	learning	_
195-94	36580-36582	in	_
195-95	36583-36600	alcohol-dependent	_
195-96	36601-36609	patients	_
195-97	36610-36613	The	_
195-98	36614-36619	human	_
195-99	36620-36630	connectome	_
195-100	36630-36631	:	_
195-101	36632-36633	A	_
195-102	36634-36644	structural	_
195-103	36645-36656	description	_
195-104	36657-36659	of	_
195-105	36660-36663	the	_
195-106	36664-36669	human	_
195-107	36670-36675	brain	_
195-108	36676-36683	Network	_
195-109	36684-36692	analysis	_
195-110	36693-36695	of	_
195-111	36696-36705	intrinsic	_
195-112	36706-36716	functional	_
195-113	36717-36722	brain	_
195-114	36723-36735	connectivity	_
195-115	36736-36738	in	_
195-116	36739-36748	Alzheimer	_
195-117	36748-36749	’	_
195-118	36749-36750	s	_
195-119	36751-36758	disease	_
195-120	36759-36770	Calculating	_
195-121	36771-36783	consequences	_
195-122	36783-36784	:	_
195-123	36785-36790	brain	_
195-124	36791-36798	systems	_
195-125	36799-36803	that	_
195-126	36804-36810	encode	_
195-127	36811-36814	the	_
195-128	36815-36821	causal	_
195-129	36822-36829	effects	_
195-130	36830-36832	of	_
195-131	36833-36840	actions	_
195-132	36841-36856	Striatocortical	_
195-133	36857-36864	pathway	_
195-134	36865-36876	dysfunction	_
195-135	36877-36879	in	_
195-136	36880-36889	addiction	_
195-137	36890-36893	and	_
195-138	36894-36901	obesity	_
195-139	36901-36902	:	_
195-140	36903-36914	differences	_
195-141	36915-36918	and	_
195-142	36919-36931	similarities	_
195-143	36932-36933	A	_
195-144	36934-36942	specific	_
195-145	36943-36947	role	_
195-146	36948-36951	for	_
195-147	36952-36961	posterior	_
195-148	36962-36974	dorsolateral	_
195-149	36975-36983	striatum	_
195-150	36984-36986	in	_
195-151	36987-36992	human	_
195-152	36993-36998	habit	_
195-153	36999-37007	learning	_
195-154	37008-37021	Abnormalities	_
195-155	37022-37024	of	_
195-156	37025-37035	functional	_
195-157	37036-37041	brain	_
195-158	37042-37050	networks	_
195-159	37051-37053	in	_
195-160	37054-37066	pathological	_
195-161	37067-37075	gambling	_
195-162	37075-37076	:	_
195-163	37077-37078	a	_
195-164	37079-37096	graph-theoretical	_
195-165	37097-37105	approach	_
195-166	37106-37109	The	_
195-167	37110-37115	Brain	_
195-168	37116-37118	on	_
195-169	37119-37124	Drugs	_
195-170	37124-37125	:	_
195-171	37126-37130	From	_
195-172	37131-37137	Reward	_
195-173	37138-37140	to	_
195-174	37141-37150	Addiction	_
195-175	37151-37160	Addiction	_
195-176	37161-37170	circuitry	_
195-177	37171-37173	in	_
195-178	37174-37177	the	_
195-179	37178-37183	human	_
195-180	37184-37189	brain	_
195-181	37190-37197	Initial	_
195-182	37197-37198	,	_
195-183	37199-37207	habitual	_
195-184	37208-37211	and	_
195-185	37212-37222	compulsive	_
195-186	37223-37230	alcohol	_
195-187	37231-37234	use	_
195-188	37235-37237	is	_
195-189	37238-37251	characterized	_
195-190	37252-37254	by	_
195-191	37255-37256	a	_
195-192	37257-37262	shift	_
195-193	37263-37265	of	_
195-194	37266-37269	cue	_
195-195	37270-37280	processing	_
195-196	37281-37285	from	_
195-197	37286-37293	ventral	_
195-198	37294-37296	to	_
195-199	37297-37303	dorsal	_
195-200	37304-37312	striatum	_
195-201	37313-37314	A	_
195-202	37315-37330	hyper-connected	_
195-203	37331-37334	but	_
195-204	37335-37339	less	_
195-205	37340-37349	efficient	_
195-206	37350-37361	small-world	_
195-207	37362-37369	network	_
195-208	37370-37372	in	_
195-209	37373-37376	the	_
195-210	37377-37396	substance-dependent	_
195-211	37397-37402	brain	_
195-212	37403-37412	Disrupted	_
195-213	37413-37418	Brain	_
195-214	37419-37429	Functional	_
195-215	37430-37437	Network	_
195-216	37438-37440	in	_
195-217	37441-37449	Internet	_
195-218	37450-37459	Addiction	_
195-219	37460-37468	Disorder	_
195-220	37468-37469	:	_
195-221	37470-37471	A	_
195-222	37472-37485	Resting-State	_
195-223	37486-37496	Functional	_
195-224	37497-37505	Magnetic	_
195-225	37506-37515	Resonance	_
195-226	37516-37523	Imaging	_
195-227	37524-37529	Study	_
195-228	37530-37545	Corticostriatal	_
195-229	37546-37558	connectivity	_
195-230	37559-37568	underlies	_
195-231	37569-37579	individual	_
195-232	37580-37591	differences	_
195-233	37592-37594	in	_
195-234	37595-37598	the	_
195-235	37599-37606	balance	_
195-236	37607-37614	between	_
195-237	37615-37623	habitual	_
195-238	37624-37627	and	_
195-239	37628-37641	goal-directed	_
195-240	37642-37648	action	_
195-241	37649-37656	control	_
195-242	37657-37660	The	_
195-243	37661-37665	role	_
195-244	37666-37668	of	_
195-245	37669-37672	the	_
195-246	37673-37684	dorsomedial	_
195-247	37685-37693	striatum	_
195-248	37694-37696	in	_
195-249	37697-37709	instrumental	_
195-250	37710-37722	conditioning	_
195-251	37723-37728	Group	_
195-252	37729-37740	comparisons	_
195-253	37741-37743	on	_
195-254	37744-37755	whole-brain	_
195-255	37756-37763	network	_
195-256	37764-37779	characteristics	_
195-257	37779-37780	.	_

#Text=No significant differences between AD group and matched HCs on whole-brain network topology, expressed as clustering coefficient (t = 0.4219, P = 0.6754), degree (t = 0.3837, P = 0.7006), eigenvector centrality (t = −0.8284, P = 0.4125) and global efficiency (t = −0.0079, P = 0.9937).
196-1	37781-37783	No	_
196-2	37784-37795	significant	_
196-3	37796-37807	differences	_
196-4	37808-37815	between	_
196-5	37816-37818	AD	_
196-6	37819-37824	group	_
196-7	37825-37828	and	_
196-8	37829-37836	matched	_
196-9	37837-37840	HCs	_
196-10	37841-37843	on	_
196-11	37844-37855	whole-brain	_
196-12	37856-37863	network	_
196-13	37864-37872	topology	_
196-14	37872-37873	,	_
196-15	37874-37883	expressed	_
196-16	37884-37886	as	_
196-17	37887-37897	clustering	_
196-18	37898-37909	coefficient	_
196-19	37910-37911	(	_
196-20	37911-37912	t	_
196-21	37913-37914	=	_
196-22	37915-37921	0.4219	_
196-23	37921-37922	,	_
196-24	37923-37924	P	_
196-25	37925-37926	=	_
196-26	37927-37933	0.6754	_
196-27	37933-37934	)	_
196-28	37934-37935	,	_
196-29	37936-37942	degree	_
196-30	37943-37944	(	_
196-31	37944-37945	t	_
196-32	37946-37947	=	_
196-33	37948-37954	0.3837	_
196-34	37954-37955	,	_
196-35	37956-37957	P	_
196-36	37958-37959	=	_
196-37	37960-37966	0.7006	_
196-38	37966-37967	)	_
196-39	37967-37968	,	_
196-40	37969-37980	eigenvector	_
196-41	37981-37991	centrality	_
196-42	37992-37993	(	_
196-43	37993-37994	t	_
196-44	37995-37996	=	_
196-45	37997-37998	−	_
196-46	37998-38004	0.8284	_
196-47	38004-38005	,	_
196-48	38006-38007	P	_
196-49	38008-38009	=	_
196-50	38010-38016	0.4125	_
196-51	38016-38017	)	_
196-52	38018-38021	and	_
196-53	38022-38028	global	_
196-54	38029-38039	efficiency	_
196-55	38040-38041	(	_
196-56	38041-38042	t	_
196-57	38043-38044	=	_
196-58	38045-38046	−	_
196-59	38046-38052	0.0079	_
196-60	38052-38053	,	_
196-61	38054-38055	P	_
196-62	38056-38057	=	_
196-63	38058-38064	0.9937	_
196-64	38064-38065	)	_
196-65	38065-38066	.	_

#Text=All analyses were corrected for age, gender and head motion.
197-1	38067-38070	All	_
197-2	38071-38079	analyses	_
197-3	38080-38084	were	_
197-4	38085-38094	corrected	_
197-5	38095-38098	for	_
197-6	38099-38102	age	_
197-7	38102-38103	,	_
197-8	38104-38110	gender	_
197-9	38111-38114	and	_
197-10	38115-38119	head	_
197-11	38120-38126	motion	_
197-12	38126-38127	.	_

#Text=Abbreviations: AD, alcohol dependent group; HC, healthy control group
#Text=Whole-brain reduction in network topology associated with alcohol dependence characteristics.
198-1	38128-38141	Abbreviations	_
198-2	38141-38142	:	_
198-3	38143-38145	AD	_
198-4	38145-38146	,	_
198-5	38147-38154	alcohol	_
198-6	38155-38164	dependent	_
198-7	38165-38170	group	_
198-8	38170-38171	;	_
198-9	38172-38174	HC	_
198-10	38174-38175	,	_
198-11	38176-38183	healthy	_
198-12	38184-38191	control	_
198-13	38192-38197	group	_
198-14	38198-38209	Whole-brain	_
198-15	38210-38219	reduction	_
198-16	38220-38222	in	_
198-17	38223-38230	network	_
198-18	38231-38239	topology	_
198-19	38240-38250	associated	_
198-20	38251-38255	with	_
198-21	38256-38263	alcohol	_
198-22	38264-38274	dependence	_
198-23	38275-38290	characteristics	_
198-24	38290-38291	.	_

#Text=(a) Clustering coefficient shows a whole-brain decrease with more severe alcohol use symptoms, as measured with the alcohol use disorder identification test (AUDIT).
199-1	38292-38293	(	_
199-2	38293-38294	a	_
199-3	38294-38295	)	_
199-4	38296-38306	Clustering	_
199-5	38307-38318	coefficient	_
199-6	38319-38324	shows	_
199-7	38325-38326	a	_
199-8	38327-38338	whole-brain	_
199-9	38339-38347	decrease	_
199-10	38348-38352	with	_
199-11	38353-38357	more	_
199-12	38358-38364	severe	_
199-13	38365-38372	alcohol	_
199-14	38373-38376	use	_
199-15	38377-38385	symptoms	_
199-16	38385-38386	,	_
199-17	38387-38389	as	_
199-18	38390-38398	measured	_
199-19	38399-38403	with	_
199-20	38404-38407	the	_
199-21	38408-38415	alcohol	_
199-22	38416-38419	use	_
199-23	38420-38428	disorder	_
199-24	38429-38443	identification	_
199-25	38444-38448	test	_
199-26	38449-38450	(	_
199-27	38450-38455	AUDIT	_
199-28	38455-38456	)	_
199-29	38456-38457	.	_

#Text=(b) Clustering coefficient, degree and global efficiency are significantly decreased with longer AD duration.
200-1	38458-38459	(	_
200-2	38459-38460	b	_
200-3	38460-38461	)	_
200-4	38462-38472	Clustering	_
200-5	38473-38484	coefficient	_
200-6	38484-38485	,	_
200-7	38486-38492	degree	_
200-8	38493-38496	and	_
200-9	38497-38503	global	_
200-10	38504-38514	efficiency	_
200-11	38515-38518	are	_
200-12	38519-38532	significantly	_
200-13	38533-38542	decreased	_
200-14	38543-38547	with	_
200-15	38548-38554	longer	_
200-16	38555-38557	AD	_
200-17	38558-38566	duration	_
200-18	38566-38567	.	_

#Text=Eigenvector centrality does not show a significant association with AD duration.
201-1	38568-38579	Eigenvector	_
201-2	38580-38590	centrality	_
201-3	38591-38595	does	_
201-4	38596-38599	not	_
201-5	38600-38604	show	_
201-6	38605-38606	a	_
201-7	38607-38618	significant	_
201-8	38619-38630	association	_
201-9	38631-38635	with	_
201-10	38636-38638	AD	_
201-11	38639-38647	duration	_
201-12	38647-38648	.	_

#Text=After removing the two outliers in the upper left corner of the CC, D and GE scatterplots, correlations remain significant.
202-1	38649-38654	After	_
202-2	38655-38663	removing	_
202-3	38664-38667	the	_
202-4	38668-38671	two	_
202-5	38672-38680	outliers	_
202-6	38681-38683	in	_
202-7	38684-38687	the	_
202-8	38688-38693	upper	_
202-9	38694-38698	left	_
202-10	38699-38705	corner	_
202-11	38706-38708	of	_
202-12	38709-38712	the	_
202-13	38713-38715	CC	_
202-14	38715-38716	,	_
202-15	38717-38718	D	_
202-16	38719-38722	and	_
202-17	38723-38725	GE	_
202-18	38726-38738	scatterplots	_
202-19	38738-38739	,	_
202-20	38740-38752	correlations	_
202-21	38753-38759	remain	_
202-22	38760-38771	significant	_
202-23	38771-38772	.	_

#Text=All analyses were corrected for age, gender and head motion
#Text=Network topology in striatum associated with alcohol dependence characteristics.
203-1	38773-38776	All	_
203-2	38777-38785	analyses	_
203-3	38786-38790	were	_
203-4	38791-38800	corrected	_
203-5	38801-38804	for	_
203-6	38805-38808	age	_
203-7	38808-38809	,	_
203-8	38810-38816	gender	_
203-9	38817-38820	and	_
203-10	38821-38825	head	_
203-11	38826-38832	motion	_
203-12	38833-38840	Network	_
203-13	38841-38849	topology	_
203-14	38850-38852	in	_
203-15	38853-38861	striatum	_
203-16	38862-38872	associated	_
203-17	38873-38877	with	_
203-18	38878-38885	alcohol	_
203-19	38886-38896	dependence	_
203-20	38897-38912	characteristics	_
203-21	38912-38913	.	_

#Text=Analyses performed in four bilateral striatal nodes of a priori interest: nucleus accumbens, caudate nucleus, anterior-putamen and posterior putamen.
204-1	38914-38922	Analyses	_
204-2	38923-38932	performed	_
204-3	38933-38935	in	_
204-4	38936-38940	four	_
204-5	38941-38950	bilateral	_
204-6	38951-38959	striatal	_
204-7	38960-38965	nodes	_
204-8	38966-38968	of	_
204-9	38969-38970	a	_
204-10	38971-38977	priori	_
204-11	38978-38986	interest	_
204-12	38986-38987	:	_
204-13	38988-38995	nucleus	_
204-14	38996-39005	accumbens	_
204-15	39005-39006	,	_
204-16	39007-39014	caudate	_
204-17	39015-39022	nucleus	_
204-18	39022-39023	,	_
204-19	39024-39040	anterior-putamen	_
204-20	39041-39044	and	_
204-21	39045-39054	posterior	_
204-22	39055-39062	putamen	_
204-23	39062-39063	.	_

#Text=(a) Local striatal network topology associated with alcohol use.
205-1	39064-39065	(	_
205-2	39065-39066	a	_
205-3	39066-39067	)	_
205-4	39068-39073	Local	_
205-5	39074-39082	striatal	_
205-6	39083-39090	network	_
205-7	39091-39099	topology	_
205-8	39100-39110	associated	_
205-9	39111-39115	with	_
205-10	39116-39123	alcohol	_
205-11	39124-39127	use	_
205-12	39127-39128	.	_

#Text=The left caudate nucleus shows reduced local clustering coefficient with more severe alcohol use disorder symptoms, measured with the alcohol use disorder identification test (AUDIT).
206-1	39129-39132	The	_
206-2	39133-39137	left	_
206-3	39138-39145	caudate	_
206-4	39146-39153	nucleus	_
206-5	39154-39159	shows	_
206-6	39160-39167	reduced	_
206-7	39168-39173	local	_
206-8	39174-39184	clustering	_
206-9	39185-39196	coefficient	_
206-10	39197-39201	with	_
206-11	39202-39206	more	_
206-12	39207-39213	severe	_
206-13	39214-39221	alcohol	_
206-14	39222-39225	use	_
206-15	39226-39234	disorder	_
206-16	39235-39243	symptoms	_
206-17	39243-39244	,	_
206-18	39245-39253	measured	_
206-19	39254-39258	with	_
206-20	39259-39262	the	_
206-21	39263-39270	alcohol	_
206-22	39271-39274	use	_
206-23	39275-39283	disorder	_
206-24	39284-39298	identification	_
206-25	39299-39303	test	_
206-26	39304-39305	(	_
206-27	39305-39310	AUDIT	_
206-28	39310-39311	)	_
206-29	39311-39312	.	_

#Text=(b) Local striatal network topology associated with the duration of alcohol dependence.
207-1	39313-39314	(	_
207-2	39314-39315	b	_
207-3	39315-39316	)	_
207-4	39317-39322	Local	_
207-5	39323-39331	striatal	_
207-6	39332-39339	network	_
207-7	39340-39348	topology	_
207-8	39349-39359	associated	_
207-9	39360-39364	with	_
207-10	39365-39368	the	_
207-11	39369-39377	duration	_
207-12	39378-39380	of	_
207-13	39381-39388	alcohol	_
207-14	39389-39399	dependence	_
207-15	39399-39400	.	_

#Text=Upper panel: bilateral caudate (L: t = −2.2376, P = 0.0374; R: t = −2.5174, P = 0.0210), left putamen (anterior: t = −2.1113, P = 0.0482, posterior: t = −2.1263, P = 0.0468) and right anterior putamen (t = −2.3070, P = 0.0325) show decreased clustering coefficient.
208-1	39401-39406	Upper	_
208-2	39407-39412	panel	_
208-3	39412-39413	:	_
208-4	39414-39423	bilateral	_
208-5	39424-39431	caudate	_
208-6	39432-39433	(	_
208-7	39433-39434	L	_
208-8	39434-39435	:	_
208-9	39436-39437	t	_
208-10	39438-39439	=	_
208-11	39440-39441	−	_
208-12	39441-39447	2.2376	_
208-13	39447-39448	,	_
208-14	39449-39450	P	_
208-15	39451-39452	=	_
208-16	39453-39459	0.0374	_
208-17	39459-39460	;	_
208-18	39461-39462	R	_
208-19	39462-39463	:	_
208-20	39464-39465	t	_
208-21	39466-39467	=	_
208-22	39468-39469	−	_
208-23	39469-39475	2.5174	_
208-24	39475-39476	,	_
208-25	39477-39478	P	_
208-26	39479-39480	=	_
208-27	39481-39487	0.0210	_
208-28	39487-39488	)	_
208-29	39488-39489	,	_
208-30	39490-39494	left	_
208-31	39495-39502	putamen	_
208-32	39503-39504	(	_
208-33	39504-39512	anterior	_
208-34	39512-39513	:	_
208-35	39514-39515	t	_
208-36	39516-39517	=	_
208-37	39518-39519	−	_
208-38	39519-39525	2.1113	_
208-39	39525-39526	,	_
208-40	39527-39528	P	_
208-41	39529-39530	=	_
208-42	39531-39537	0.0482	_
208-43	39537-39538	,	_
208-44	39539-39548	posterior	_
208-45	39548-39549	:	_
208-46	39550-39551	t	_
208-47	39552-39553	=	_
208-48	39554-39555	−	_
208-49	39555-39561	2.1263	_
208-50	39561-39562	,	_
208-51	39563-39564	P	_
208-52	39565-39566	=	_
208-53	39567-39573	0.0468	_
208-54	39573-39574	)	_
208-55	39575-39578	and	_
208-56	39579-39584	right	_
208-57	39585-39593	anterior	_
208-58	39594-39601	putamen	_
208-59	39602-39603	(	_
208-60	39603-39604	t	_
208-61	39605-39606	=	_
208-62	39607-39608	−	_
208-63	39608-39614	2.3070	_
208-64	39614-39615	,	_
208-65	39616-39617	P	_
208-66	39618-39619	=	_
208-67	39620-39626	0.0325	_
208-68	39626-39627	)	_
208-69	39628-39632	show	_
208-70	39633-39642	decreased	_
208-71	39643-39653	clustering	_
208-72	39654-39665	coefficient	_
208-73	39665-39666	.	_

#Text=Middle panel: bilateral caudate also showed decreased weighted degree (L: t = −2.1393, P = 0.0456; R: t = −2.2824, P = 0.0342) with longer disease history.
209-1	39667-39673	Middle	_
209-2	39674-39679	panel	_
209-3	39679-39680	:	_
209-4	39681-39690	bilateral	_
209-5	39691-39698	caudate	_
209-6	39699-39703	also	_
209-7	39704-39710	showed	_
209-8	39711-39720	decreased	_
209-9	39721-39729	weighted	_
209-10	39730-39736	degree	_
209-11	39737-39738	(	_
209-12	39738-39739	L	_
209-13	39739-39740	:	_
209-14	39741-39742	t	_
209-15	39743-39744	=	_
209-16	39745-39746	−	_
209-17	39746-39752	2.1393	_
209-18	39752-39753	,	_
209-19	39754-39755	P	_
209-20	39756-39757	=	_
209-21	39758-39764	0.0456	_
209-22	39764-39765	;	_
209-23	39766-39767	R	_
209-24	39767-39768	:	_
209-25	39769-39770	t	_
209-26	39771-39772	=	_
209-27	39773-39774	−	_
209-28	39774-39780	2.2824	_
209-29	39780-39781	,	_
209-30	39782-39783	P	_
209-31	39784-39785	=	_
209-32	39786-39792	0.0342	_
209-33	39792-39793	)	_
209-34	39794-39798	with	_
209-35	39799-39805	longer	_
209-36	39806-39813	disease	_
209-37	39814-39821	history	_
209-38	39821-39822	.	_

#Text=Lower panel: the left posterior putamen showed a higher eigenvector centrality with longer duration of alcohol dependence (t = 2.5677, P = 0.0188).
210-1	39823-39828	Lower	_
210-2	39829-39834	panel	_
210-3	39834-39835	:	_
210-4	39836-39839	the	_
210-5	39840-39844	left	_
210-6	39845-39854	posterior	_
210-7	39855-39862	putamen	_
210-8	39863-39869	showed	_
210-9	39870-39871	a	_
210-10	39872-39878	higher	_
210-11	39879-39890	eigenvector	_
210-12	39891-39901	centrality	_
210-13	39902-39906	with	_
210-14	39907-39913	longer	_
210-15	39914-39922	duration	_
210-16	39923-39925	of	_
210-17	39926-39933	alcohol	_
210-18	39934-39944	dependence	_
210-19	39945-39946	(	_
210-20	39946-39947	t	_
210-21	39948-39949	=	_
210-22	39950-39956	2.5677	_
210-23	39956-39957	,	_
210-24	39958-39959	P	_
210-25	39960-39961	=	_
210-26	39962-39968	0.0188	_
210-27	39968-39969	)	_
210-28	39969-39970	.	_

#Text=Significant results reported at P < 0.05 uncorrected for multiple testing for the four separate bilateral striatal nodes.
211-1	39971-39982	Significant	_
211-2	39983-39990	results	_
211-3	39991-39999	reported	_
211-4	40000-40002	at	_
211-5	40003-40004	P	_
211-6	40005-40006	<	_
211-7	40007-40011	0.05	_
211-8	40012-40023	uncorrected	_
211-9	40024-40027	for	_
211-10	40028-40036	multiple	_
211-11	40037-40044	testing	_
211-12	40045-40048	for	_
211-13	40049-40052	the	_
211-14	40053-40057	four	_
211-15	40058-40066	separate	_
211-16	40067-40076	bilateral	_
211-17	40077-40085	striatal	_
211-18	40086-40091	nodes	_
211-19	40091-40092	.	_

#Text=All analyses were corrected for age, gender and head motion.
212-1	40093-40096	All	_
212-2	40097-40105	analyses	_
212-3	40106-40110	were	_
212-4	40111-40120	corrected	_
212-5	40121-40124	for	_
212-6	40125-40128	age	_
212-7	40128-40129	,	_
212-8	40130-40136	gender	_
212-9	40137-40140	and	_
212-10	40141-40145	head	_
212-11	40146-40152	motion	_
212-12	40152-40153	.	_

#Text=Abbreviations: AD, alcohol dependence; CCi, nodal clustering coefficient; Di, nodal degree; ECi, nodal eigenvector centrality; x,y,z, MNI-coordinates
#Text=Demographic and clinical characteristics.
213-1	40154-40167	Abbreviations	_
213-2	40167-40168	:	_
213-3	40169-40171	AD	_
213-4	40171-40172	,	_
213-5	40173-40180	alcohol	_
213-6	40181-40191	dependence	_
213-7	40191-40192	;	_
213-8	40193-40196	CCi	_
213-9	40196-40197	,	_
213-10	40198-40203	nodal	_
213-11	40204-40214	clustering	_
213-12	40215-40226	coefficient	_
213-13	40226-40227	;	_
213-14	40228-40230	Di	_
213-15	40230-40231	,	_
213-16	40232-40237	nodal	_
213-17	40238-40244	degree	_
213-18	40244-40245	;	_
213-19	40246-40249	ECi	_
213-20	40249-40250	,	_
213-21	40251-40256	nodal	_
213-22	40257-40268	eigenvector	_
213-23	40269-40279	centrality	_
213-24	40279-40280	;	_
213-25	40281-40282	x	_
213-26	40282-40283	,	_
213-27	40283-40284	y	_
213-28	40284-40285	,	_
213-29	40285-40286	z	_
213-30	40286-40287	,	_
213-31	40288-40303	MNI-coordinates	_
213-32	40304-40315	Demographic	_
213-33	40316-40319	and	_
213-34	40320-40328	clinical	_
213-35	40329-40344	characteristics	_
213-36	40344-40345	.	_

#Text=AD, n = 24\tHC, n = 20\tTest statistic\tP\t \tAge, M (SD)\t48.54 (7.77)\t46.05 (9.17)\tU=177.500\t0.140\t \tEducation level (1–10), M (SD)\t6.67 (2.10)\t6.65 (1.98)\tU=230.500\t0.819\t \tYears of education, M (SD)\t14.38 (3.65)\t14.25 (3.32)\tU=246.500\t0.876\t \tMale, n (%)\t13 (54.2)\t8 (40.0)\tχ2=0.878\t0.349\t \tRight handed, n (%)\t22 (91.7)\t18 (90.0)\tχ2=0.037\t0.848\t \tAUDIT score, M (SD)\t20.67 (7.97)\t4.00 (3.03)\tt = 24.221\t<0.001\t \tSmokers, n (%)\t13 (54.2)\t1 (5.0)\tχ2 = 12.156\t<0.001\t \tDepression symptom score (IDS), M (SD)\t22.79 (12.55)\t13.80 (14.93)\tU=137.500\t0.016\t \tAnxiety symptom score (BAI), M (SD)\t11.25 (8.84)\t10.65 (10.20)\tU=219.500\t0.628\t \tAD duration (years), M (SD)\t15.50 (11.50)\t\t\t\t \tAD onset age (years), M (SD)\t33.29 (11.52)\t\t\t\t \tDuration of abstinence (days), M (SD)\t15.17 (23.38)\t\t\t\t \tTotal grey matter volume (ml), M (SD)\t690.05 (72.88)\t698.47 (69.82)\tt =−0.389\t0.700\t \tMean head motion (mm), M (SD)\t0.0672 (0.048)\t0.0609 (0.0543)\tU=201\t0.358\t \t
#Text=AD=alcohol dependence; HC=healthy controls;
214-1	40347-40349	AD	_
214-2	40349-40350	,	_
214-3	40351-40352	n	_
214-4	40353-40354	=	_
214-5	40355-40357	24	_
214-6	40358-40360	HC	_
214-7	40360-40361	,	_
214-8	40362-40363	n	_
214-9	40364-40365	=	_
214-10	40366-40368	20	_
214-11	40369-40373	Test	_
214-12	40374-40383	statistic	_
214-13	40384-40385	P	_
214-14	40388-40391	Age	_
214-15	40391-40392	,	_
214-16	40393-40394	M	_
214-17	40395-40396	(	_
214-18	40396-40398	SD	_
214-19	40398-40399	)	_
214-20	40400-40405	48.54	_
214-21	40406-40407	(	_
214-22	40407-40411	7.77	_
214-23	40411-40412	)	_
214-24	40413-40418	46.05	_
214-25	40419-40420	(	_
214-26	40420-40424	9.17	_
214-27	40424-40425	)	_
214-28	40426-40427	U	_
214-29	40427-40428	=	_
214-30	40428-40435	177.500	_
214-31	40436-40441	0.140	_
214-32	40444-40453	Education	_
214-33	40454-40459	level	_
214-34	40460-40461	(	_
214-35	40461-40462	1	_
214-36	40462-40463	–	_
214-37	40463-40465	10	_
214-38	40465-40466	)	_
214-39	40466-40467	,	_
214-40	40468-40469	M	_
214-41	40470-40471	(	_
214-42	40471-40473	SD	_
214-43	40473-40474	)	_
214-44	40475-40479	6.67	_
214-45	40480-40481	(	_
214-46	40481-40485	2.10	_
214-47	40485-40486	)	_
214-48	40487-40491	6.65	_
214-49	40492-40493	(	_
214-50	40493-40497	1.98	_
214-51	40497-40498	)	_
214-52	40499-40500	U	_
214-53	40500-40501	=	_
214-54	40501-40508	230.500	_
214-55	40509-40514	0.819	_
214-56	40517-40522	Years	_
214-57	40523-40525	of	_
214-58	40526-40535	education	_
214-59	40535-40536	,	_
214-60	40537-40538	M	_
214-61	40539-40540	(	_
214-62	40540-40542	SD	_
214-63	40542-40543	)	_
214-64	40544-40549	14.38	_
214-65	40550-40551	(	_
214-66	40551-40555	3.65	_
214-67	40555-40556	)	_
214-68	40557-40562	14.25	_
214-69	40563-40564	(	_
214-70	40564-40568	3.32	_
214-71	40568-40569	)	_
214-72	40570-40571	U	_
214-73	40571-40572	=	_
214-74	40572-40579	246.500	_
214-75	40580-40585	0.876	_
214-76	40588-40592	Male	_
214-77	40592-40593	,	_
214-78	40594-40595	n	_
214-79	40596-40597	(	_
214-80	40597-40598	%	_
214-81	40598-40599	)	_
214-82	40600-40602	13	_
214-83	40603-40604	(	_
214-84	40604-40608	54.2	_
214-85	40608-40609	)	_
214-86	40610-40611	8	_
214-87	40612-40613	(	_
214-88	40613-40617	40.0	_
214-89	40617-40618	)	_
214-90	40619-40621	χ2	_
214-91	40621-40622	=	_
214-92	40622-40627	0.878	_
214-93	40628-40633	0.349	_
214-94	40636-40641	Right	_
214-95	40642-40648	handed	_
214-96	40648-40649	,	_
214-97	40650-40651	n	_
214-98	40652-40653	(	_
214-99	40653-40654	%	_
214-100	40654-40655	)	_
214-101	40656-40658	22	_
214-102	40659-40660	(	_
214-103	40660-40664	91.7	_
214-104	40664-40665	)	_
214-105	40666-40668	18	_
214-106	40669-40670	(	_
214-107	40670-40674	90.0	_
214-108	40674-40675	)	_
214-109	40676-40678	χ2	_
214-110	40678-40679	=	_
214-111	40679-40684	0.037	_
214-112	40685-40690	0.848	_
214-113	40693-40698	AUDIT	_
214-114	40699-40704	score	_
214-115	40704-40705	,	_
214-116	40706-40707	M	_
214-117	40708-40709	(	_
214-118	40709-40711	SD	_
214-119	40711-40712	)	_
214-120	40713-40718	20.67	_
214-121	40719-40720	(	_
214-122	40720-40724	7.97	_
214-123	40724-40725	)	_
214-124	40726-40730	4.00	_
214-125	40731-40732	(	_
214-126	40732-40736	3.03	_
214-127	40736-40737	)	_
214-128	40738-40739	t	_
214-129	40740-40741	=	_
214-130	40742-40748	24.221	_
214-131	40749-40750	<	_
214-132	40750-40755	0.001	_
214-133	40758-40765	Smokers	_
214-134	40765-40766	,	_
214-135	40767-40768	n	_
214-136	40769-40770	(	_
214-137	40770-40771	%	_
214-138	40771-40772	)	_
214-139	40773-40775	13	_
214-140	40776-40777	(	_
214-141	40777-40781	54.2	_
214-142	40781-40782	)	_
214-143	40783-40784	1	_
214-144	40785-40786	(	_
214-145	40786-40789	5.0	_
214-146	40789-40790	)	_
214-147	40791-40793	χ2	_
214-148	40794-40795	=	_
214-149	40796-40802	12.156	_
214-150	40803-40804	<	_
214-151	40804-40809	0.001	_
214-152	40812-40822	Depression	_
214-153	40823-40830	symptom	_
214-154	40831-40836	score	_
214-155	40837-40838	(	_
214-156	40838-40841	IDS	_
214-157	40841-40842	)	_
214-158	40842-40843	,	_
214-159	40844-40845	M	_
214-160	40846-40847	(	_
214-161	40847-40849	SD	_
214-162	40849-40850	)	_
214-163	40851-40856	22.79	_
214-164	40857-40858	(	_
214-165	40858-40863	12.55	_
214-166	40863-40864	)	_
214-167	40865-40870	13.80	_
214-168	40871-40872	(	_
214-169	40872-40877	14.93	_
214-170	40877-40878	)	_
214-171	40879-40880	U	_
214-172	40880-40881	=	_
214-173	40881-40888	137.500	_
214-174	40889-40894	0.016	_
214-175	40897-40904	Anxiety	_
214-176	40905-40912	symptom	_
214-177	40913-40918	score	_
214-178	40919-40920	(	_
214-179	40920-40923	BAI	_
214-180	40923-40924	)	_
214-181	40924-40925	,	_
214-182	40926-40927	M	_
214-183	40928-40929	(	_
214-184	40929-40931	SD	_
214-185	40931-40932	)	_
214-186	40933-40938	11.25	_
214-187	40939-40940	(	_
214-188	40940-40944	8.84	_
214-189	40944-40945	)	_
214-190	40946-40951	10.65	_
214-191	40952-40953	(	_
214-192	40953-40958	10.20	_
214-193	40958-40959	)	_
214-194	40960-40961	U	_
214-195	40961-40962	=	_
214-196	40962-40969	219.500	_
214-197	40970-40975	0.628	_
214-198	40978-40980	AD	_
214-199	40981-40989	duration	_
214-200	40990-40991	(	_
214-201	40991-40996	years	_
214-202	40996-40997	)	_
214-203	40997-40998	,	_
214-204	40999-41000	M	_
214-205	41001-41002	(	_
214-206	41002-41004	SD	_
214-207	41004-41005	)	_
214-208	41006-41011	15.50	_
214-209	41012-41013	(	_
214-210	41013-41018	11.50	_
214-211	41018-41019	)	_
214-212	41025-41027	AD	_
214-213	41028-41033	onset	_
214-214	41034-41037	age	_
214-215	41038-41039	(	_
214-216	41039-41044	years	_
214-217	41044-41045	)	_
214-218	41045-41046	,	_
214-219	41047-41048	M	_
214-220	41049-41050	(	_
214-221	41050-41052	SD	_
214-222	41052-41053	)	_
214-223	41054-41059	33.29	_
214-224	41060-41061	(	_
214-225	41061-41066	11.52	_
214-226	41066-41067	)	_
214-227	41073-41081	Duration	_
214-228	41082-41084	of	_
214-229	41085-41095	abstinence	_
214-230	41096-41097	(	_
214-231	41097-41101	days	_
214-232	41101-41102	)	_
214-233	41102-41103	,	_
214-234	41104-41105	M	_
214-235	41106-41107	(	_
214-236	41107-41109	SD	_
214-237	41109-41110	)	_
214-238	41111-41116	15.17	_
214-239	41117-41118	(	_
214-240	41118-41123	23.38	_
214-241	41123-41124	)	_
214-242	41130-41135	Total	_
214-243	41136-41140	grey	_
214-244	41141-41147	matter	_
214-245	41148-41154	volume	_
214-246	41155-41156	(	_
214-247	41156-41158	ml	_
214-248	41158-41159	)	_
214-249	41159-41160	,	_
214-250	41161-41162	M	_
214-251	41163-41164	(	_
214-252	41164-41166	SD	_
214-253	41166-41167	)	_
214-254	41168-41174	690.05	_
214-255	41175-41176	(	_
214-256	41176-41181	72.88	_
214-257	41181-41182	)	_
214-258	41183-41189	698.47	_
214-259	41190-41191	(	_
214-260	41191-41196	69.82	_
214-261	41196-41197	)	_
214-262	41198-41199	t	_
214-263	41200-41201	=	_
214-264	41201-41202	−	_
214-265	41202-41207	0.389	_
214-266	41208-41213	0.700	_
214-267	41216-41220	Mean	_
214-268	41221-41225	head	_
214-269	41226-41232	motion	_
214-270	41233-41234	(	_
214-271	41234-41236	mm	_
214-272	41236-41237	)	_
214-273	41237-41238	,	_
214-274	41239-41240	M	_
214-275	41241-41242	(	_
214-276	41242-41244	SD	_
214-277	41244-41245	)	_
214-278	41246-41252	0.0672	_
214-279	41253-41254	(	_
214-280	41254-41259	0.048	_
214-281	41259-41260	)	_
214-282	41261-41267	0.0609	_
214-283	41268-41269	(	_
214-284	41269-41275	0.0543	_
214-285	41275-41276	)	_
214-286	41277-41278	U	_
214-287	41278-41279	=	_
214-288	41279-41282	201	_
214-289	41283-41288	0.358	_
214-290	41292-41294	AD	_
214-291	41294-41295	=	_
214-292	41295-41302	alcohol	_
214-293	41303-41313	dependence	_
214-294	41313-41314	;	_
214-295	41315-41317	HC	_
214-296	41317-41318	=	_
214-297	41318-41325	healthy	_
214-298	41326-41334	controls	_
214-299	41334-41335	;	_
